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Abstract 
After the successful eradication of smallpox, mass vaccination stopped and the herd immunity 
against orthopoxvirus (OPXV) infections has been waning. In the light of bioterrorism, the 
interest in the development of antiviral drugs and safer vaccines against OPXVs increases. 
Therefore, a non-human primate model for OPXVs was established. Common CM (CM, 
Callithrix jacchus) are intranasally infected with a cowpox virus that is lethal for this non-
human primate species and designated calpox virus. 
A pathogenesis study was performed to determine the portal of viral entry and to analyze the 
early dissemination of the virus and the pathological sequelae. Groups of three animals were 
infected with either 3.5x105 plaque forming units (pfu) calpox virus and euthanized on day 3, 
or with 8.3x103 pfu and euthanized on 5, 7, 10 and 12 days post infection (dpi). Blood and 
various organs were analyzed for infectious virus using the endpoint dilution assay and for 
viral DNA by real-time PCR. To detect the calpox virus infection in immune cells, PBMCs 
and buffy coat were analyzed by flow cytometry for calpox virus. Two vaccination studies 
aimed at identifying immune correlates of protection. Two attenuated smallpox vaccines, i.e. 
modified VACV Tian Tan (MVTT) and modified VACV Ankara (MVA) were tested for their 
efficacy after a 4- and 10-week waiting period. Humoral and cellular responses were analysed 
during immunization and after challenge, as well as viral DNA copy numbers and replicating 
virus after challenge.  
Occurrance of viremia (DNA copies in blood) was dose dependent and already observed at 3 
dpi (with the high inoculation dose) and after inoculation with the low viral dose at 7 dpi. The 
data suggests that the calpox virus initially replicated in the upper respiratory tract followed 
by systemic spread. In the prefinal phase, all organs became infected. Calpox antigen was de-
tected in immune cells at different time points. With respect to the vaccine studies, overall, 67 
% protection was observed following immunization with MVTT and 13 % after MVA vac-
cination independently of the waiting period. All vaccine failures became virus positive. Vi-
rus-specific T-cell proliferation was observed in some animals vaccinated with MVTT. How-
ever, binding and neutralizing antibodies as well as the proliferative activity were not associ-
ated with the protection of the CM from calpox virus challenge. Peptide microarrays revealed 
antibodies against linear B cell epitope regions in different proteins (A33, B5 and L1) that 
were present almost exclusively in protected animals post challenge. Phenotyping of innate 
and adaptive immune cells by flow cytometric staining revealed no significant differences 
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between vaccine groups in T and B cell numbers as well as in their expression of activation 
markers. 
In conclusion, intranasal infection of CM with calpox virus led to a first local viral replication 
in nasal tissue. From there, the virus spread to various organs and in the prefinal phase all or-
gans became infected. Highest protection was mediated by MVTT which therefore is superior 
to MVA in this model. So far, no obvious correlates of immune protection were identified. 
Keywords: Calpox virus, pathogenesis, non-human primate model, calpox virus/marmoset model, smallpox vaccine, MVTT, MVA, New 
World 
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1 INTRODUCTION 
1.1 Historical overview of orthopoxvirus infection 
1.1.1 The smallpox virus 
Origin of smallpox disease 
Smallpox is caused by the variola virus (VARV). The death rate of this devastating disease 
was estimated at 50 % or more in young or over 40-years olds (Hanna and Baxby, 2002). Va-
riola major and variola minor are the two known forms of the disease. Case-fatality rates be-
tween 5 % and 40 % were reported for variola major (Henderson and Moss, 1999). Variola 
minor occurs less often and is less severe than variola major with case-fatality rates between 1 
% and 2 %. Unfortunately, a therapy has not been found until today. Smallpox spreads be-
tween humans without another animal reservoir. 
Even though there is no evidence of the origin of smallpox, it is believed to have appeared in 
northeastern Africa at the time of the first agricultural settlement in 10,000 BC (Barquet and 
Domingo, 1997; Hopkins, 1983). It is assumed, that ancient Egyptian merchants were respon-
sible for the spread of the disease from northeastern Africa to India (Riedel, 2005). The earli-
est reports of skin lesions resembling those of smallpox were found on faces of mummies of 
18th and 20th Egytian Dynasties (1570-1085 BC). Evidence of the disease was found on the 
head of the mummy of the Egyptian pharaoh Ramses V, who died 1156 BC (Lyons and 
Petrucelli, 1987). Parallel to that, reports of a smallpox disease in ancient Asia appeared. In 
China, smallpox was described in ancient Sanskrit texts in 1122 BC. Smallpox first appeared 
in Europe between the 5th and the 7th centuries. 
History of variolation 
Material from smallpox-infected individuals was used in order to protect against pustules. 
During the 16th century, Asians and Indians, inserted the fluid of smallpox scabs from an in-
fected person into the nasal mucosa or carved into the skin of healthy persons (Needham, 
1980). The method of treatment was called variolation and it caused a disease that was less 
severe than the one acquired via the respiratory system. Variolated patients were protected 
from death but still highly contagious and the risk of a new epidemic outbreak was high. This 
variolation was the first immunization method against smallpox (Variola) and was later intro-
duced to Europe.  
However, other diseases such as tuberculosis and syphilis were also transferred by variolation 
(Langer, 1976; Riedel, 2005). In the 18th century, the method of immunization was replaced 
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by the smallpox vaccine (Henderson, 2011). The smallpox vaccine introduced by Edward 
Jenner (Figure 1-1) was found to be safer. This vaccine was based on the finding that the 
maidservants, who developed cowpox lesions, were protected against poxvirus infections. In 
1796, Jenner inoculated the eight year-old boy James Phipps with the material of a cowpox 
infection taken from the milkmaid Sarah Nelmes, and six weeks later with VARV (Paul, 
2008). His experiment was successful and it produced complete protection against the disease 
and in 1798 Jenner described the safer and effective alternative to variolation. He named the 
infectious material of a cowpox infection “vaccine” after the Latin word “vacca” for cow. 
Although misleading, the English word “vaccination” is nowadays still in use (1.6.2 Cowpox 
viruses). Jenners discovery ranks among one of the greatest achievements in human history 
(Belongia and Naleway, 2003). His report on the usage of cowpox for vaccination against 
smallpox led to the confusion of the vaccinia virus (VACV) with cowpox virus (CPXV). 
When it was realized that the virus used for vaccination was not, or no longer the same as 
CPXV, the name ´vaccinia´ was used for the virus in smallpox vaccine. Although the origin is 
unknown, it has been assumed that VACV was originally isolated from horses (Huygelen, 
1996). Even if they were often considered to be the same, VACV and CPXV represent a dis-
tinct species among the genus Orthopoxvirus (OPXV) (Huygelen, 1996). Nevertheless, it was 
also reported that all available smallpox vaccines were based on VACV (Downie, 1939). It 
remains unclear whether Jenner originally used VACV or CPXV for his vaccination (Paran 
and Sutter, 2009).  
 
Figure 1–1: Edward Jenner (1749-1823) (Riedel, 2005). Jenner described the safer and more effective alternative “vaccina-
tion” to variolation in 1798. His discovery of the cross protection of cowpox and smallpox led to the eradication of smallpox 
as certified by the World Health Organization (WHO) in 1980 and is known as one of the outstanding achievements of medi-
cine. Photo courtesy of the National Library of Medicine.  
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After the discovery of the first vaccine consisting of the material of a cowpox infection, vac-
cinations were later performed by transmitting material from pustules of a vaccinated person 
to another individuum with the arm-to-arm method. This also brought the disadvantage of the 
accidential transmission of other diseases via blood. A further improvement for vaccine pro-
duction was to grow the virus on calf skin. This method offered a safer and constant supply of 
vaccine material and increased the number of vaccinations in Europe (Moss and Henderson, 
1999). A stable freeze-dried vaccine was commercially processed for large-scale production 
and established in the late 1940´s (Collier, 1955). The smallpox vaccine was live vaccinia vi-
rus and belongs, like variola virus, to the OPXVs against which strongly cross-protective an-
tibodies are induced after an infection (Essbauer et al., 2010; Gilchuk et al., 2016). 
Smallpox eradication 
Smallpox´ lethal wanderings had an enormous influence on the human population (WHO, 
1980). Five reigning monarchs died of smallpox in the eighteenth century in Europe. An esti-
mated 400,000 Europeans were annually killed by the disease and by the end of the eighteenth 
century it was responsible for a third of blindness in Europe (Radetsky, 1999). Moreover, 
smallpox decimated Native American populations and thus facilitated the colonization of 
America (WHO, 1980). Except for Australia and on certain islands, smallpox was at its zenith 
endemic throughout the inhabited world (Buller and Palumbo, 1991). During the 20th century, 
estimated 300-500 million people died from smallpox infections before a global smallpox 
vaccination campaign was initiated (Smith and McFadden, 2002). Despite of the discovery of 
the vaccination, many people died from the disease worldwide.  
Following the decision of the Pan American Sanitary Organization in 1950, an eradication 
program was implemented. With the exception of Brasil, Argentina, Colombia and Ecuador, 
the attempt to eliminate smallpox in 1967 was successful in the Americas. The World Health 
Organization (WHO) initiated a global eradication program in 1959. The last naturally occur-
ing case of smallpox was diagnosed in the town of Merca, Somalia in 1977 and the eradica-
tion of smallpox was certified by the WHO on May 8, 1980 (Figure 1-2) (Deria et al., 1980; 
WHO, 1980).  
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Figure 1–2: Location of the world´s last known endemic case of smallpox (Deria et al., 1980). The last naturally occur-
ring case of smallpox was diagnosed in the town of Merca, Somalia. 
 
Because there was no effective animal reservoir for VARV, the global immunization program 
with the vaccinia virus was successful in eradicating this disease (Buller and Palumbo, 1991). 
Millions of lives were saved and the eradication of smallpox remains one of the outstanding 
medical achievements (Moss, 2011). In the case of smallpox, a virus was eradicated for the 
first and only time in human history. Officially, the variola virus is nowadays stored at only 
two institutes, the Vector Insitute in Novosibirsk, Russia and the Center for Disease Control 
and Prevention (CDC), USA.  
Many different strains of VACV have been used for vaccination in the last two centuries 
(1.9.1 Vaccinia virus (VACV)). Due to the lack of information (origin, history of serial pas-
sage) about these strains, the origin of the present VACV strains is unknown.  
1.1.2 The potential threat of bioterrorism and zoonotic events 
In order to avoid severe side effects, vaccination with VACV stopped soon after the success-
ful eradication of smallpox in 1980. Therefore, herd immunity is no longer given. If re-
introduced, the human population remains unprotected. Routine smallpox vaccination ended 
in Europe between 1976 and 1984 (Fenner et al., 1988c). Third generation smallpox vaccines 
do exist, but the main purpose of these vaccines is for the protection of the military personnel 
and selected laboratories that work with OPXVs.  
Because of the careful and exclusive storage of the virus, a voluntary or accidentially re-
introduction of VARV is less likely yet existent and VARV pose a potential thread. However, 
the existence of other unregistered VARV stocks cannot be excluded. In June 2014, tubes la-
beled as “variola” were found in an unsecured freezer of a laboratory in Bethesda (Reardon, 
2014). Furthermore, bioterrorist attacks, such as anthrax attacks in 2001, have sensitized the 
population and the awareness of the possible misuse of viruses in this context is ever present. 
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Biological weapons, including VARV, have accidentially been used or exposed in planned 
tests. Smallpox is included in the category A of the CDC list of potential biological weapons 
(CDC, 2008) because of VARV´s easy airborne transmission from one person to another as 
well as the high mortality rate and the low or not existing smallpox immunity in the majority 
of the human population (Wenzel, 2002). The re-introduction of VARV through a bioterrorist 
attack poses one of the greatest threats (Callaway, 2008; Henderson, 1999; Henderson et al., 
1999; Jahrling et al., 2005; Kortepeter and Parker, 1999). Because of the risk of accidential or 
voluntary reintroduction through bioterrorism, the constant monitoring of smallpox must con-
tinue (Morand et al., 2017).  
1.2 Orthopoxvirus diseases 
1.2.1 Virus transmission 
VARV is mainly transmitted through the respiratory route via virus containing droplets 
(Kempe et al., 1969), but infections via the conjunctiva have also been reported (Rao et al., 
1960). Epidemiological studies have shown that the presence of VARV in scabs do not play a 
noteworthy role in virus transmission. A fetus can presumably be infected in the placenta dur-
ing the second viremic phase of the mother (Marsden, 1936). No reports for infections via the 
alimentary tract or that of the involvement of arthropods exist.  
Monkeypoxvirus (MPXV) is a zoonotic poxvirus (Essbauer et al., 2004) and the virus is 
therefore transmitted to humans through contact with wild animals that includes infected non-
human primates (NHPs). The transmission rate increased from 30 % in 1988 (Fenner et al., 
1988a) to 73 % in 2008 (WHO, 1980). Transmission chains beyond secondary infection have 
been reported (Hutin et al., 2001; Learned et al., 2005), but are rare (Jezek et al., 1986; Jezek 
et al., 1988). Therefore, it is assumed that MPXV infections only persists in the human popu-
lation, if it is repeatedly re-introduced by the main reservoir (Fine et al., 1988). 
Unlike VARV that is mainly airborne-transmitted, CPXV is another zoonotic poxvirus that is 
mainly transmitted to humans via skin or mucosal lesions. Most of the time it derives from 
scratches or bites of infected cats or pet rats leading to skin lesions commonly on fingers and 
hands. Virus-transfer from these lesions can later infect the face. CPXV infections transmitted 
by pet rats or other pet or zoo animals are increasingly reported and the number of animal 
species that are susceptible to CPXV infections increase similarily (Figure 1-3) (Baxby et al., 
1979; Baxby et al., 1994; Becker et al., 2009; Campe et al., 2009; Kurth et al., 2009; Mätz-
Rensing et al., 2012; Pilaski et al., 1986; Schupp et al., 2011; Vorou et al., 2008; Wolfs et al., 
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2002). CPXV infections are usually self-limiting. Severe generalized infections can occur in 
atopic persons, who receive glucocorticoids for therapeutic reasons or immunsuppressed 
HIV-patients (Blackford et al., 1993; Czerny et al., 1991; Klingebiel et al., 1988). 
 
Figure 1–3: First proven case of rat-to-human transmission of cowpox in 2002 (Wolfs et al., 2002). Zoonotic infection of 
a 14-year-old girl who got infected (eyelid) after contact with a clinically ill wild rat that later succumbed to its infection.  
1.2.3 Clinical symptoms 
The most common clinical form of smallpox was the ordinary type and was caused by variola 
major and minor. Other clinical forms of smallpox were the modified type, the flat type and 
the hemorrhagic type where the last two types were usually fatal. Clinical symptoms of the 
ordinary type occur after an incubation period of approximately 12 days with a range from 7 
to 17 days. The symptoms include headache, backache, high fever, malaise, prostration, and 
vomiting in rare cases that is followed by a maculopapular rash lasting for two to five days. 
The maculopapular rash develops to papules, vesicles and then to pustules. Most of the pus-
tules are found on the soles of the foot, the face, the forearms, the palms of the hands, the 
mouth and the neck (Moore et al., 2006). Crusts start to form on day eight or nine. When they 
fall off, the skin underneath is pigment-free and remains scarred. Perhaps because of the de-
veloping antibodies, the fever sinks with the development of the rash and rises again with the 
development of the pustules. Conjunctivitis, which often leads to blindness in the patient, ap-
pears during the first eight days. The severeness of the disease is dependent on the immune 
response of the host and the cause of death is still not clear. The reason might be intravascular 
coagulation, massive secretion of cytokines and a cytopathic effect caused by a strong virus 
replication in the tissue that end in multi-organ dysfunction (Bray and Buller, 2004; Downie 
et al., 1953; Martin, 2002). Variola major was generally more severe than variola minor with a 
higher death rate.  
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Other clinical forms can be observed in CPXV infections. The first typical lesion appears as 
an inflamed macula that turns into a papule and a vesicle within 12 days. The vesicle begins 
to ulcerate and becomes increasingly hemorrhagic. At the end of the second week the vesicle 
becomes incrusted (Dugmore and Dabir, 1992; Simcock et al., 1993). The degree of inflam-
mation of the lesions varies, whilst the size of the extremely painful lesions ranges from one 
to three centimetres in diameter. An often marked and prolonged lymphadenopathy occurs. 
Systemic symptoms, such as fever, malaise, lethargy, in some cases vomiting and sore throat 
that lasts three to ten days, have been reported. It takes ten to 12 weeks or longer for the pa-
tient to fully recover. Ocular infections of the conjunctiva and cornea have occasionally been 
reported in localized CPXV infections (Hall and Stevens, 1987; Klingebiel et al., 1988). In 
more serious generalized infections, symptoms, such as atopic eczema, dermatitis, allergic 
asthma or immunosuppression, can occur and have a severe or lethal progression (Blackford 
et al., 1993; Czerny et al., 1991; Klingebiel et al., 1988).  
1.2.4 Pathogenesis  
Most of the information on the pathogenesis of VARV infections stem from previous small-
pox cases that originated from artificial infections of animals with different OPXV (Buller 
and Palumbo, 1991; Hahon and Wilson, 1960; Zaucha et al., 2001). VARV initally infects the 
mucosa and the upper respiratory tract, the mucosal membranes of the mouth, the nasal cavi-
ty, the oropharynx or the alveoli of the lungs. After local replication, the virus then spreads 
through infected macrophages via the lymph system to the regional lymph nodes, in which 
replication continues. B cell and cytotoxic T cell responses are induced in the regional lymph 
nodes. The following virus replication leads to a first asymptomatic viremia between day five 
and six post infection (Fenner et al., 1988a). The virus is then disseminated to many organs 
(e.g. spleen, bone marrow, lymph nodes). After the invasion of the mononuclear phagocyte 
system, a short second viremia follows and VARV is characterised by the entry of the virus 
into the bloodstream at day eight post infection. The virus completely disseminates through-
out the body and also the blood vessels of the dermis, the oral and pharyngeal mucosa in sec-
ond viremia. Because of infected macrophages, VARV is spread from small dermal vessels to 
the epidermis. This leads to the typical pox lesions in the epidermis that occur through the de-
velopment of edema, ballooning degeneration and splitting of the epidermis. The typical le-
sions (maculopapular, vesicular and papular rash) occur between days ten and 14 post infec-
tion. The infection starts with the occurance of the skin lesions. Skin lesions usually occur as 
soon as enanthems, mucosal lesions in the mouth and oropharynx occur. Fever and also cyto-
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kine secretion/cytokine storm occur during the second viremia. In addition, several Guarnieri 
bodies and extensive necrosis of epithelial cells of infected skin tissue can be detected through 
histological analyses. In hemorragic cases of VARV infections, the virus is only detectable 
after the death of the infected person in the pox lesions, spleen, kidney, liver, bone marrow 
and also other organs (Fenner et al., 1988a; Fenner et al., 1988b; Martin, 2002). Main source 
of virus transmission is oropharyngeal secret (saliva) that contaminates objects and can be 
easily transmitted via droplets. In some cases, the virus was also detected in urine. The conta-
giosity is highest in the first week after occurance of the skin lesions (Mac et al., 1950). Intra-
vascular coagulation, massive secretion of cytokines that is associated with circulating im-
mune complexes, soluble VARV antigens and a cytopathic effect based on massive virus rep-
lication in the tissues ending in multi-organ dysfunction have been discussed as the cause of 
death (Bray and Buller, 2004; Downie et al., 1953; Martin, 2002). Nevertheless, it remains 
unclear why individuals die. 
1.2.5 Calpox virus  
The studies presented herein are based on the findings of a private keeping of common CM 
(CM, Callithrix jacchus) in 2002 (Matz-Rensing et al., 2006). The animals developed a se-
vere systemic disease with hemorrhagic lesions that resembled human smallpox, fever, de-
pression, severe erosive-ulcerative lesions of the oral membranes and lymphadenopathy 
(Schmitt et al., 2014). The infected animals of a group of 30 to 80 New World monkeys died 
within one week after the onset of symptoms of the unknown disease. Mätz-Rensing and col-
leagues have found a new virus. The not yet fully characterized virus was named after its host 
Callithrix jacchus, calpox virus and was used to develop a promising OPXV model with CM. 
The virus was sequenced and identified to be the closest related to cowpox viruses. Neverthe-
less, calpox virus differs from the already described species and cannot be assigned to a pre-
viously known cowpox species (Carroll et al., 2011). It therefore represents a distinct and new 
CPXV strain. 
In order to identify the cause of the animals´ death, several pathological and histological ana-
lyzes and investigations in the CM followed (Kramski et al., 2010; Mätz-Rensing et al., 
2012). Previously conducted studies focused on the final stage of the disease. Mätz-Rensing 
and colleagues detected the characteristic pox-like lesions in skin, mucous membranes, lymph 
nodes, liver and spleen. In parallel, Schmitt and colleagues experimentally infected CM with 
the calpox virus and analyzed different organs and tissues by histopathology, immunohisto-
chemistry and transmission electron microscopy (Schmitt et al., 2017). The data indicates an 
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early replication in nasal and bronchial epithelia as well as secondary replication in sub-
mandicular lymph nodes and spleen. A monocytic-cell associated viremia is followed by the 
detection of the virus in mainly epithelial cells and macrophages, but also in endothelial cells. 
The incubation period lasts about 12 days and resembles that of human smallpox. The defini-
tion is based on the histological and ultrastructural lesions, the onset of clinical symptoms and 
the immunohistochemical distribution pattern of the virus. The immune system obviously col-
lapsed around day 12 post infection and animals start to die. Kramski and colleagues also 
found out that intranasal inoculation with very low infectious doses of the calpox virus leads 
to a severe, fatal disease course (Kramski et al., 2010). The intranasal inoculation route re-
sembles the natural transmission route of smallpox.   
1.3 Orthopoxviruses within the Poxviridae family 
Two subfamilies belong to the Poxviridae family, the Chordopoxvirinae and Entomopoxviri-
nae. Entomopoxvirinae infect insects, whilst Chordopoxviridae infect vertebrates (Buller and 
Palumbo, 1991). Orthopoxvirus belongs to the Chordopoxvirinae and is one of the four gene-
ra of the poxviruses, notably Orthopox, Parapox, Yatapox and Molluscipox that may infect 
humans. The genera Orthopoxvirus (OPXV) with the type species vaccinia virus can be sub-
divided into ten species: Camelpox virus, Cowpox virus, Ectromelia virus, Monkeypox virus, 
Raccoonpox virus, Skunkpox virus, Vaccinia virus, Variola virus and Volepox virus (Interna-
tional Committee on Taxonomy of Viruses (ICTV), 2017). All OPXV species are serological-
ly very closely related and therefore cross-reactive.  
1.4 Virus structure and genome 
With a size of 200 nm in diameter and 300 nm in length, the poxvirus virions are considered 
to be exceptionally large (Figure 1-4). The poxviridae viral particles (virions) are enveloped 
and generally brick shaped and carry the genome in a single, double-stranded DNA segment. 
The genome lies within a nucleoprotein complex in a biconcave capsid. In VACV, four dif-
ferent types of virions are produced in an infected cell: the extracellular enveloped virus 
(EEV), the intracellular enveloped virus (IEV), the cell-associated enveloped virus (CEV) and 
the intracellular mature virus (IMV). The virus particles differ in morphology, proteins and 
numbers of membrane layers. The enveloped virions (EV) have two membranes and are 
formed as long as the cell is still intact. After cell lysis, mainly mature virions (MV) are set 
free (Condit et al., 2006). Within CPXV- and ectromelia virus (ECTV)-infected cells also ac-
idophilic-type inclusion bodies (ATI), or A-type inclusion bodies are formed and can be 
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found in the cytoplasm (Patel et al., 1986). At the replication site (infected epithelial cells) B-
type inclusion bodies or Guarnieri bodies are found, also virus particles aggregate during the 
infection.  
 
Figure 1–4: Drawing of extracellular enveloped vaccinia virus particle (Fenner et al., 1988a). Orthopoxviruses are re-
markable large.  
 
OPXV have a linear double stranded, linear DNA-genome of 180-190 kb in length and en-
code over 250 genes (Craighead, 2000). The ends are coupled by covalent hairpin structures 
(VARV) (Shchelkunov et al., 2000). OPXV replicate in the cytoplasm. Since replication ma-
chinery of the host is located in the nucleus and cannot be used by the virus, poxviruses en-
code for the complete functions of the replication cycle including polymerases, RNA-capping 
and RNA-modifying enzymes. The genomes of the Chordopoxvirinae are highly homologous. 
In the center of the genome there are 90 conserved genes that encode proteins for basal func-
tions such as replication, transcription, virion assembly and release (Upton et al., 2003). The 
non-conserved genes are located at the ends of the genome and are species specific (Gubser et 
al., 2004; Shchelkunov et al., 1998). They determine the pathogenicity of the respective virus 
and encode for host range-factors and immunomodulators. Inverted terminal repetitions are 
located at the two ends of the OPXV genome (Garon et al., 1978). They consist of an AT-rich 
base-paired hairpin loop that connects the two DNA strands. The inverted terminal repetitions 
are variable in length but have a highly conserved region that is necessary for the processing 
of replicating concatemeric forms of DNA (DeLange and McFadden 1990; Merchlinsky 
1990).    
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1.5 Virus life cycle 
1.5.1 Virus entry and uncoating 
A ubiquitous receptor or the use of many cellular receptors has been assumed for OPXVs 
ability to infect a variety of cells. Although no specific cellular receptor has been detected for 
any of the OPXVs, glycosaminoglycans (GAGs) are thought to fulfill this function. The virus 
then enters the cell and uncoats in two steps. In the first step the outer membrane is removed 
when the virus enters the cell. In the second step the virus particle fuses with the cellular 
membrane and releases the virus core into the cytoplasm to express the virual genes (1.5.2 
Virus gene expression). Furthermore, different virus particle subtypes probably enter the cells 
via different routes. It has been suggested that EEVs enter the cell via endocytosis. It is as-
sumed that the low pH disrupts the virions outer membrane and released IMV fuses with en-
dosomal membranes (Doms et al., 1990; Vanderplasschen et al., 1998). It is also assumed that 
vesicles are formed by surface invaginations (Gong et al., 1990; Kochan et al., 2008; 
Senkevich and Moss, 2005; Townsley et al., 2005; Vazquez et al., 1998). 
There have been evidence that IMV and EEV have different binding sites (Vanderplasschen 
and Smith, 1997).  When two types of virus bind to a cell, efficacy of infection may increase. 
Different proteins are involved in the cell attachment of EEVs (Chung et al., 1998a; Hsiao et 
al., 1998; Lin et al., 2000). 
1.5.2 Virus gene expression 
Expression of early-, intermediate-, and late-phase genes takes place in the cytoplasm of the 
host cell (Broyles, 2003). Viral RNA-polymerase begins expression of early-phase genes at 
approximately 30 minutes post-infection. This process starts inside the viral core which in the 
meantime becomes completely uncoated.  At the time the early expression ends, the viral ge-
nome is released into the cytoplasm. Approximately half of all OPXVs genes belong to the 
early class (Oda and Joklik, 1967). The early mRNAs encode factors and enzymes that are 
needed for host interactions, viral DNA synthesis and transcription of the intermediate phase 
genes (Baldick and Moss, 1993). After early gene transcription, intermediate genes are ex-
pressed in the cytoplasm. At this time point, approximately 2 hours post infection, genomic 
DNA replication is triggered by viral DNA polymerase (1.5.3 DNA replication).  
The intermediate genes are expressed from 140 minutes to 48 hours post infection and encode 
structural proteins to form a new mature virus particle (1.5.4 Virion assembly, maturation and 
release).  
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1.5.3 DNA replication 
DNA replication by viral DNA polymerase takes place entirely in the cytoplasm of the infect-
ed host cell and involves several stages (Broyles, 2003). DNA-replication occurs in discrete 
cytoplasmic structures known as virus factories or virosome (foci of replication, termed virus 
factor areas or Guarnieri bodies). The two strands of the linear, double-stranded DNA are 
linked by hairpin ends. Several viral proteins are involved in DNA synthesis: a 117-kDa DNA 
polymerase, a helicase-primase, an uracil DNA glycosylase, a progressivity factor, a single-
stranded DNA-binding protein, a protein kinase and a DNA ligase (Moss, 2013). Replication 
begins with introduction of a nick in one of the viral DNA strands near the terminal region 
creating a free 3’OH primer. This leads to strand displacement and elongation of the newly 
formed 3’end by the viral DNA polymerase. The elongated DNA strand possesses self-
complementarity which allows it to fold back on itself and prime further elongation. This 
elongation can progress through the hairpin terminus. The replicated DNA appears as head-
to-tail concatemers, which could form by a rolling circle mechanism. In VACV about 10,000 
genome copies per cell are generated by DNA replication and half of them are packaged into 
new virions (Joklik and Becker, 1964).  
1.5.4 Virion assembly, maturation and release 
The assembly of the virus particles is a complex process consisting of five stages and occurs 
in the cytoplasm of the cell. The assembly and virus morphogenesis occur together with the 
transcription of the late genes and genome replication in the viral factories (Rodriguez et al., 
1997). Crescent membranes appear within the factories as first distinct structures of virus 
morphogenesis (Moss, 2015). It has been suggested that the crescent membrane is derived 
from the endoplasmatic reticulum. Crescents grow until they become three dimensional 
spheres to form the immature virion (IV). While crescent membranes develop, they become 
filled with viroplasm containing viral core proteins. Before the membrane is sealed, viral ge-
nomic DNA is packed into the viroplasm. The detailed mechanism of how the viral DNA is 
transported and incorporated into the virion remains unclear. VACV regulatory protein E6 is 
known to be essential for core protein association. By condensing into the dense brick-shaped 
mature virions (MVs), the IVs then maturate into intracellular mature virus (IMV), the infec-
tious particles (Gaylord and Melnick, 1953; Morgan et al., 1954; Morgan and Wyckoff, 
1950). The virus core condensates in this step and the major structural proteins enter the im-
mature envelopes by proteolytic processing (Morgan, 1976; Moss and Rosenblum, 1973). 
Depending on the poxvirus genus, IMVs/MVs can also remain within the cell or may be 
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wrapped into an additional membrane (Hiller and Weber, 1985; Schmelz et al., 1994; Tooze 
et al., 1993). The wrapped virions or intracellular enveloped viruses are transported to the cell 
periphery and in the final stage of maturation, the new extracellular enveloped virions are 
formed by exocytosis and exit the cell (Smith and Law, 2004). By losing the outermost Golgi-
derived membrane, the extracellular enveloped virions and cell-associated enveloped virions 
are formed. Cell-associated enveloped virions are important for cell-to-cell spread and remain 
attached at the cell surface. EEVs mediate the long-range dissemination of the virus in cell 
culture (Smith et al., 2002).  
1.6 Orthopoxviruses in humans 
1.6.1 Zoonotic poxvirus infections in humans 
Humans and other primates are susceptible to OPXV infections. Five OPXVs can infect hu-
mans: variola, vaccinia, cowpox, monkeypox and camelpox. 
One of the most devastating OPXV diseases in humans is known as the infection with VARV, 
the etiologic agent of smallpox (1.1.1 The smallpox virus). It has been assumed that VARV 
may have evolved from an enzootic pathogen of African rodents that spread from Africa, but 
no evidence exists (Li et al., 2007). Therefore, smallpox might have originally been acquired 
by humans as a zoonosis, from a terrestrial African rodent 16,000 to 68,000 years ago. How-
ever, smallpox was spread from human to humans without another animal reservoir.  
Monkeypox, vaccinia, camelpox as well as cowpox are zoonotic (Goyal et al., 2013) and 
therefore regarded as infectious diseases of animals that can be transmitted to humans. Vac-
ciniation of humans with live VACV against smallpox stopped soon after its eradication and 
since the waning herd immunity in the human population, other OPXV infections such as 
MPXV, CPXV or VACV in humans increased.  
Worldwide MPXV and CPXV are sporadically occuring and humans are more often affected, 
especially by MPXV in Africa and CPXV in Europe, respectively (Bourquain et al., 2013; 
McCollum et al., 2015; Reed, 2004; Vorou et al., 2008). 
MPXV-infection naturally occurs in Africa and particularly in the Democratic Republic of the 
Congo (DRC). MPXV is a zoonotic OPXV and an emerging infectious disease that causes 
serious smallpox-like illness in humans (Figure 1-5) (Rimoin et al., 2010; Thomassen et al., 
2013). MPXV is endemic to West- and Central Africa since the 1970s (Nalca et al., 2005; 
Orba et al., 2015) and has been considered to be the most important poxvirus that affects hu-
man health since the global eradication of smallpox in 1977 (Breman, 2000). During the last 
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30 years, human MPXV incidents have dramatically inreased in the DRC (Johnston et al., 
2015). A comparison of active surveillance data from 1980s and 2006-07 suggest a 20-fold 
increase in human monkeypox incidents in the central DRC (Rimoin et al., 2010).  
 
Figure 1–5: 7-year-old female child with the typical clinical presentation of human monkeypox, Sankuru District, 
Democratic Republic of Congo (Rimoin et al., 2010). Human monkeypox incidences increase 30 years after smallpox vac-
cination ceased in the Democratic Republic of Congo.  
 
Another MPXV case shows that it was even able to spread to another continent. In 2003 a 
mild form of MPXV infected 69 people in the United States of America. Rodents and infected 
prairie dogs were imported from Ghana and transmitted the disease to humans. It can be as-
sumed that vaccines against poxviruses also protect against MPXV and therefore the devel-
opment of new and safer vaccines becomes more important (Hammarlund et al., 2005).  
VACV occurs worldwide and infects a variety of host species such as cattle, rabbits, pigs, 
humans and buffalos (Bhanuprakash et al., 2010; Essbauer et al., 2004; Singh et al., 2008; 
Singh et al., 2007; Singh et al., 2006; Yadav et al., 2010). Since 1960 innumerous VACV 
outbreaks have been documented in different regions of Brazil. Also, reports of VACV spe-
cies transmitted to humans via cows or Indian buffaloes were reported in Brasil and India 
(Goyal et al., 2013; Pereira Oliveira et al., 2014). 
The number of reported VACV infections in humans are on the rise in South America and 
India, but it is not clear whether VACV infections are actually increasing or if the reports 
have just recently begun.  
Camelpox is a disease restricted to camels and its causative agent is the OPXV camelpox vi-
rus (CMLV). Except for Australia, the disease is enzootic in almost every region, where cam-
els are reared and naturally occurs on the African and Asian continents (Balamurugan et al., 
2013). Although it only rarely infects humans, Jezek and colleagues have shown that camel-
pox can be transmitted to humans and arthropods (Jezek et al., 1983). Therefore, it also be-
longs to the zoonotic diseases. The emergence of zoonotic camelpox outbreaks in India is a 
serious public health concern (Bera et al., 2011). Due to increasing reports of camelpox cases 
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and outbreaks in camels, Camelpox was considered an emerging public health problem 
(Balamurugan et al., 2013). 
Furthermore, the threat of new emerging zoonotic poxvirus species exists (Shchelkunov, 
2013). 
1.6.2 Cowpox viruses 
CPXV which is closely related to VACV is indigenous to Great Britain, and both the tradi-
tional cowpox virus strain and slightly different strains of the so-called `cowpox-like` viruses 
can be found in Europe (Baxby et al., 1979; Carroll et al., 2011; Fenner et al., 1988a) and ad-
jacent Russian states. Phylogenetic analyzes have shown that the CPXV isolates form two 
major monophyletic clades (cowpox-like and vaccinia-like) (Carroll et al., 2011). It can fur-
ther be split into five distinct monophyletic clusters. All German CPXV isolates are in the 
cowpox-like clade (group 1-4), a sister to camelpox virus (CMLV), taterapox virus (TATV) 
and variola virus (VARV), whereas the vaccinia-like clade (group 5) is a sister to MPXV 
clade. 
Of all the OPXVs, CPXV has the broadest host range. Contradictory to its name, CPXV rare-
ly occurs in cattle and it is doubtful if cowpox was ever common in cattle (Baxby, 1977). 
Human cowpox is uncommon, but more commonly reported than bovine CPXV cases (Baxby 
and Bennett, 1990). CPXV maintains a reservoir in wild rodents and is endemic in bank voles 
(Clethrionomys glareolus) and wood mice (Apodemus sylvaticus) in Great Britain (Chantrey 
et al., 1999). CPXV has also been reported to infect a variety of animals in European zoos, 
e.g. elephants that also resulted in human infections (Kurth et al., 2008). Although several 
carriers have been reported, it is mainly transmitted by cats and pet rats (Begon et al., 1999; 
Bonnekoh et al., 2008). Most reports of human cowpox infections can be traced back to con-
tact with infected cats (Casemore et al., 1987; Pether et al., 1986; Willemse and Egberink, 
1985). However, CPXV infections have also been reported in monkeys. A fatal cowpox virus 
infection in the cotton-top tamarins (Saguinus oedipus) a New World monkey, have been de-
tected in Germany (Figure 1-6) (Kalthoff et al., 2014). A low pathogenicity was found when 
the isolate was characterized in a Wistar rat model.  
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Figure 1–6: Cowpox virus-infected cotton-top tamarin (Kalthoff et al., 2014). The New World monkey shows the typical 
skin lesions on the face.  
 
Other CPXV infections in Germany and the Netherlands have also been reported in New 
World monkeys and macaques (Martina et al., 2006; Matz-Rensing et al., 2006) and a distinct 
and new CPXV strain, named calpox virus, was found in 2002 in common CM (CM, 
Callithrix jacchus) (Matz-Rensing et al., 2006) (1.2.4 Calpox virus). 
Because of its broad host range and genetic features, CPXV is assumed as a candidate and 
threat for new emerging zoonotic poxvirus species (Essbauer et al., 2010). Of all OPXV, 
CPXV has the largest genetic repertoire (Gubser et al., 2004). This underlines CPXV as an 
emerging hazard.  
1.7 Immune response 
The severeness of the disease, clearance of the virus and protection against (re-)infection is 
determined by the immune responses of the host. Humoral as well as the cellular immune re-
sponses play an important role in OPXV infections (Smith and Kotwal, 2002). The immune 
system is differentiated into the innate and adaptive immune system. The innate immune sys-
tem is fast and unspecific, whilst the adaptive immune system takes more time, but is specific 
and has memory.  
Innate immune response to poxvirus infection  
Following infection the immune system is activated, whereas the innate immune response 
constitutes the first line of defense against invading pathogens. At first, poxvirus infection 
induces the production of interferons as well as the activation of the complement system, nat-
ural killer (NK) cells and inflammatory cells (Smith and Kotwal, 2002). Monocytes and neu-
trophils are the most important parts in early innate immunity against poxvirus infection, be-
cause of their positive poxvirus antigen staining (Song et al., 2013b). Besides the cellular re-
sponse, the humoral-mediated immunity (e.g. complement system) is of importance. The 
complement system has the ability to recognize a large panel of viruses as well as virus-
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infected cells, and trigger effector pathways (Agrawal et al., 2017). Interferons can e.g. kill 
the virus directly. The complement system marks the infected cells (opsonization) and conse-
quently phagocytes can detect and kill them. 
Adaptive immune response to poxvirus infections – Cellular immune response  
The cellular immune response and the implied poxvirus-specific cytotoxic T-lymphocytes 
(CTLs) (CD8+) are thought to play an important role in controlling poxvirus infections (Smith 
and Kotwal, 2002). CD8+ T cells detect early expressed proteins whilst CD4+ T cells, like an-
tibodies, detect late expressed proteins (Sette et al., 2009). Experiments in knockout mice and 
macaques have shown that T cell response plays a more important role in the primary, acute 
infection than in the late phase (Gordon et al., 2011; Xu et al., 2004b). In addition, the devel-
opment of severe vaccination complications, such as a progressive vaccinia in humans with an 
impaired cellular immunity, leads to the assumption that T cells play an important role in pri-
mary infections (Bray and Wright, 2003).  
Poxviruses have a variety of immune evasion mechanisms to create an environment where the 
virus can not only survive but also replicate (Seet et al., 2003). There are two ways for the 
virus to interact with the host: the poorly understood inhibition of the host macromolecular 
synthesis by the virus and the defense of the virus against host antiviral mechanisms.  
Several viral defense proteins are expressed by OPXVs in order to modulate and combat the 
host´s antiviral response. They encode for proteins that induce the synthesis of steroids, inhib-
it the function of interferons, intercept interleukins and capture chemokines, inflammatory 
cytokines and antibodies. They also encode proteins that can interfere with the function of 
apoptosis. The activity of cytotoxic T-lymphocytes and NK cells can be inhibited and coun-
teract the complement system (Alcami and Koszinowski, 2000; Haga and Bowie, 2005; 
Kotwal et al., 1990; Lustig et al., 2004; McFadden and Murphy, 2000; Perdiguero and 
Esteban, 2009; Taylor and Barry, 2006). Poxviruses can also shut down the synthesis of the 
cell´s own products while keeping up their own protein synthesis (Langland et al., 2006). The 
immunomodulatory proteins are not shared across all OPXV species and each OPXV strain 
has its own combination of proteins. The deletion of some genes leads to the attenuation or an 
altered disease (Johnston and McFadden, 2004). Although each virus has its own variety of 
immunomodulatory proteins, some of the immunomodulatory viral genes are similar to cellu-
lar genes of the host. It is assumed that these genes were integrated into the viral genome via 
horizontal gene transfer through coevolution with the host.  
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Poxviruses can harm the host through replication in the tissue, cause immunomodulation and 
furthermore, a strong reaction of the immune system can be triggered: an exessive inflamma-
tory response (cytokine storm), which is discussed as the reason for many symptoms and for 
the cause of death of severe VARV-infections (Stanford et al., 2007). For instance, it has been 
reported that an intensive early inflammatory response by the host is thought to damage the 
host inadvertetly to such an extent that the individuum becomes ill or dies after the infection 
(Stanford et al., 2007). 
Adaptive immune response to poxvirus infections – Humoral immune response 
A human orthopoxvirus infection can elicit a complex B cell immune response that is reactive 
to antigens from diverse OPXV species (Gilchuk et al., 2016a; Gilchuk et al., 2016b).  
Neutralising antibodies (nAbs) - as part of the humoral arm of the adaptive immune response 
- are most important because they bind directly to the poxvirus, cause aggregation and also 
prevent the adsorption and intake into the cell. They also enable phagocytosis and antibody-
dependent cell-mediated cytotoxycity through their function at opsonisation (process of mark-
ing the virus and ingestion or elimination by phagocytosis) (Edghill-Smith et al., 2005).  
Results from animal studies indicated that neutralizing antibodies are essential and sufficient 
for an immunological protection (Edghill-Smith et al., 2005). Antibodies against specific 
OPXV-species have a wide cross-reactivity among the whole virus genus and depending on 
the antigenic relationship, they also have a wide cross-reactivity among the genus (Gilchuk et 
al., 2016a). NAbs are directed against gene products (Demkowicz et al., 1992) as well as dif-
ferent virus particles such as intracellular mature virions and enveloped virions generated dur-
ing the infection (Amanna et al., 2006; Demkowicz et al., 1992; Jones-Trower et al., 2005; 
Viner and Isaacs, 2005). 
In patients that suffered from non-hemorrhagic smallpox disease nAbs were detectable by day 
six of illness (about 18 days after infection). Titres increased over the course of the disease 
(Downie et al., 1969). A delayed, reduced or even missing antibody response was found in 
patients with a hemorrhagic-type of disease (Fenner et al., 1988c). NAbs were detected from 
day 12-14 and until day 25-30 in smallpox (Frey et al., 2003; McClain et al., 1997). Neutral-
izing antibodies are generated after 12-14 days when immunized with VACV and the highest 
titres are measured about two weeks later. After a re-vaccination the titres of nAbs increase 
already after seven days (Moss, 2011). Because of the eradication of VARV, it is difficult to 
calculate the protective effect of an immunization. Nevertheless, the antibody levels detected 
by ELISA or neutralization of VACV can persist for many decades as in memory B cells and 
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CD4+ and CD8+ T cells (Crotty et al., 2003; el-Ad et al., 1990; Frey et al., 2003; Hammarlund 
et al., 2003; Taub et al., 2008). Studies have shown that in 90 % of the observed individuals, a 
stable humoral immune response was detected up to 75 years after the immunization (Crotty 
et al., 2003; Hammarlund et al., 2003). It has also been observed that antibody titres were at a 
comparable level in immunized individuals and non-immunized individuals that survived 
VARV infections (Hammarlund et al., 2010; Taub et al., 2008).  
Studies that induced the protection of macaques against monkeypox have suggested that nAbs 
are sufficient for protection (Edghill-Smith et al., 2005). Different proteins of the inner and 
outer membrane of the virus have been identified as neutralising determinants (Moss, 2011). 
It is supposed that nAbs against both enveloped viruses well as mature viruses are necessary 
for the protection against OPXV infections (Bray and Buller, 2004; Fogg et al., 2004; Heraud 
et al., 2006; Hooper et al., 2000; Lustig et al., 2005; Viner and Isaacs, 2005). The inoculation 
with VACV elicits nAbs against major antigens on the extracellular enveloped virus and the 
intracellular mature virion and confer protection against smallpox (Davies et al., 2005; Davies 
et al., 2007; Lawrence et al., 2007; Putz et al., 2006). The neutralising determinants A27, D8 
and H3 are important for binding of the virus to the host cell on the inner membrane (Chung 
et al., 1998b; Hsiao et al., 1999). One protective antibody that binds to the heparan sulfate 
binding site of A27 was identified (Kaever et al., 2016). A17, L1 and A28 are involved in vi-
rus-cell membrane fusion (Nelson et al., 2008; Wallengren et al., 2001; Wolffe et al., 1995). 
A protective antibody response is induced by the protein B5 and A33 of the outer membrane, 
but only binding of antibodies to B5 has a neutralizing effect (Galmiche et al., 1999; Putz et 
al., 2006). The effect of neutralization of anti-B5-antibodies can be enhanced by the isotype-
specific complement system (Benhnia et al., 2009). Antibodies against A33 also function in 
association with the complement system. By destroying the outer membrane of the virus par-
ticle, the inner membrane is set free and binding of anti-mature virus-antibodies is enabled 
(Lustig et al., 2004).  
1.8 Immune correlates of smallpox virus protection 
The smallpox eradication occurred prior to modern techniques in virology and immunology 
(Moss, 2011) and some live vaccines of VACV strain caused generalized VACV infections in 
patiens with severe T cell abnormalies, but not in others with an immunodeficiency (agam-
maglobulinemia). Therefore, evidence for the importance of a cell-mediated immunity in con-
trolling the primary infection exists. Increased levels of cytokines correlated with low-grade 
fever, headache, myalgia, fatigue and regional lymphadenopathy after VACV infection. NAb 
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titres to VACV correlated with the “vaccine take” (i.e. development of pustules) in naive in-
dividuals (Mc et al., 1958). In individuals who were already vaccinated and re-vaccinated cor-
related the successful vaccination inversely with the pre-existing nAb levels (Orr et al., 2004). 
Studies have shown that the route of vaccination is important. A higher nAb response was 
induced by percutaneous vaccination than with intradermal or intramuscular vaccination 
(McClain et al., 1997). Children developed 83 % nAbs with percutaneous and 23 % nAbs 
with subcutaneous vaccination (Galasso et al., 1977). Some studies have also found that 
smallpox vaccination induced CD4+ and CD8+ T cells (Ennis et al., 2002; Rock et al., 2005).  
1.9 Prevention (vaccine) and treatment of OPXV infection 
1.9.1 Vaccinia virus (VACV) 
The origin of the vaccinia virus (VACV) remains unknown due to the lack of recording the 
repeatedly cultivating and passaging in research (Moss and Henderson, 1999). VACV is 
closely related to the cowpox virus (CPXV).  
The disease pattern of a VACV infection closely resembles that of the local human CPXV 
infections (Paran and Sutter, 2009). Naïve individuals inoculated with VACV through vac-
cination or by accident, develop local infections of the eye or skin. However, VACV infec-
tions of at-risk individuals that are for example immunocompromised can lead to a severe dis-
ease or fatalities.  
Vaccination with VACV comes with several advantages. Reports have shown that vaccination 
with VACV induces an antibody response that is developed much faster than after a natural 
VARV infection. Antibodies were detected ten days after primary vaccination and four to 
seven days after the second vaccination (Mc et al., 1958). The titres of neutralizing antibodies 
(nAbs) also increased as a reaction to the re-vaccination.  
VACV strains have been used to establish more virulent laboratory viruses like VACV West-
ern Reserve (WR) or VACV International Health Department-J (IHD-J) but have also been 
used for new vaccines. Various VACV strains were used as smallpox vaccines (McCollum 
and Damon, 2014; Verardi et al., 2012). The first generation smallpox vaccines were pro-
duced and used during the worldwide eradication program. Different VACV strains such as 
Lister-Elstree (Lister Institute, Elstree, England; propagated by the National Public Health 
Institute, Netherlands) (Fenner et al., 1988a), the New York City Board of Health strain 
(NYCBH e.g. Dryvax) (propagated by Wyeth Laboratories, USA) (Moss and Henderson, 
1999), the Tiantan strain (Temple of Heaven) that was used in Asia (Zhang et al., 2013) and 
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the EM-63 strain (NYCBOH) that was used in Russia (Fenner et al., 1988a) belongs to these 
first-generation smallpox vaccines. Because of the serious side effects, such as eczema vac-
cinatum, progressive vaccinia, generalized vaccinia, postvaccinal encephalopathy and en-
cephalitis in some individuals, the production and licensing of these vaccines stopped in the 
late 1980´s. 
The same smallpox vaccine strains employed for the manufacturing of first-generation vac-
cines were used for second-generation smallpox vaccines. These include the live attenuated 
smallpox vaccine ACAM2000 (NYCBOH; licensed in August 2007 by the FDA, USA) (Frey 
et al., 2007) or VACV LE-BN (Lister-Elstree strain produced by Bavarian Nordic, Mar-
tinsried, Germany) (Stittelaar et al., 2006; Uebler, 2008) produced in embryonic chicken fi-
broblast cells. Also, clonal virus variants plaque purified from traditional vaccine stocks were 
used. The second-generation vaccine strains were in vitro serially passaged in high numbers 
with sterile cultivation in cell culture with the purpose to increase attenuation and safety. 
Third-generation smallpox vaccines are even more attenuated vaccine strains that were devel-
oped by further passage in cell culture or animals as safer vaccines at the end of the eradica-
tion. A safer third-generation smallpox vaccine is for example the replication competent 
LC16m8 (licensed in 1975, Japan) (Kennedy et al., 2011) that was developed from Lister 
strain. It was passaged in primary rabbit kidney cells and has a deletion in B5R. Another 
third-generation vaccine is the replication-deficient MVA strain Imvanex (also designated 
Imvamune or MVA-BN, licensed in July 2013 by the European Commission) (Frey et al., 
2007; Garza et al., 2009) that was passaged on chicken embryo fibroblasts and its replication 
competency is limited in mammalian cell lines. Modified vaccinia virus Tiantan (MVTT) is a 
third-generation smallpox vaccine that was developed from the Asian Tiantan strain by re-
moving the hemagglutinin gene. Its mucosal application protected mice against the VACV 
Western Reserve (WR) strain (Yu et al., 2010). 
Fourth-generation smallpox vaccines represent non-infectious subunit vaccines that are com-
posed of few viral antigens or proteins  (Paran and Sutter, 2009). The proteins are expressed 
from DNA, recombinant viruses or replicons. The most frequently used proteins that were 
detected and used in combination are B5, L1, A33 and A27 (Aldaz-Carroll et al., 2005; 
Aldaz-Carroll et al., 2007; Fogg et al., 2004; Fogg et al., 2007; Golovkin et al., 2007; Heraud 
et al., 2006; Hooper et al., 2000; Hooper et al., 2004; Lustig et al., 2005; Xiao et al., 2007). 
They were effective in several animal models (e.g. non-human primates infected with MPXV) 
(Heraud et al., 2006). Fourth generation vaccines are for example a DNA vaccine that com-
prises a combination of IMV and EEV genes and core antigen and gave protection in rhesus 
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macaques against monkeypox challenge (Hirao et al., 2011). Another experimental vaccine 
consisted of a combination of IMV and EEV proteins and also provided protection in animal 
models (Buchman et al., 2010). A multi T cell epitope vaccine based on conserved VACV 
and VARV sequences is another fourth generation vaccine (Moise et al., 2011). It gave pro-
tection in a mouse model. 
1.9.2 Modified vaccinia virus Ankara (MVA) 
The highly attenuated strain modified vaccinia virus Ankara (MVA) belongs to the third gen-
eration of vaccinia strains and was developed in the 1960s. It was attenuated by more than 
570 passages in primary chicken embryo fibroblasts (CEFs). In comparison to the original 
strain, it contains six deletions that come with a 15 % loss of genetic information (Antoine et 
al., 1998; Meyer et al., 1991). The high number of MVA passaging led to a strongly reduced 
replication competency on most mammalian cell lines and the virus only replicated in CEFs 
(Earl et al., 2004; Meyer et al., 1991). MVA was proven to be avirulent (Mayr et al., 1978). 
Several studies have confirmed the good tolerability of MVA and in the 1970s over 120,000 
humans received primary vaccination in Germany (Hochstein-Mintzel et al., 1975; Mayr and 
Danner, 1978; Mayr and Danner, 1979). The ability of MVA to protect humans against 
VARV infections was not tested due to smallpox´ eradication (Frey et al., 2007; Garza et al., 
2009; Kennedy and Greenberg, 2009; Vollmar et al., 2006; von Krempelhuber et al., 2010). 
Studies later confirmed the good compatibility even in immunosuppressed individuals in dif-
ferent animal models (Cosma et al., 2003; Earl et al., 2004; Meyer et al., 1991; Stittelaar et 
al., 2001). MVA was also tested in an atopic mouse model and protective immunity against a 
lethal poxvirus challenge with VACV WR was proven (Knitlova et al., 2014). 
The smallpox vaccine Imvamune (also Imvanex or MVA-Bavarian Nordic (BN) is a deriva-
tive of MVA. It differs to all other MVA strains in that it has undergone six rounds of plaque 
purification and is based on a single clone from the passage MVA-597 that was derived from 
MVA-584 (i.e. 584th passage in CEF cells) and could induce an immune response in several 
studies. In several phase-II studies, Imvamune was tested to be safe in atopic and immuno-
suppressed individuals (Frey et al., 2007; Frey et al., 2013; Greenberg et al., 2013; von 
Krempelhuber et al., 2010; Walsh et al., 2013). However, Imvamune (also Imvanex or MVA 
BN) was tested in the calpox virus/marmoset model and did not induce protection (Dr. Stahl-
Hennig and Dr. Mätz-Rensing, personal communication). Its suitability as smallpox vaccine is 
yet unclear. 
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MVA (Imvamune and recombinant vaccinia virus) also gave solid protection in mice and ma-
caques against MPXV (Hatch et al., 2013; Zielinski et al., 2010). 
1.9.3 Modified vaccinia virus Tiantan (MVTT) 
During the smallpox eradication campaign in 1960-1970s, vaccinia Tian Tan (VTT) was the 
most extensively used smallpox vaccine in China for millions of people beween 1920 and 
1980 (Fang et al., 2005). The immunogenicity is good and the complications in humans are 
relatively mild. VTT is less virulent than VACV WR, but is still neurovirulent in mice and 
causes over 25 % body weight loss after an intranasal inoculation. Therefore, the use as a non-
invasive vaccine is restricted (Fang et al., 2005). The results showed that VTT should not be 
applied mucosally in humans and the need for further attenuation has been demonstrated 
(Fang et al., 2005). The virulence of VTT is of significant risk to children and immunocom-
promised adults (e.g. with HIV/AIDS, cancer, leukemia, lymphoma, multiple myeloma, etc) 
(Yu et al., 2010). As VTT was further attenuated through the deletion of inter alia, the he-
magglutinin gene, leading to the generation of the modified vaccinia virus Tiantan (MVTT) 
(Yu et al., 2010; Zhu et al., 2007). The weight loss and neurovirulence in mice after intranasal 
inoculation was not observed in MVTT. Unlike VTT, MVTT did not replicate in mouse brain 
and was also safe in immunideficient mice (Yu et al., 2010). Protection was induced after an 
infection with VACV WR after one-time intranasal and intramuscular vaccination with 
MVTT in a mouse model (Yu et al., 2010). So far it has only been tested in the mouse model 
and therefore represents a promising approach to test the vaccine efficacy in a primate model 
(Huang et al., 2009; Zhu et al., 2007).  
The needle-free mucosal application of MVTT was applied in the present studies (peroral and 
intranasal) and presents an easy alternative to intramuscular inoculation. It would also facili-
tate vaccination especially in developing countries (Meseda et al., 2005).  
1.9.4 Treatment of OPXV infections 
OPXV infections can be treated with ST-246, which is a specific inhibitor of EEV and pro-
vided 100 % protection against a lethal infection of different OPXVs in different animal mod-
els (Grosenbach et al 2008, Quenelle et al 2007, Quenelle et al 2007, Yang et al 2005). It was 
also efficiently used in the treatment of a two-year old with a severe eczema vaccinatum 
(CDC 2008). Although therapeutics for OPXV infections do exist (e.g. ST-246) cidofovir is 
the only approved treatment of OPXV infection. Cidofovir is a nucleoside analog and has 
been used for the treatment of Cytomegalovirus infections (De Clercq 2002). There are sever-
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al compounds for OPXVs existent that were studied in cell culture or in animal models (Har-
rison et al 2004, Smee et al 2002, Smee and Sidwell 2003, Kern 2003, Byrd et al 2004, 
Damaso and Moussatche 1998, Quenelle et al 2006, Reis et al 2006, Su et al 2005). Other an-
tiviral therapies like passive immunotherapy with anti-VACV immune serum (Berhanu et al 
2008), siRNAs against potential OPXVs (Dave et al 2006) or DNA aptamers with antiviral 
activity (Nitsche et al 2007) were tested. 
1.10 The common marmoset – Callithrix jacchus  
The common marmoset (CM, Callithrix jacchus) belongs to the Callitrichidae family and is a 
New World monkey. They are originally found in the northeastern coast of Brazil, in the 
states of Piaui, Paraiba, Ceará, Rio Grande do Norte, Pernambuco, Agolas and Bahia. The 
monkeys are brown, grey and yellow and have white ear tufts. They also have a long, banded 
tail (Zhang et al., 1996). The males and females have a small size of 16 to 21 cm and a weight 
of 300 to 350 g. Characteristic for this species are the claw-like nails (tegulaes) on their fin-
gers except for their halluxes (big toes). This characteristic is necessary for their diet and ar-
boreal lifestyle and is unique for this group. They live in small groups or in family organiza-
tions of about nine to 15 members with a flexible social structure and pairing system (Digby 
and Barreto, 1993; Rowe et al., 1996). Whilst most matings are monogamous, polygamy and 
polyandry have been observed in CM. CM commonly give birth to non-identical twins (Fig-
ure 1-7).  
 
Figure 1–7: Two adult Callithix jacchus individuals with twins (www.dpz.eu, 2017). Adults showing the typical white ear 
tufts. Photo by Manfred Eberle. 
 
The CM is exudativore-insectivore and feeds on plant exudates like gum, sap, latex and resin. 
They also feed on fruits, seeds, flowers, fungi, nectar, snails, lizards, tree frogs, bird eggs, 
nestlings and infant mammals. In the wild, CM can reach the age of 12 years (Rowe et al., 
1996). New World monkeys are increasingly used in biomedical research (Abbott et al., 
2003).  
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We used the CM as in the non-human primate model because compared to Old World mon-
keys it is more convenient and has certain advantages, such as lower breeding and animal 
husbandry costs and an easier handling. The CM is also immunological related to humans but 
natural chimerism occurs (bone marrow chimerism) (Uccelli et al., 1997). CMs are used in 
several animal models for human diseases e.g. infectious diseases like anthrax (Carrion et al., 
2007; Lever et al., 2008; Woollard et al., 2008), multiple sclerosis (Genain and Hauser, 1997; 
t Hart et al., 2000). Parkinson´s disease (Eslamboli, 2005; van Vliet et al., 2008), Alzheimer´s 
disease, stroke (Marshall and Ridley, 2003) and immunotoxicological studies (Neubert et al., 
1995) or spinal cord injury. Therefore, the CM represents a suitable model for studying vac-
cines and therapeutics. 
1.11 Animal models – a non-human primate model of OPXV infection 
Due to the fear of bioterrorism, and the increasing cases of MPXV and CPXV infections, re-
search for therapeutics and prevention of OPXV infection is ongoing e.g. DNA vaccines 
(Hirao et al., 2011; Hooper et al., 2003; Pulford et al., 2004; Sakhatskyy et al., 2008), protein 
vaccines (Buchman et al., 2010; Davies et al., 2005; Fogg et al., 2004), T cell epitope vac-
cines (Moise et al., 2011; Puissant and Combadiere, 2006; Sakhatskyy et al., 2006; Verardi et 
al., 2012).  
Beside mouse models, two well established NHP models exists: MPXV infection of cyno-
molgus macaques (Macaca fascicularis) (Hooper et al., 2004) and rhesus macaques (Macaca 
mulatta) as well as VARV-infected infection of cynomolgus macaques (Jahrling et al., 2004). 
So far, the best model for human smallpox is the MPXV-infected cynomolgus macaque mod-
el (Mucker et al., 2013). Because of the challenging handling with VARV (BSL-4), this mod-
el can only be used in BSL-4 laboratories. Howerver, working with MPXV (BSL-3) is lim-
ited. Compared to other, smaller animals, the macaques used in these studies are relatively 
expensive to keep. Also, a very high infectious dose via intravenous inoculation is necessary. 
Because of their close relation to humans these primates are the gold standard for OPXV 
models and for the testing of safer vaccines and antiviral drugs (Jordan and Hruby, 2006).  
The CPXVs, calpox virus, was accidentally discovered (1.2.5 Calpox virus) and represents a 
suitable virus to infect common CM (CM, Callithrix jacchus). It induces a reproducibly lethal 
and systemic disease that leads to cutaneous pox lesions (Kramski et al., 2010). CPXVs have 
been used in other non-human primate (NHP) models (Johnson et al., 2015; Johnson et al., 
2011) and the advantages and disadvantages of the here used calpox virus/marmoset model 
have been discussed in chapter 4.3.1 (4.3.1 Advantages and disadvantages of the calpox vi-
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rus/marmoset model). Schmitt and colleagues reviewed the different models of OPXV infec-
tions (see also Schmitt et al., 2014; Kramski et al., 2010). Mucker and colleagues successfully 
tested the susceptibility of CM to MPXV (Mucker et al., 2015). The CM were susceptible to 
MPXV but did not develop the classical pox-lesions (enanthema and exanthema) in contrast 
to the calpox virus where papulovesicular lesions were observed (Mätz-Rensing et al., 2012). 
Some of the main advantages of the here used calpox virus/marmoset model to other NHP 
models are their ability to work under BSL-2 conditions, the low infectious dose of calpox 
virus and the intranasal application route resembling the natural transmission route of human 
poxvirus infections. Furthermore, the disease in the calpox virus/marmoset model is compa-
rable to human smallpox infections. Therefore, this model was used to test the efficacy of two 
attenuated smallpox vaccines MVA and MVTT with different vaccination strategies. 
1.12 Aims and Scope 
The aim of the study was to give insight into the early pathogenesis of CPVX infection in the 
calpox virus/marmoset model. The study aimed to determine the portal of viral entry, analyze 
the early dissemination as well as the pathological sequelae of infection in a time-course 
pathogenesis study. 
The purpose of this study was also to analyze the immune response of the different vaccines 
and vaccination routes and the identification of protective immune correlates. 
This work is therefore composed of two parts (i) a pathogenesis study and (ii) vaccine studies. 
1.12.1 Pathogenesis study 
Earlier studies conducted with calpox virus primarily focused on the final stage of disease 
with characteristic pox-like lesions detected in skin, mucous membranes, lymph nodes, liver 
and spleen (Mätz-Rensing et al., 2012). The main purpose of this study was the further char-
acterization of calpox virus infection (1.2.4 Calpox virus) through the investigation of the ear-
ly phase of the disease for clarification of the pathogenesis since several aspects are still un-
clear (e.g. mode of transmission, reason of death).  
Therefore, a time-course pathogenesis study was conducted. Two different doses of calpox 
virus were used for intranasal inoculation of 15 CM. A group of three animals was infected 
with a high dose (3.5 x 105 pfu) of calpox virus and euthanized 3 dpi. Another group of 
twelve animals was infected with a 42-fold lower dose, with 10 median monkey infectious 
doses (MID50) 8.3 x 10
3 pfu of calpox virus. Each group consisted of three animals that were 
euthanized 5, 7, 10 and 12 days post inoculation. Serial necropsy was performed at predefined 
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time points to collect different samples and detect different parameters in organs and blood 
using virological analyses (2.1.5 Pathogenesis study). 
1.12.2 Vaccination studies 
Two vaccination studies were conducted to evaluate the protective effect of differently atten-
uated vaccines after intranasal inoculation of a lethal dose of calpox virus in common CM 
(CM). Kramski and colleagues have already reported on the calpox virus/marmoset model as 
a suitable animal model for the evaluation of new vaccination strategies and antiviral thera-
pies (Kramski et al., 2010).  
Vaccination experiments have been conducted using VACV LE BN, MVA and MVTT. 
The aim of this study was to analyze the cellular and humoral immune response of the differ-
ent vaccines and vaccination routes and to identify immune correlates of protection retrospec-
tively. 
Studies at the German Primate Center (Deutsches Primatenzentrum GmbH, DPZ) have shown 
that intradermal VACV LE BN vaccination protected the four tested CM against a calpox vi-
rus challenge after a 10-week, but not after a 4-week waiting period (unpublished data; Dr. 
Stahl-Hennig and Dr. Mätz-Rensing, personal communication). VACV LE BN is the “gold 
standard” for vaccine efficacy in this animal model.  
An early passage of MVA (MVA P568) was used in this study because the third generation 
smallpox vaccine Imvamune (also Imvanex or MVA BN) (Verardi et al., 2012) unexpectedly 
protected only two of four animals after a 4-week waiting period and did not induce protec-
tion after a 10-week waiting period in the calpox virus/marmoset model (Dr. Stahl-Hennig 
and Dr. Mätz-Rensing, personal communication) (1.9.2 Modified vaccinia virus Ankara 
(MVA)). Vaccination was done intramusculary (i.m.). While MVA provided solid protection 
in mouse and macaque models against MPXV infection, protection in the calpox vi-
rus/marmoset model is questionable. Here, CM were vaccinated intramuscularly with the ear-
ly passage of MVA (MVA P568) and challenged with calpox virus after a four and 10-week 
waiting period. 
Another attenuated vaccine used here was a MVTT, an attenuated variant of the vaccinia virus 
Tiantan that was used in China for vaccination against smallpox (Huang et al., 2009) (1.9.3 
Modified vaccinia virus Tiantan (MVTT)). MVTT is replication competent in many mamma-
lian cell lines but did not replicate in the mouse brain (Yu et al., 2010). Intranasal immuniza-
tion with MVTT protected mice from VACV WR (Knitlova et al., 2014). It is more attenuat-
ed than VACV LE BN, but less than MVA which did not provide solid protection of the CM. 
  39 
In this study, CM were vaccinated with MVTT and challenged with calpox virus. Intranasally 
vaccinated macaques were challenged after a four and 10-week waiting period while perorally 
vaccinated macaques were challenged after a 10-week waiting period.  
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2 MATERIAL AND METHODS 
2.1 Material 
The in this study used materials are listed in the Tables 2-1 – Table 2-6. 
Table 2-1: General laboratory equipments and consumables.  
Name  Manufacturer  
-20 °C freezer 
-20 °C freezer, 4 °C fridge 
-80 °C freezer ultralow u57085 
4 °C fridge eco energysaver  
5-Plex Rotor-Gene Q  
96-well MaxiSorp Nunc-Immuno Plates  
Agar dishes (100 mm)  
Agilent DNA microarray scanner 
Centrifugation tube (15 ml, 50 ml) 
Centrifuge 3 s-r 
Centrifuge 5415R 
Centrifuge 5415R and 5424 
Centrifuge 5424 
Centrifuge sorvall discovery 90 with rotor tft 80.4 
Cover slips 
Cryotubes (1.8 ml) NUNC 
DNA-ExitusPlus 
Exsiccator, "Space Saver" F42025 
FACS tubes 
fine scale (0.1 mg-200 g) 
Flasks (750 mm2, 1750 mm2)  
Freezing device “mr. Frosty” 
Gel chamber 
Gel Documentation System 
Glascontainers 
Harmony MIXER UZUSIO VTX-3000L  
Hera freeze (-70 °C) fridge 
Heraeus Thermo Scientific, Multifuge 3S-R 
Hybridization System HybriWell HBW6L-2L 
Ice mashine 
Incubation chamber, Rotilabo-Dying chamber Stain Tray 
Incubator BBD6220 
Incubator Heracell 240i 
Incubator series 5400 
Inverted microscope, Axiovert 25 
L-60 Ultraspeed Centrifuge 
LSR II (multi-laser flow cytometer) 
magnetic stirrer MR 2002 
Multi well plates (12-well, 351143; 96-well, 353072) 
Grundig 
Liebherr 
Labotect 
Privileg  
Qiagen 
Thermo Scientific 
Sarstedt 
Agilent Technologies 
Greiner Bio-One 
Heraeus 
Eppendorf 
Eppendorf 
Eppendorf 
ThermoScientific 
ThermoScientific  
ThermoScientific  
AppliChem 
KNFLAB Neuberger 
GmBH 
Sarstedt 
Sartorius 
Sarstedt 
Nalgene 
BIO-RAD 
INTAS 
Schott 
LLG, Lab Logistic Group  
Heraeus 
Thermo Scientific 
Grace Bio-Labs 
Scotsman 
Carl Roth 
Heraeus 
ThermoScientific 
NAPCO 
Carl Zeiss GmbH 
Beckmann Coulter 
BD Biosciences 
Heidolph 
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Multichannel micropipette 
NanoDrop, ND-1000 Spectrophotometer  
Neubauer counting chamber  
Nitrogen tank 
Nitrogen tank -140 °C  
Non tissue culture treated plates (96-well) 
Öko -20 °C 
Parafilm m 
Pipette filter tips (10 µl, 100 µl, 200 µl, 1000 µl) 
Pipette tips rnase/dnase free (10 µl, 100 µl, 200 µl, 1000 µl) 
Pipettes (1-10 µl, 10-100 µl, 2-200 µl, 100-1000 µl) 
Polymax 1040 
PowerPac Basic power suppy 
Reaction tube (0.2 ml, 0.5 ml, 1.5 ml, 2 ml) 
Reaction tube (1.5 ml, 2 ml) 
Rotilabo-Dying chamber and slide holder 
Safe Lock Tubes 2.0 ml 
scale ED4202S-CW (0.01-4200 g) 
Serological pipette (2 ml, 5 ml, 10 ml, 25 ml)  
SONOPLUS ultrasound-homogenizer 
Sorvall Combi Plus Ultraspeed Centrifuge, DuPont 
Sorvall® RC-5B Refrigerated Superspeed Centrifuge; GS-3 
rotor 
sterile bench Safe 2020 
Sterile cell culture work bank 
Tecan Sunrise photometer  
Tissue culture treated paltes (96-well) 
TissueLyser, Retsch 
TruCount tubes 
Vortex Genie 2 
Water bath 
Water bath 
 
BD Falcon 
Eppendorf 
NanoDrop Technologies 
Carl Roth 
Chronos Messer 
Thermo Scientific  
BD falcon 
Privileg 
Carl Roth 
Eppendorf  
Sarstedt 
Eppendorf 
Heidolph 
BIO-RAD 
Sarstedt 
Eppendorf 
Carl Roth 
Eppendorf 
Sartorius 
Sarstedt  
Bandelin 
Thermo Scientific 
Thermo Scientific 
Thermo Scientific 
ThermoScientific 
Tecan Trading AG 
BD falcon 
Qiagen  
BD Biosciences 
Scientific Industries  
GFL 
Gebr. Rettberg 
 
 
Table 2-2: Chemicals and Reagents.  
Reagent/ chemical  Source  
3-Amino-9-EthylCarbazole 
3,3′,5,5′-Tetramethylbenzidine (TMB) Liquid Sub-
strate 
Agrose  
Albumin Fraction V 
anti-MVA rabbit immune serum 
anti-VACV serum 
Carboxyfluorescein succinimidyl ester  
casein 
Compensation beads 
Concanavalin-A  
Crystal Violet  
Sigma Aldrich 
Sigma Aldrich 
Biozyme 
Roth 
 
 Invitrogen 
Roth 
SpheroTech 
Sigma Aldrich 
Sigma Aldrich  
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Dimethylformamide 
Dimethylsulfoxid (DMSO) 
dNTPs  
Ethanol  
Ethanol for spectroscopy 
FACS flow, FACS rinse, FACS safe  
Fetal calf serum 
Fetal calf serum  
Formaldehyde (37 %)  
glucose (C6H12O6) 
Human TruStain FcX  
hydrogen chloride (HCl) 
Hydrogen peroxide (3 %) 
Isopropanol 
Loading dye (6x)  
Lymphocyte separation medium   
Methanol  
Milk powder 
Nuclease free water  
Pancoll 
PBS/0.5 % BSA 
Penicillin/streptomycin 
potassium chloride (KCl) 
potassium dihydrogen phosphate (KH2PO4) 
Primer  
RCB Lysis/Fixation Solution (10x) 
RPMI-1640 cell culture medium  
SecureSeal 
single-antibody-labeled compensation beads 
Sodium acetate (NaOAc) 
Sodium carbonate (Na2CO3) 
sodium chloride (NaCl) 
Sodium hydrogen carbonate (NaHCO3) 
Sodium hydrogen phosphate (Na2HPO4 ∙ 12 H2O) 
Streptavidin, V500 
TaqMan probes 
Trypsin, trypsin/EDTA 0.25%  
Tween 20 
Β-mercaptoethanol  
 
Sigma Aldrich 
Fermentas 
Sigma Aldrich 
Merck 
BD Biosciences  
PAN Biotech 
PAA laborato-
ries 
Roth 
Sigma Aldrich 
BioLegend 
Merck 
 Roth 
 PAA laborato-
ries  
Roth 
Roth 
Merck  
PAN Biotech 
BioLegend 
PAN Biotech 
Roth 
Roth 
TIB Molbiol 
BioLegend 
PAN Biotech 
Sigma Aldrich 
SpheroTech 
Merck 
Merck 
Roth 
Merck 
Roth 
BD Biosciences 
TIB Molbiol 
PAN Biotech 
Merck  
Roth 
 
 
Table 2-3: Reaction components and commercial kits.  
Kit/ component Source  
Fixable Viability Kit, Brilliant Violet 570 
ImmoMix 
Plasmid DNA purification NucleoSpin Plasmid  
QIAamp DNA Mini Kit (250)  
TaqMan® Universal PCR Master Mix  
BioLegend 
Bioline 
Macherey- Nagel  
Qiagen 
Life Technologies 
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Zombie yellow Fixable Viability Kit, Brilliant Violet 570, Live/Dead 
 
BioLegend  
 
 
Table 2-4: List of Antibodies. 
Antigen Clone Fluorochrome Manufacturer 
anti-CD45-Biotin 
anti-CD3 
anti-CD14 
anti-CD16    
anti-CD69 
anti-CD69    
anti-CD4  
anti-CD123   
anti-CD11b   
anti-HLA-DR    
anti-CD80 
anti-CD20    
anti-CD159a 
anti-CD45RA   
anti-CD8 
anti-CD28    
anti-CD95   
anti-CD95      
anti-CD4  
anti-CD11c    
anti-CD86    
anti-human IgG Fc   
anti-CD27  
anti-ɣδTCR  
anti-CD8a   
6C9 
SP 34-2  
M5E2 
3G8 
L78 
FN50 
RPA-T4 
9F5 
ICRF44 
L243 
L307.4 
H299 (B1) 
Z199.1 
2H4  
HIT8a 
L293 
DX2 
DX2 
L200 
3.9 
IT2.2  
HP6017 
O323 
5A6.E9 
DK25 
V500 
AF 700 
PerCP-Cy5.5 
APC-Cy7 
PerCP-Cy5.5  
APC 
V450 
PE 
Pacific Blue 
APC-Cy7 
V450 
FITC 
APC 
ECD 
PE 
PE-Cy7 
PE-Cy7 
APC 
PerCP-Cy5.5 
PE-Cy7 
APC  
PE 
Brilliant Violet 650 
FITC  
PE 
BD Biosciences 
BD Biosciences 
BD Biosciences 
BD Biosciences 
BD Biosciences 
BD Biosciences  
BD Biosciences 
BD Biosciences 
BD Biosciences 
BD Biosciences 
BD Biosciences 
Beckman Coulter 
Beckman Coulter 
Beckman Coulter 
BioLegend 
BioLegend 
BioLegend 
BioLegend 
BioLegend 
BioLegend 
BioLegend  
BioLegend 
BioLegend  
Caltag Laboratories 
Dako 
 
Table 2-5: List of secondary Antibodies.  
Antigen Manufacturer 
Alexa Fluor 647 peroxidase-conjugated AffiniPure F(ab´)2, 
(H+L1)-conjugated goat anti-human IgG antibody 
Cy5-conjugated AffiniPure F(ab´)2, (H+L1)-conjugated goat 
anti-mouse IgG antibody 
Alexa Fluor 647-conjugated AffiniPure F(ab´)2 fragment goat 
anti-human IgG (H+L1)    
Cy3-conjugated IgG Fraction Monoclonal Mouse Anti-Biotin 
 
 
 
Jackson ImmunoResearch Laboratories 
 
 
1detects heavy and light side chains 
 
Table 2-6: List of buffers and medium.  
Reagent/ chemical  Source/ ingredients  
FOXP3 Fix/Perm Buffer Set 
RBC Lysis/Fixation, 10x stock, diluted 
with ddH2O to 1x Solution 
PBS/BSA  
BioLegend 
BioLegend 
 
PBS/0.5 % BSA 
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FA-solution, 0.37 % formaldehyde (FA)-
solution 
Blocking buffer  
Coating buffer   
 
 
 
Phosphate-buffered saline (PBS) 
 
 
Dulbecco´s Modified Eagle Medium 
(DMEM) with 4.5 g/L Glucose 
tissue DMEM medium 
 
 
TMB-Substrate, 3,3′,5,5′ Tetra-
methylbenzidine (TMB) Liquid Substrate  
solution, System for ELISA, T0440  
1 mM TRIS buffer 
Stop solution 
Na2CO3 buffer  
 
Blocking buffer  
diluted in PBS 
 
2 % (w/v) milk powder + 10 % (v/v) FCS in PBS  
sodium carbonate (Na2CO3) buffer, 0.03 M (w/v), pH 11, diluted 1:2 in sodium 
hydrogen carbonate (NaHCO3) buffer, 0.07 M (w/v), pH 8 
1 % (w/v) sodium chloride (NaCl), 0.02 % (w/v) potassium chloride (KCl), 
0.289 % (w/v) sodium hydrogen phosphate (Na2HPO4 ∙ 12 H2O), 0.02 % (w/v) 
14 mM potassium dihydrogen phosphate (KH2PO4∙ 12 H2O), 1.37 mM sodium 
chloride (NaCl), 27 mM potassium chloride (KCl), 43 mM sodium hydrogen 
phosphate (Na2HPO4) 
PAN-Biotech 
 
DMEM, 2 % fetal calf serum (FCS) and a mixture of antibiotics (1 % penicillin-
streptomycin; 50 µg/ml neomycin; 100 µl/ml nystatin; 1 µg/ml amphotericin and 
1 % gentamycin)  
Sigma Aldrich  
 
 
1 mM TRIS, pH 9.0 
Hydrogen chloride, 1 M 
0.03 M (w/v), pH 11, diluted 1:2 in sodium hydrogen carbonate NaHCO3 buffer 
(0.07 M (w/v), pH 8)  
2 % (w/v) milk powder + 10 % (v/v) FCS in PBS 
 
2.2 Animal experiments 
2.2.1 Ethical statement 
All animal experiments were performed at the German Primate Centre Göttingen (Deutsches 
Primatenzentrum GmbH, DPZ) and followed the laws of the German Animal Welfare Act. It 
complies with the European Union guidelines (EU directive 2010/63/EU) on the use of non-
human primates for biomedical research. 
Animal experiments were supervised by governmental veterinary authorities. The experi-
ments were performed under licence number 33.9-42502-04-12/0745 issued by the LAVES 
(Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit). 
2.2.2 Non-human primates and animal husbandry 
All animals used for the present studies were bred and housed at the DPZ under standard con-
ditions. In total, 45 common CM (CM, Callithrix jacchus) were used for the present studies. 
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19 animals entered the pathogenesis study and 26 animals were used for the vaccination stud-
ies (Table 2-7 and 2-8).  
Prior to the experiments, CM were kept in the animal unit at Biosafety Level 2 (BSL-2) at the 
DPZ for acclimatisation purposes. They were housed in individual cages (130 x 58 x 80 cm), 
at room temperature (25 °C ± 1 °C). At any time, they had the opportunity to get in touch with 
each other. Balanced diet consisted of food pellets for primates supplemented with fresh fruits 
and mash. Fresh water was provided ad libitum. Naïve animals served as negative controls for 
the detection of calpox antigen by flow cytometry (3.2.2 Detection of calpox virus antigen in 
various immune cells by flow cytometry). 
Table 2-7: Specification of common CM (Callithrix jacchus) used for the pathogenesis study.  
Group Animal ID Sex  Age  
(years) 
Euthanasia 
(dpi) 
I 
 
 
14325 
14484 
14991 
m 
m 
m 
6 
5 
6 
31  
31 
31 
II 
 
 
14973 
14592 
14647 
f 
f 
m 
3 
4 
4 
52 
52 
52 
III 
 
 
14483 
14966 
14917 
f 
m 
f 
4 
3 
3 
72 
72 
72 
IV 
 
 
15149 
15121 
14306 
f 
f 
f 
2 
3 
4 
102 
10 2 
10 2 
V 
 
 
14702 
15122 
15095 
m 
m 
m 
5 
5 
5 
122 
122 
122,3 
control 15995 
15968 
16000 
15970 
f 
f 
m 
m 
5 
5 
5 
5 
-4 
-4 
-4 
-4 
1Animals were infected with 3.5 x 105 pfu calpox virus. 
2Animals were infected with 8.3 x 103 pfu calpox virus.  
3Animal was at the final stage of disease. 
4Naïve animals, not infected. 
dpi, days post infection; f., female; m., male. 
 
Table 2-8: Specification of common CM (Callithrix jacchus) used for the vaccination studies. 
Study  Vaccination  
group 
Vaccine Animal ID Sex  Age  
 
Waiting period  
between second  
immunisation 
and challenge1 
timepoint 
of death  
(dpi) 
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Study I  
 
 
 
 
 
 
 
 
 
I  
 
 
 
MVA i.m. 
 
 
14144 
14403 
14482 
14707 
f 
f 
m 
f  
5 
5 
5 
4 
4 weeks 
 
 
 
24* 
21* 
23* 
18*** 
control PBS i.m. 14406 
14646 
m 
m 
5 
5 
4 weeks 13* 
14* 
II MVTT i.n. 
 
 
14327 
14414 
14575 
15007 
f 
f 
m 
f 
5 
5 
5 
4 
4 weeks 84** 
90** 
90** 
19* 
control PBS i.n. 15006 
14415 
f 
f 
4 
5 
4 weeks 16*** 
12*** 
Study II III 
 
 
 
MVA i.m. 
 
 
14233 
14309 
14248 
14372 
m 
f 
m 
m 
6 
6 
6 
6 
10 weeks 
 
 
 
17* 
99** 
21* 
21* 
IV 
 
 
 
MVTT i.n. 
 
 
14169 
14603 
14409 
14469 
m 
f 
m 
f  
6 
6 
6 
6 
10 weeks 
 
 
 
17* 
16* 
99** 
101** 
control PBS i.n. 14365 f 5 10 weeks 12*** 
V MVTT p.o. 
 
 
15098 
14478 
14334 
15100 
m 
f 
m 
m 
5 
6 
6 
5 
10 weeks 
 
98** 
101** 
98** 
17* 
control PBS p.o. 14974 m 5 10 weeks 14* 
1The boost immunisation (control groups were mock-immunized with PBS) followed four weeks after the first vaccination in 
study I and ten weeks after first vaccination in study II. *Euthanasia because termination score was reached. **euthanasia at 
the end of the experiment. ***sudden death. dpi, days post infection; f., female; i.m., intramuscular; i.n., intranasal;  MVA, 
modified vaccinia virus Ankara ; MVTT, modified vaccinia virus Tiantan; m., male; PBS, phosphate-buffered saline; p.o., 
peroral. 
2.2.3 Necropsy 
All CM were adspected daily and checked for clinical symptoms. For the pathogenesis study 
animals were euthanised at predefined time points (2.1.6 Pathogenesis study). Serial necropsy 
was then performed at 3, 5, 7, 10 and 12 dpi. 
In the vaccination studies, animals were euthanized when the level of the predefined humane 
endpoint criteria was reached.  
Animals were anaesthetized with Göttinger Mixture II (GM II) (see Appendix: Table A.2–1) 
before intraperitoneal euthanasation with 100 mg/kg pentobarbital-sodium (Narcoren, Merial 
GmbH, Hallbergmoos, Germany).  
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2.2.4 Sampling 
Tissue  
Tissue samples of 29 organs (adrenal gland, axillary lymph node (LN), urinary bladder, bone 
marrow, buccal musoca, central nervous system (CNS), colon, esophagus, eyes, heart, ingui-
nal LN, kidney, liver, lung, mesenteric LN, muscle, nasal mucosa, ovar/epididymis, parotid 
gland, skin, small intestine, spleen, stomach, submandibular LN, tongue, tonsil, trachea, uter-
us/prostate, vagina/testicle) per animal were collected and stored -80 °C.  
Blood samples  
For taking blood animals were anaesthetized with 20-30 mg ketamine/kg body weight intra-
muscularly (i.m.). Syringes used for blood drawing contained EDTA to avoid clotting. Blood 
samples were collected at 0, 3, 5, 7, 10 and 12 dpi for the pathogenesis study. Samples were 
taken for the vaccination study I at 0, 5, 7, 10, 12, 14, 17, 19, 21, 28, 42, 56, 72 dpi and for the 
vaccination study II at 0, 5, 7, 10, 12, 14, 17, 21, 25, 29, 35, 42, 49 dpi.  
Plasma samples  
For vaccination study I and II plasma samples were obtained prior to vaccination and at 0 and 
14 dpi as well as at the latest available time points for serological assays.  
Plasma was either prepared from whole blood by centrifugation for 15 min at 3000 rpm or by 
centrifugation on a ficoll gradient for 25 min at 800 g.  
2.2.5 Design of the pathogenesis study 
For the pathogenesis study, in total 15 animals were infected intranasally with 100 µl of dif-
ferent doses of calpox virus suspension (Table 2-7). Initially, twelve animals were infected, 
three each group, with 10 median monkey infectious doses (MID50) corresponding to 8.3 x 
103 plaque forming units (pfu) of calpox virus according to Kramski et al. (2010), and three 
each were sacrificed at days 5, 7, 10 and 12 post inoculation (Figure 2-1). Because most sam-
ples from 5-dpi-animals were virus negative, another group of three animals was infected with 
a 42-fold higher dose (3.5 x 105 pfu) of calpox virus and euthanised at 3 dpi. All animals were 
infected by pipetting 50 µl of the calpox virus suspension into each nostril. 
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Figure 2–1: Design of the pathogenesis study. Three animals (group I, high dose) were infected intranasally with 3.5 x 105 
pfu of calpox virus and were sacrificed 3 days post infection. Each three CM of group II-V (low dose), were inoculated in-
tranasally with 10 median monkey infectious doses (MID50) corresponding to 8.3x 103 plaque forming units (pfu) of calpox 
virus and euthanised at days 5, 7, 10 and 12 post inoculation (low dose). 
 
Analysis plan of the pathogenesis study 
In total 29 organs (2.1.5 Sampling) per NHP were collected and tissue homogenates were 
prepared for virus titration and quantification of viral DNA by real-time polymerase chain 
reaction (PCR). In addition, 1 ml blood was collected from each animal for viral DNA quanti-
fication at the day of necropsy and only day 3 and day 12 animals for virus titration. Additon-
ally, in the day-3 and day-12 groups the presence of calpox virus antigen was determined by 
flowcytometric analysis of purified PBMCs and buffy coat. 
2.2.6 Vaccination studies 
Two vaccination studies were performed in the calpox virus/marmoset model to test the effi-
cacy of different live-attenuated vaccinia viruses (VACV), i.e. modified VACV Ankara 
(MVA) (kindly provided by Prof. Czerny, Microbiology and Animal Hygiene, Georg-August 
University Göttingen) and modified VACV Tiantan (MVTT) (kindly provided by Prof. Chen, 
AIDS Institute, Hong Kong University, China).  
Vaccination study I: Immunization and challenge 
Twelve animals were used for the vaccine study I (Figure 2-2) and distributed to three groups 
with four CM each. One group was immunized intranasally with 5x 107 plaque forming units 
(pfu) of MVTT. 50µl of the virus suspension was administered into each nostril. Another 
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group received MVA passage 568 intramuscularly at the same dose like that used for immun-
ization with MVTT. The applied volume was 1 ml, and 500 µl were injected into each ham-
string muscle. Four weeks after the final immunization (four-week waiting period) all vac-
cinees together with four mock-treated controls were exposed intranasally to 8.3x 103 pfu cal-
pox virus as described above (2.2.5 Design of pathogenesis study). Animals of the control 
group were mock immunized with PBS (Table 2-8). 
  
 
Figure 2–2: Scheme of vaccination study I. Four animals were immunized intramuscularly (i.m.) with 5x107 pfu of Modi-
fied Vaccinia virus Ankara (MVA) passage (P) 568 (vaccination group I). Vaccination group II was immunized with 5x107 
pfu of modified vaccinia virus Tiantan strain (MVTT) intranasally (i.n.). The respective control groups were mock immun-
ized. All animals were challenged i.n. with calpox virus four weeks after the second immunisation.  
 
Vaccination study II 
In the follow-up study (vaccination study II) fourteen CM were used (Figure 2-3). Four ani-
mals each were allocated to three vaccine groups, two mock-immunized animals served as 
controls. Two groups were identically immunized as described for vaccination study I. The 
third group received the same dose of MVTT identically as outlined above, but by the peroral 
route. For immunization with MVTT the two mucosal application sites were chosen because 
mucosal vaccination with the parental VTT in mice (i.n. or oral) induced higher and more sus-
tained levels of neutralizing antibodies then the i.m. and subcutaneous vaccination routes (Lu 
et al., 2011). In contrast to vaccination study I the time span between the booster immunisa-
tion and challenge virus exposure was prolonged to a 10-week waiting period to potentially 
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increase the protection of the CM. The challenge was performed as described (2.2.5 Design of 
pathogenesis study).  
 
Figure 2–3: Scheme of vaccination study II. The study design was modified from vaccination study I. Animals of Vaccina-
tion group III were immunized intramuscularly (i.m.) with 5x107 pfu of modified vaccinia virus Ankara (MVA) passage (P) 
568. Vaccination group IV was immunized with 5x107 pfu of modified vaccinia virus Tiantan strain (MVTT) intranasally 
(i.n.). Peroral (p.o.) immunisation with 5x107 pfu of MVTT was included as vaccination group V. There was a 10-week wait-
ing period between last vaccination and challenge with calpox virus. The control animals were mock immunized. i.m., intra-
muscularly; i.n., intranasally; MVA, Modified Vaccinia virus Ankara; P, passage. 
 
Analysis plan of the Vaccination studies 
Part of the results of vaccination study I were already compiled before the beginning of this 
thesis (detection and quantification of viral DNA copies in blood by real time-PCR). There-
fore, this study predominantly focused on the analysis of vaccination study II. The humoral 
response in plasma was analysed by ELISA, neutralisation assay, and antibody fine mapping 
by peptide microarray. In order to analyse subsets of innate and adaptive immune cells in 
whole blood, polychromatic flow cytometry was applied. The cellular response was analysed 
with the T cell proliferation assay using carboxyfluorescein succinimidyl ester (CFSE) for cell 
labelling. Calpox virus in blood was determined by virus isolation and real-time PCR.  
2.3 Cell culture 
Vero E6 cells are susceptible to calpox virus infection and were therefore used for analyses in 
these presented studies. According to the recommendations of the European Collection of 
Cell Cultures, Vero E6 cells were cultivated with Dulbecco´s Modified Eagle Medium 
(DMEM) with 4.5 g/L Glucose (PAN-Biotech GmbH, Aidenbach, Germany), 10 % FCS and 
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1 % Penicillin-Streptomycin in culture flasks (Sarstedt, Nümbrecht, Germany). When the 
cells reached 90 % confluence, they were washed once with phosphate-buffered saline (PBS) 
and incubated with trypsin/EDTA (PAN-Biotech GmbH, Aidenbach, Germany) at 37 °C. Af-
ter cells were properly detached from the surface of the culture flask which required approxi-
mately 5-7 min, they were washed in Vero E6 cell culture medium once. Thereafter, they 
were split 1:10 and seeded into new culture flasks.  
2.4 Viruses  
Calpox virus Calpox virus was isolated from the skin of an infected Callithrix jac-
chus, 2002, Robert Koch Insitute, Berlin, Germany, kindly provided by 
Dr. Ellerbrok, Robert Koch Institut, Germany 
VACV LE Vaccinia virus Lister Elstree, kindly provided by Prof. Czerny, Division 
of Microbiology and Animal Hygiene, Georg-August University of 
Goettingen, Germany 
MVTT Modified vaccinia virus Tiantan, working stock was kindly provided by 
Prof. Chen, AIDS Institute and Department of Microbiology, University 
of Hong Kong, China 
MVA, passage 568 Modified vaccinia virus Ankara, kindly provided by Prof. Czerny, Divi-
sion of Microbiology and Animal Hygiene, Georg-August University of 
Goettingen, Germany 
2.5 Isolation of peripheral blood mononuclear cells (PBMCs) and buffy coat 
from whole blood  
Whole blood was diluted 1:2 with PBS and added onto Pancoll (PAN-Biotech GmbH, Aiden-
bach, Germany). A centrifugation step followed at 800 x g for 25 min at room temperature. 
PBMCs banded at the interphase between Pancoll and plasma. Plasma was removed and 
stored at -80 °C for later analysis. Next, the PBMCs were removed and washed twice with 
PBS which included centrifugation at 135 relative centrifugal force (rcf) or xg (times gravity) 
for 10 min at room temperature in a total volume of 10 ml. Finally, the cell pellet was resus-
pended in 1 ml PBMC cell culture medium (RPMI-1640, PAN-Biotech GmbH, Aidenbach, 
Germany, + 10 % FCS, + 1 % P/S) and cell numbers were counted with a hemocytometer (2.3 
Cell culture). Purified cells were either immediately processed for further analyzes or shortly 
stored in the refrigerator.  
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Buffy coat was isolated from 600 µl of whole blood which was centrifuged for 15 min at 564 
x g. EDTA plasma was separated and stored at -20 °C for serological analyses. The phase un-
der the plasma contained the buffy coat and was visible as a white layer. The buffy coat was 
aspirated and washed in 1 ml PBMC cell culture medium, centrifuged for 5 min at 1200 rpm 
and the supernatant discarded. The pellet was resuspended in 120 µl PBS and 50 µl were used 
for flow cytometric analysis. 
2.6 Extraction of nucleic acid 
2.6.1 DNA extraction from blood samples 
Calpox virus DNA was extracted from whole blood. To this end, 100 µl of whole blood was 
diluted 1:2 with PBS. For DNA extraction the manufacturer´s protocol of the QIAamp® DNA 
Mini Kit was followed except that the DNA was finally eluted in 100 µl AE buffer provided 
from the kit. Eluates containing the DNA were stored at -20 °C. 
2.6.2 DNA extraction from tissue samples 
Calpox virus DNA was extracted from 29 tissue samples per animal (2.2.5 Design of the 
pathogenesis study). After defining the weight of each tissue sample, PBS and one 5 mm di-
ameter steel beads were added. The TissueLyser II (Qiagen) was then used for homogenisa-
tion. The homogenisation times varied among tissues (20 sec – 3 min). The supernatant was 
taken out gently after a centrifugation step (125 x g for 10 min). Aliquots of 100 µl served as 
the base for DNA extraction and for plaque assay. Manufacturer´s protocol of the QIAamp® 
DNA Mini Kit (Qiagen) was followed for DNA extraction from tissues. DNA was eluated in 
100 µl AE buffer and stored at -20 °C. 
2.7 Polychromatic flow cytometry  
Cells were stained with antibodies conjugated with fluorescent dyes and acquired using a LSR 
II (BD) equipped with three lasers (violet, blue and red). Compensation was calculated using 
appropriate single-antibody-labeled compensation beads (SpheroTech) to correct the overlap-
ping of emission spectra. The calculation was done by FACS DIVA software 6.1.3. Analysis 
was done with FlowJo 9.6 (Treestar, Ashland, Oregon). 
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2.7.1 Preparation of compensation controls 
Compensations were calculated with compensation beads (SpheroTech, Lake Forest, Illinois) 
and the respective antibodies and dyes. Compensation beads were resuspended in PBS and 20 
µl of this solution were added to FACS tubes. 1 µl of each antibody listed below was added to 
the respective FACS tube and the suspension mixed Beads were incubated at room tempera-
ture for 30 min in the dark. Next, 500 µl of RBC Lysis/Fixation solution (1x) were added. Af-
ter vortexing and incubation for 15 min in the dark at room temperature, the mixture was cen-
trifuged for 5 min at 1200 rpm and the supernatant discarded. 250 µl PBS/BSA were added, 
the mixture was vortexed and centrifuged. The supernatant was discarded and the single-
stained compensation beads were resuspended in 50 µl PBS/BSA, acquired and the compen-
sation was calculated using the FACS DIVA software 6.1.3. 
2.7.2 Polychromatic flow cytometric staining for calpox antigen in PBMCs  
PBMCs were stained and analysed by polychromatic flow cytometry in order to identify the 
type of immune cells infected with calpox virus. Blood from all animals sacrificed at the pre-
defined time points day 3 and 12 post infections were available for this kind of analysis (2.2.5 
Design of the pathogenesis study). First, 5 x 105 PBMCs purified from whole blood were 
stained for a number of cell surface markers. The staining cocktail comprised the following 
antibody conjugates: anti-human IgG Fc-PE, anti-CD45-Biotin, anti-CD3-AF700, anti-CD14- 
PerCP-Cy5.5, anti-CD16- APC-Cy7, anti-CD20-FITC, and anti-CD159a-APC, and a strep-
tavidin-V500 conjugate. All antibodies and the streptavidin were used at pretitrated concen-
trations. As a very first step, anti-CD45-Biotin was preincubated with Streptavidin-V500 for 
15 min (1:1000). 50 µl of the CD45-Biotin/Streptavidin mixture per test was added to 8 µl of 
the mixture of the antibody cocktail. This mixture (58 µl/test) was added to FACS tubes. 5 x 
105 PBMCs in 50 µl PBS/BSA were added and incubated with the antibodies for 30 min in 
the dark at room temperature (RT). Thereafter, one ml FOXP3 FIX/Perm Buffer (1x) was 
added, the mixture vortexed and incubated for 20 min in the dark at RT. Following centrifu-
gation for 5 min at 1200 rpm, the supernatant was discarded, and cells were resuspended in 
250 µl PBS/BSA and stored at 4 °C over night. The next day PBMCs were pelleted for 5 min 
at 1200 rpm, the supernatant discarded, and 1 ml FOXP3 Perm Buffer added. The mixture 
was then vortexed and incubated for 20 min in the dark at RT followed by cell pelleting for 5 
min at 1200 rpm. After that, the supernatant was discarded, 250 µl Perm Buffer added, and 
the mixture vortexed. The samples were centrifuged for 5 min at 1200 rpm and the superna-
tant was discarded again. 500 µl Perm Buffer were added, the mixture vortexed and incubated 
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for 15 min in the dark at RT. The samples were then centrifuged for 5 min at 1200 rpm and 
the supernatant was discarded. Next, 5 µl Human TruStain FcX™ in 100 µl PBS/BSA was 
added and vortexed. The mixture was incubated for 10 min in the dark at RT. 100 µl of anti-
VACV serum (1:50 or 1:100) in PBS/BSA were added. The mixture was incubated for 1 h in 
the dark at RT. 250 µl PBS/BSA were added, vortexed and centrifuged for 5 min at 1200 rpm. 
Thereafter, anti-human IgG antibody was added in 100 µl PBS/BSA according to the manu-
facturer´s instructions. The mixture incubated for another hour in the dark at RT. Finally, cells 
were washed once in Perm Buffer and then resuspended in 50 µl PBS/BSA. Cells were ac-
quired by flow cytometry and data analyzed by the FlowJo software.  
2.7.3 Polychromatic flow cytometric calpox antigen staining of cells from buffy coat 
In order to also test granulocytes for the presence of calpox antigen, buffy coats were isolated 
as described (2.5 Isolation of peripheral blood mononuclear cells (PBMCs) and buffy coat 
from whole blood) and analyzed essentially as described for PBMCs (2.5 Isolation of periph-
eral blood mononuclear cells (PBMCs) and buffy coat from whole blood). Blood from healthy 
donor animals was included to assess background reaction (Table 2-7), because no autologous 
prevalues were available.  
2.7.4 T cell proliferation assay 
T cell proliferation assay was performed through labeling PBMCs with carboxyfluorescein 
succinimidyl ester (CFSE), and analyzing cell division. After isolation (2.4 Isolation of pe-
ripheral blood mononuclear cells (PBMCs)) PBMCs were stained with 100 µl CFSE (10 µM) 
for 15 min at 37 °C and 5 % CO2. CFSE is a non-fluorescent and colourless cell staining dye, 
which passively diffuses into cells. It is covalently coupled with its succinimidyl group to in-
tracellular amines and is therefore retained within the cell. CFSE acetate groups are then 
cleaved by intracellular esterases, which convert CFSE molecules into fluorescent esters. 100 
µl FCS was added to stop the reaction. Cells were then washed in a centrifugation step at 350 
x g for 8 min at room temperature. After the supernatant was discarded, cells were resuspend-
ed in 1 ml PBMC cell culture medium (2.4 Isolation of peripheral blood mononuclear cells 
(PBMCs)). Subsequently, PBMCs were washed again (as decribed before), the supernatant 
was discarded and cell numbers were adjusted to 1.3 x 106 cells/ml PBMCs. 
One portion of the cells was left untreated as controls (RPMI), another portion was stimulated 
with 1 % concanavalin A (ConA, Sigma) and a further portion with inactivated modified vac-
cinia virus Ankara at a multiplicity of infection of 3. Cells were seeded for each formulation 
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in triplicate at a cell density of 2 x 105 cells per well of a U-bottom shaped 96-well plates in a 
total volume of 150 µl RPMI medium Next, either 50 µl of RPMI or the stimulating agents in 
the same volume were added and incubated at 37 °C and 5 % CO2 for six days. Cells were 
checked daily for proliferation using a microscope.  
Polychromatic flow cytometriy staining of the T cell proliferation assay   
After this stimulation period, cells were stained with a cocktail of fluorophore-labelled anti-
bodies to assess proliferation of T cell subsets. This cocktail contained anti-CD8-PE, anti-
CD45RA-ECD, anti-CD28-PerCP-Cy5.5, anti-CD69-PE-Cy7, anti-CD95-APC, anti-CD3-
AF700, anti-CD4-V450, and Zombie Yellow and fixable Viability kit for live/dead staining. 
CFSE-stained cells from triplicates were pooled, transferred to FACS tubes and washed once 
with 250 µl PBS/BSA. After centrifugation for 5 min at 1200 rpm, the supernatant was dis-
carded the cell pellet resuspended in 250 µl PBS/BSA, vortexed and the cells again centri-
fuged. Supernatant was discarded and the cells were stained with antibody mixture for 30 min 
in the dark at room temperature. All antibodies were used at pretitrated concentrations. Cells 
were then washed again with 250 µl PBS/BSA and were resuspended in 50 µl FA-solution. 
Cells were acquired and analyzed (see 2.7.2 Polychromatic flow cytometric staining for cal-
pox antigen in PBMCs).  
2.7.5 Polychromatic flow cytometric analysis of whole blood 
Polychromatic flow cytometric analysis of whole blood was performed in order to analyze the 
proportions of different adaptive and innate immune cells in the vaccination studies during 
immunization and after challenge.  
The staining cocktail comprised the following antibody conjugates: anti-CD45-Biotin, anti-
ɣδTCR-FITC, anti-CD3-AF700, anti-CD14- PerCP-Cy5.5, anti-CD16- APC-Cy7, anti-
ɣδTCR-FITC, anti-CD123-PE, anti-CD11c-PE-Cy7, anti-CD86-APC, anti-CD11b-Pacific 
Blue, and, and a streptavidin-V500 conjugate. All antibodies were used at pretitrated concen-
trations. CD45-Biotin was preincubated with Streptavidin-V500 for 15 min (1:1000). Per test 
50 µl of the CD45-Biotin/Streptavidin mixture was added to 23.5 µl of the mixture of the an-
tibodies. This mixture was added to FACS tubes. 50 µl of whole blood were incubated with 
this mixture for 30 min in the dark at RT. 1 ml of RBC Lysis/Fixation solution (1x) was add-
ed. The mixture was then vortexed and incubated for 15 min in the dark at RT. Cells were 
washed with 250 µl PBS/BSA, after pelleting dissolved in 50 µl PBS/BSA, and acquired and 
analyzed.  
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Results of the samples are given in % cell proportions after baseline correction. 
2.7.6 Polychromatic flow cytometric staining of whole blood for the determination of 
absolute numbers of different immune cell subsets 
Absolute cell numbers of different immune cells were assessed by staining whole blood. For 
this approach the staining cocktail comprised the following antibody conjugates:  anti-CD45-
Biotin, anti-CD3-AF700, anti-CD20-FITC, anti-CD8a-PE, anti-CD4-PerCP-Cy5, anti-CD69-
PE-Cy7, anti-CD159a-APC, anti-HLA-DR-APC-Cy7, anti-CD80-V450, anti-CD27-Brilliant 
Violet 650, and a streptavidin-V500 conjugate. All antibodies were used at pretitrated concen-
trations. CD45-Biotin was preincubated with Streptavidin-V500 for 15 min (1:1000). 50 µl of 
the CD45-Biotin/Streptavidin mixture per test was added to the mixture of the antibodies. 
This mixture was added to Trucount™ tubes. 50 µl of whole blood was carefully added above 
the metal retainer and the tube was vortexed. Then, cells were incubated with the mixture of 
the antibodies for 15 min in the dark at RT. Next, 450 µl of RBC Lysis/Fixation solution (1x) 
were added followed by vortexing followed by an incubation step for 15 min in the dark at 
RT. Each Trucount™ tube contains a known number of fluorescent beads, which are released 
when the lyophilised pellet is dissolved. Cells were acquired immediately after the incubation 
time and analyzed. The absolute number of positive cells (cells/µl) in each sample was then 
determined by comparing cellular events to bead events. The number of positive cellular 
events was divided by the number of bead events and then multiplied by the respective 
Trucount™ bead concentration divided by the used blood volume (50 µl). 
2.8 Virus quantification 
2.8.1 Virus quantification by endpoint dilution assay in tissue homogenates  
Infectious calpox virus in tissue homogenates was determined by endpoint dilution assay. For 
this, 100 µl of the tissue homogenate (2.6.2 DNA extraction from tissue samples) were used. 
The tissue homogenates were tenfold serially diluted from 10-1 to 10-4 with tissue DMEM 
medium. Viral dilutions were analysed in quadruplicate adding100 µl of each dilution to the 
pre-seeded Vero E6 cells in 96-well plates.  
Plates were kept at 37 °C and 5 % CO2. The cell monolayer was washed three times with 100 
µl PBS 24 h after inoculation and each well was supplemented with 100 µl of the tissue 
DMEM medium.  
Overall, the plates were incubates for four days at 37 °C and 5 % CO2. After that, intracellular 
immunostaining of the cells was performed. For permeabilization of cell membranes, the cells 
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were treated with methanol for 15 min at -20 °C. Thereafter, plates were washed PBS three 
times. Unspecific binding was blocked by incubating the cells with 2 % milk powder in PBS 
for 1 h, at 37 °C. To detect intracellular calpox virus antigen, a human anti-VACV hyperim-
mune serum kindly provided by Prof. Czerny. The human anti-VACV serum was diluted in 
1:100 in 2 % milk powder in PBS, and 50 µl were added to each well and incubated for 1 h at 
37 °C. After three washing steps with PBS an incubation with horseradish peroxidase-
conjugated secondary antibody (peroxidase-conjugated AffiniPure F(ab´)2, (H+L)-conjugated 
anti-goat anti-human IgG antibody) followed. The secondary antibody was 1:1000 diluted in 
2 % milk powder in PBS. 50 µl were added to each well and incubated for 1 h at 37 °C. The 
wells were then washed 3 times with PBS. Binding of conjugate to the calpox antigen was 
visualized by adding 50 µl per well of a substrate containing 2 µg AEC (3-Amino-9-
EthylCarbazole), 6 ml/l DMF (Dimethylformamide), 0.25 µl 3 % H2O2 (Hydrogen peroxide) 
and 1 ml/l 50 µl NaOAc (sodium acetate)) for 20 min. The colour reaction resulted in a dark 
reddisch-brown intracytoplasmic staining which was evaluated unter the microscope. Results 
are given as 50 % tissue culture infective dose (TCID50)/g tissue which were calculated ac-
cording to Reed and Muench method (Fridholm&Everitt, 2005; LaBarre& Lowy, 2001) 
2.8.2 Virus quantification by endpoint dilution assay in buffy coat  
A plaque assay was conducted to detect replicating calpox virus in blood by cocultivation of 
buffy coat leucocytes with Vero E6 cells. To this end, 100 µl of whole blood was used. Blood 
was centrifuged for 15 min at 2455 rpm. The upper phase containing the plasma was taken off 
and stored at -20 °C for serological analyses. The phase under the plasma contained the buffy 
coat and was visible as a white layer. The buffy coat was washed in 1 ml titration medium 
(Dulbecco´s modified Eagle´s medium (DMEM), 4.5 g/L glucose (PAN-Biotech) with 2 % 
fetal calf serum (FCS) and 1 % penicillin-streptomycin (P/S)), centrifuged for 5 min at 1200 
rpm, and the supernatant discarded. Leukocytes were resuspended in 1ml titration medium 
corresponding to an initial 1:10 dilution of the cell suspension. Samples were then serially 
diluted in log 2 steps up to 1:5120. 500 µl of each dilution were added to pre-seeded Vero E6 
cells in 12-well plates. As a control cells were incubated with 500 µl of Vero E6 cell culture 
medium. The plates were incubated for three days at 37 °C and 5 % CO2. In order to remove 
unadsorbed virus, cell monolayers were washed 24 h after inoculation, and 500 µl of fresh 
titration medium was added to each well. 
Further processing followed the protocol decribed in paragraph 2.8.1 except that the required 
volume were adapted to the 12-well plates. For the hyperimmune serum, the conjugated sec-
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ondar antibody and the substrate 500 µl per well were used. Primary plaques were defined as 
the biggest plaques of the same size and counted under the microscope. The secondary comets 
were not counted. Results are given in plaque forming units per µl blood [pfu/µl]. 
2.9 Detection of calpox virus 
Gating strategy for the detection of calpox virus antigen in immune cells 
The gating strategy for the identification of calpox infected innate and adaptive immune cells 
is depicted in Figure 2-4. In the first step, doublets were excluded from analysis by applying a 
singlets gate using forward scatter (FSC)-height (-H) against FSC-area (-A). Neutrophils, 
monocytes and lymphocytes as populations of leukocytes were analyzed based on side scatter 
(SSC)-area (-A) versus CD45 expression. Three different subsets of monocytes were classi-
fied by CD14 and CD16. Lymphocytes were characterized by CD3 and CD20 expression to 
distinguish between CD3+ T cells and CD20+ B cells as well as to identify CD3+CD20+ cells. 
NK cells were analyzed by gating on the CD3-CD20- population, followed by gating on 
CD159a+ cells. Intracellular calpox antigen was visualized through an anti-VACV immune 
serum.  
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Figure 2-4. Gating strategy for the detection of calpox virus antigen in immune cells from buffy coat by flow cytome-
try. Representative gating strategy is depicted. Following exclusion of doublets lymphocytes, monocytes and neutrophils 
were gated on CD45 expression. Within the lymphocyte population CD3+ T cells and CD20+ B cells were distinguished. NK 
cells were defined as CD3- CD20- CD159a+. Monocytes were further distinguished based on CD14 vs. CD16 expression. Cell 
populations are demonstrated as dot plots. Pink lines, one gate; pink number, events within a gate given as percentages of 
the previous population. 
2.10 Quantitative real-time PCR  
A real-time PCR assay was used for the detection and quantification of calpox virus DNA 
(Table 2-9 and 2-10). The plasmid standard contained the target sequence and was used for 
viral DNA quantification. The amplicon of the target region of the “ankyrin repeat-containing 
protein” (CAM58389.1, target size of 78 bp) was cloned into a TOPO-TA vector (Invitrogen, 
Karlsruhe, Germany) which was kindly provided by Dr. Constanze Yue (RKI, Berlin, Germa-
ny). Plasmid DNA was quantified in NanoDrop photospectrometer and plasmid copy numbers 
were calculated. The real-time PCR quantification of all samples was performed in duplicate. 
Primers used are given in Table 2-9, real-time PCR cycling conditions and components in Ta-
ble 2-10. Each real-time PCR run was analysed using the 5-Plex Rotor-Gene Q using the Ro-
tor-Gene Q Series Software 2.1.0. The viral DNA quantities were expressed as calpox DNA 
copy numbers per g tissue. The detection limit was 50,000 calpox DNA copy numbers/g tis-
sue. For blood the detection limit was 10 calpox DNA copies/µl blood. The data of viral load 
in blood in the vaccination study I were acquired by Tingchuan Shi preliminarily to this the-
sis. 
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Table 2-9: Oligonucleotides used in calpox virus-specific real-time PCR assay.  
Oligonucleotide name  Oligonucleotide sequence 5´3´ 
 
Calp1for 
Calp1rev 
TIB-1 
Amplicon length: 78 bp 
CCggCATgCgTgACTgAATT 
TAAgATgCgAgCCgAgAAgC 
FAM-TgCTCCgTgTTCTACCATCgTgCg-TMR 
The base “G” is given as small letter to avoid confusion with “C”; FAM = 5´-Modification 6-FAM label; TMR = 3´-
Modification TAMRA label. 
 
 
Table 2-10: Cycling conditions and components for calpox virus-specific real-time PCR.  
For detailed information about the oligo nucleotides, see Table 2-9. 
2.11 Serological analyses  
2.11.1  Binding antibodies by enzyme-linked immunosorbent assay (ELISA)  
An ELISA was performed to analyse the humoral plasma response for binding antibodies 
against whole viral particles of vaccinia virus (VACV) Lister Elstree (LE) and calpox virus. 
Antibody levels of different plasma samples (2.1.4 Sampling, Plasma samples) were deter-
mined to identify immune correlates. 
Virus purification 
To harvest and concentrate VACV LE and calpox virus which was then to be used as antigen 
for coating 17 tissue culture flasks (T175) were cultured with Vero E6 cells in a volume of 45 
ml. The cells were infected with a sufficient amount of the respective virus at 95 % confluen-
cy and harvested.  The cells were inoculated with VACV LE for two days and with calpox 
virus three days. Each virus/cell suspensions (VACV LE and calpox virus) were frozen at -80 
°C. Cell culture material was then thawed and centrifuged in a Sorvall centrifuge (Thermo 
Scientific, Sorvall® RC-5B Refrigerated Superspeed Centrifuge; GS-3 rotor) at 9000 rpm for 
Cycling conditions  
95 °C 10 min  
45  
repeats 
 
95 °C 
58 °C 
15 sec 
45 sec 
 
Approach 15 µl 
 
 
H2O 
Primer “Calp 1 for” 100 µM 
Primer “Calp 1 rev” 100 µM 
Probe “TIB-1” 100 µM 
TaqMan® Universal PCR Master Mix 
DNA 
4 µl 
1 µl  
1 µl 
0.5 µl 
7.5 µl 
1 µl 
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2 h, at 4 °C. The supernatant was discarded and the pellet resuspended in 40 ml 1 mM TRIS 
buffer, pH 9.0. Next, the resuspended cell debris was incubated for 30 min and then frozen at 
-80 °C. 
The next day the suspension was thawed in a waterbath at 37 °C, refrozen in liquid nitrogen 
and thawed again. The suspension was vortexted and treated thrice with a SONOPLUS ultra-
sound-homogenizer for one min followed by a centrifugation at 3218 rpm for 10 min, at 4 °C 
(Thermo Scientific, Heraeus, Multifuge 3S-R; 6446 rotor). Thereafter, the supernatant was 
transferred to a new falcon tube and purified with a sucrose cushion. To this end, as a first 
step purification was done with 10 ml of 36 % sucrose. A centrifugation step at 25000 rpm for 
90 min followed at 4 °C (Thermo Scientific, Sorvall Combi Plus, DuPont, Sorvall Ultraspeed 
Centrifuge, Sorvall AH0-629 Rotor 29000 rev/min MAX; SW 28 rotor). The pellet was re-
suspended in 200 µl 1 mM TRIS buffer, pH 9.0 and incubated overnight at 4 °C. The pellet 
was then again resuspended and transferred into a 1.5 ml E-cup. In the next step a sucrose 
gradient was prepared with a gradient mixer. For that, 20 % and 60 % sucrose and 1 mM 
TRIS buffer, pH 9.0 were used. The pellet was resuspended, vortexed and treated thrice with 
a SONOPLUS ultrasound-homogenizer for 1 min. After that, the virus was layered onto the 
sucrose gradient and a centrifugation step at 15000 rpm of 90 min at 4 °C followed (Beck-
mann Coulter Centrifuge, L-60 Ultraspeed Centrifuge; SW 40 rotor). The virus was visible as 
a band in the centrifugation tube and aspirated with a syringe by puncturing the tube. To elim-
inate the sucrose the concentrated virus suspension was then washed with 1 mM TRIS buffer, 
pH 9.0 in a centrifugation step at 25000 rpm of 1 h, at 4 °C (Beckmann Coulter Centrifuge, L-
60 Ultraspeed Centrifuge; SW 40 rotor). The pellet was incubated with 100 µl 1 mM TRIS, 
pH 9.0 at 4 °C overnight. The following day, the pellet was resuspended and aliquoted into 
cryotubes. After a protein determination according to LOWRY the aliquots were stored at -80 
°C. 
Enzyme-linked immunosorbent assay (ELISA)  
The respective antigen (VACV LE or calpox virus) was bound to 96-well MaxiSorp™ Nunc-
Immuno™ plates in a first coating step. For this, 100 µl/well of 5 µg/ml whole virus in coat-
ing buffer (Na2CO3 buffer) were added to each well. Plates were closed with a sealing foil. 
After an incubation period of 24 h at 4 °C, plates were washed three times with 200 µl/well of 
PBS. The plates were then treated with 100 µl/well of blocking buffer for 2 h at 37°C and 5 % 
CO2 to prevent unspecific binding of antibodies. Plasma samples were diluted 1:200 in block-
ing buffer and 100 µl/well were added in dublicate.  
  62 
Plasma samples of each animal obtained prior to vaccination were used to calculate the cut-
off. Plates were closed with a sealing foil and an incubation step for 1 h at 37 °C. Plates were 
then washed five times with PBS. For detection of the primary antibody, the peroxidase-
conjugated AffiniPure F(ab´)2 Fragment Goat Anti-human IgG (H+L) antibodies were diluted 
1:1000 in blocking buffer and 100 µl/well was added to the plates. Plates were sealed fol-
lowed by incubation for 1 h at 37 °C. Plates were then washed ten times with PBS to elimi-
nate unbound secondary antibodies. In the next step, 100 µl/well TMB-substrate solution 
(3,3’,5,5’-tetramethylbenzidine) was added and incubated for 20 min at room temperature in 
the dark. The reaction was stopped by adding 50 µl/well Stop solution. Optical density was 
then measured using a Tecan Sunrise™ photometer equipped with the Magellan 6.4 Software. 
The samples were measured at 450 nm with a reference wavelength of 630 nm. A plasma 
sample with a known antibody status (anti-MVA rabbit 1987, kindly provided by Prof. Czer-
ny) served as positive control. 8 wells per plate were used as no template controls. 
Twice the OD value determined for each pre-immunization plasma was used to define the in-
dividual cut-off value and was subtracted from the values from immune plasma.  
2.11.2  B cell epitope fine mapping by peptide microarray  
2.11.2.1  Poxvirus peptide microarray layout 
The poxvirus peptide microarray was used to detect antibodies against linear epitopes of dif-
ferent orthopoxvirus antigens. 
15mer peptides overlapping by twelve amino acids were synthetised via SPOT technique 
(Frank, 1992), passed through the SC process (Dikmans, 2006) and spotted onto microscope 
glass slides. The spot size was between 200-250 µm and the peptide concentration in each 
spot was 360 fmol.  
Six proteins of VACV Western Reserve i.e. A27, A33, B5, D8, H3 and L1 were selected and 
used for synthesis of 475 peptides covering the entire proteins (Figure 2-5B).  
The GenBank accession numbers are as follows: A27 (YP_233032.1), A33 (YP_233038), B5 
(YP_233069.1) D8 (YP_232995.1), H3 (YP_232983.1) and L1 (YP_232970.1).  
The mature virion (MV) membrane-associated proteins (A27, D8, H3 and L1) and transmem-
brane proteins that are exposed on the outer surface of the enveloped virion (EV) (A33 and 
B5) were chosen because these determinants play a role in neutralization (Moss, 2011).  
In addition, ten cellulose-conjugated biotin spots served as positive controls and for orienting 
the Spot Calling program. Each chip contained eight identical arrays (Figure 2-5, A) with the 
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same arrangement of the spots on each array (Figure 2-5, B). An exemplary reaction of the 
first three peptides covering A27 and its respective amino acid sequence corresponding to 
spots #1-#3 in B is demonstrated (Figure 2-5, C).  
 
Figure 2–5: Layout of the poxvirus microarray chip. (A) The chip contained eight arrays arranged in the same manner. 
(B) Arrangement of spots on each array: yellow represents peptides of A27 antigen of Vaccinia virus Western Reserve; red, 
D8; blue, H3; grey, L1; green, A33 and orange, B5. The number serves as the batch identification and letters represent the 
chip name. (C) Amino acid sequence of the first three peptides covering A27, corresponding to spots #1-#3 in B (boxed in 
red).               
 
2.11.2.2  Microarray chamber  
The microarray chamber (Figure 2-6) was supposed to be used for the incubation of the mi-
croarray chips and was designed to analyze four microarray chips simultaneously. A home-
made microarray chamber was used (Hotop, 2014) to avoid leakage and for multiple analysis 
in a humidified system. It was slighty modified in this study. The D-197 metal springs ena-
bled a consistent pressure between the lid and the bottom that contains the microarray chips. 
To increase the pressure a 1 mm thick rubber cover (Figure 2-7) of 65 shore was glued with a 
special adhesive SB 2444 (Henkel AG & Co. KGaA, Düsseldorf, Germany) to the lid. 
   
Figure 2–6: The poxvirus microarray chamber was designed to analyze four microarray chips simultaneously. Four 
microarray chips were placed into the metal chamber and the first antibody mixture that contained the plasma samples was 
added to the microarray chip. 
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Figure 2–7: Rubber cover of the poxvirus microarray chamber´s lid depicted from below.               
2.11.2.3  Validation of the chip using mAbs against known epitope regions 
The poxvirus peptide microarrays were pretested to evaluate the reactions by using monoclo-
nal antibodies (mAbs) against a known epitope. The screening procedure of the microarray 
chip was performed as previously reported with few modifications (Hotop et al., 2014). Brief-
ly, the microarray chip was washed with absolute ethanol for 3 min. It was then washed with 
Tris-buffered saline (TBS) thrice for 3 min. The blocking step was done with blocking buffer 
using 2 % casein in 0.05 % Tween TBS (T-TBS) for 60 min, at room temperature to block 
unspecific reactions. Then it was washed with T-TBS three times, each for 3 min. Protein 
concentrations were measured using NanoDrop® ND-1000 Spectrophotometer (NanoDrop 
Technologies, Inc., Wilmington, DE, USA). Next, the monoclonal antibody was diluted to 20 
mg/µl in the blocking buffer. Then 60 µl of the diluted antibody were placed onto the chip. 
The poxvirus microarray chip was designed to screen 4 samples simultaneously in repeated 
determination, using an adhesive chamber (SecureSealTM, Sigma-Aldrich Co. LLC, USA) be-
cause the incubation had to be done under humidified conditions. Additionally, a microarray 
chamber, homemade press tool (2.11.2.2 Microarray chamber) was used to avoid leakage. Af-
ter incubation of the antibody was incubated overnight in a cooling room at 4 °C, three wash-
ing steps were performed with T-TBS for 5 min. Next, 60 µl of the secondary antibody mix-
ture containing 1:240 diluted Cy3-conjugated streptavidin and Cy5-conjugated goat anti-
mouse IgG (Jackson Immunoresearch Laboratories, West Grove, PA, USA) was added onto 
the chip together with an object plate.  
After an incubation of the chip for 90 min at room temperature in a humidified chamber it 
was washed two times with T-TBS, three times with distilled water, each for 5 min. The chip 
was then dried using compressed air and immediately analyzed with an Agilent DNA micro-
array scanner (Agilent Technologies, USA).  
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2.11.2.3  Poxvirus scanning chip in the calpox virus/marmoset model  
Samples from the vaccination studies I and II were tested with the optimized protocol. The 
blocking buffer was 2 % casein in 0.05 % Tween TBS (T-TBS) with 5 % Albumin Fraction 
V. The first antibody solution contained the plasma sample diluted 1:60 in blocking buffer. 
The mixture of secondary binding reagents contained 1:240 diluted Cy3-conjugated streptavi-
din and Alexa Fluor® 647-conjugated AffiniPure F(ab´)2 fragment goat anti-human IgG 
(H+L) (Jackson Immunoresearch Laboratories, West Grove, PA, USA). All other steps were 
identical to those described in the previous paragraph. 
2.11.2.4  Screening procedure and data acquisition of the microarray chip 
The microarray chips were scanned with an Agilent DNA microarray scanner (Agilent Tech-
nologies, USA). The true signals were identified by the semi-automated Spot Calling method 
(Hotop et al., 2014) as followed: after screening, the obtained photo was first saved as a TIFF 
file. The fluorescence intensity of each spot was calculated using the ImageJ Software 
(Schneider et al., 2012). Two times the averages of the sum of fluorescence intensities from 
all spots plus one standard deviation were calculated and used as cut off using Excel (Mi-
crosoft, version 2010).  
2.11.3 Plaque reduction neutralization test (PRNT)  
Staining reagents and antibodies 
Crystal Violet   Sigma-Aldrich C3886-25G; 077K07401 Crystal Violet 
anti-MVA rabbit  kindly provided by Prof. Czerny, Microbiology and animal 
immunserum;   hygiene, Georg-August University Göttingen 
11.06.1997 
 
To analyze the anti-poxvirus neutralization capacity of the different plasma samples of vac-
cination study I and II, a microtiter plaque reduction neutralization test (PRNT) was estab-
lished because of the small amounts of plasma available from each animal. First, 3 x104 Vero 
E6 cells/well were seeded into 96-well plates with DMEM and incubated for approximately 
24 h at 37 °C and 5 % CO2. The cells should be 70 % confluent at the start of the test for a 
good read-out.  Plasma samples were serially diluted with DMEM and 100 µl were mixed 
with 100 TCID50 of the respective virus (VACV LE and calpox virus) in 100µl. Sample/virus 
mixture incubated for 1 h at 37 °C and was then added to the Vero E6 cells. After adsorbance 
for 1 h at 37 °C and 5 % CO2 plates were washed twice with PBS. Cells were then incubated 
in 200 µl DMEM at 37 °C and 5 % CO2 for 72 h. After that, medium was removed and plates 
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were stained with 100µl crystal violet (1.5 % in 80 % ethanol)/well for 2 min and finally 
washed with H2O. The plaques per well were then counted. When 50 % plaque reduction 
compared to the virus control was observed, the reciprocal of the respective dilution was con-
sidered the neutralizing titre. The average result of a duplicate was determined. Anti-MVA 
rabbit immunserum was used as positive control (rabbit hyperimmune serum, anti-MVA anti-
body was kindly provided by Claus Peter Czerny). 
2.11.4 Gating strategy for the identification of innate and adaptive immune cells 
Gating strategy for the identification of innate and adaptive immune cells is depicted in Figure 
2-8. After gating on singlets, lymphocytes were analyzed by gating on SSC-Alow CD45+ cells. 
γδ T cells and T cells were analyzed in the next step (expression of γδ-TCR vs. CD3).  
To analyze monocytes and DCs, another gating scheme was used (Figure 2-8). Following ex-
clusion of doublets (by a single gate) as well as γδ T cells and conventional T cells, macro-
phages (MQs; CD14- CD16+) and monocytes (CD14+ and CD16+) were gated. The CD14- and 
CD16- population was further analyzed regarding CD11c and CD123 expression to differenti-
ate between myeloid dendritic cells (mDCs; CD11c+ CD123-) and plasmacytoid dendritic 
cells (pDCs; CD11c- CD123+). Expression of the activation marker CD86 was analyzed on 
monocytes and macrophages. 
 
                             
Figure 2-8. Gating strategy for the identification of innate and adaptive immune cells by flow cytometry. Representa-
tive dot plots of #15095 are shown. Following exclusion of doublets lymphocytes were gated based on CD45 expression. γδ 
T cells and T cells were then analyzed. Monocytes and DCs were analyzed using another gating scheme. Following exclu-
sion of doublets as well as γδ T cells and conventional T cells, macrophages (CD14- CD16+) and monocytes (CD14+ and 
CD16+) were gated. The CD14- and CD16- population was analyzed based on CD11c and CD123 expression to differentiate 
between myeloid dendritic cells (CD11c+ CD123-) and plasmacytoid dendritic cells (CD11c- CD123+). Expression of the 
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activation marker CD86 was analyzed on monocytes and macrophages and CD14++ cells. Pink lines, one gate; pink num-
ber, events within a gate given as percentages of the population before. 
2.11.5 Gating strategy to assess absolute cell counts of innate and adaptive immune cells 
The gating strategy for the identification of absolute counts of innate and adaptive immune 
cells is depicted in Figure 2-9. First, doublets were excluded by gating on singlets. Thereafter, 
lymphocytes were analyzed by gating on side scatter SSC-A against CD45 expression. CD3+ 
T cells and CD20+ B cells were analyzed in the next step. T cells were divided into CD4+, 
CD8+ and CD4+ CD8+ T cells and expression of the activation markers CD69 and HLA-DR 
(human leukocyte antigen – antigen D related). B cells were further analyzed for their expres-
sion of the activation marker CD80 and the memory marker CD27. NK cells were identified 
by gating on CD3- CD20- cells, followed by gating on CD8+ CD159a+ cells. Finally, CD69 
and HLA-DR expression by NK cells and T cells was analyzed.  
 
Figure 2-9. Gating strategy for the identification of absolute counts of innate and adaptive immune cells by flow cy-
tometry. Representative dot plots of #15095 are shown. To calculate absolute cell counts the number of cells of interest is 
put in relation to a defined amount of beads. The bead gate is set based on the fluorescence signal of FITC versus Alexa Fluor 
700. Following exclusion of doublets lymphocytes were gated based on CD45 expression. CD3+ T cells and CD20+ B cells 
were then analyzed. T cells were divided into CD4+, CD8+ and CD4+ CD8+ T cells and expression of the activation markers 
CD69 and HLA-DR. B cells were analyzed regarding expression of the activation marker CD80 and the memory marker 
CD27, NK cells were identified by gating on CD3- CD20- cells, followed by gating CD8+/- CD159a+ cells, CD69 and HLA-
DR expression by NK cells was analyzed. Pink lines, one gate; pink number, events within a gate given as percentages of 
the population before. 
2.11.6 Gating strategy for T cell proliferation assay 
The gating strategy is depicted in Figure 2-10. CD3+ T cell proliferation was analyzed by gat-
ing first on singlets (exclusion of doublets) by applying forward scatter FSC-A against FSC-
H. Then gating was done on CD3+ T lymphocytes excluding dead cells. Next CD4+, CD8+ 
and CD4+CD8+ cells (T cells) were identified. Stimulation of Callithrix jacchus T cells using 
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concanavalin A (Con A) results in activation, proliferation and differentiation of both CD4+ 
and CD8+ T cells and served as positive control. The proliferative activity of live CD3+ T 
cells treated with ConA, MVA or medium (negative control) were exemplified for one animal 
(#14478) at 29 days post challenge (dpc).  
CFSE- cells represent the proliferating cells. 
 
Figure 2-10. Representative gating strategy of CFSE-stained T cells from ConA or MVA-stimulated PBMCs from 
vaccination study II. PBMCs were labeled with the fluorescent dye CFSE to analyze T cell proliferation. PBMCs were ei-
ther left untreated or stimulated with MVA or ConA as a control for 6 days. Subsequently PBMCs were stained for flow 
cytometric analyses. Representative dot plots from #14478 are shown. Following exclusion of doublets, dead cells were ex-
cluded and CD3+ T cells were gated. These were further divided into CD4+, CD4+CD8+ and CD8+ T cells. Loss of CFSE 
signal was analyzed to evaluate proliferating cells (CFSE- cells). ConA, Concavalin A; MVA, modified vaccinia virus Anka-
ra; pfu, plaque forming units; pink lines, one gate; pink number, events within a gate given as percentages of the population 
before. 
2.12 Statistical analyses 
Statistical analyses were performed with GraphPad Prism v5.0. The mean  standard devia-
tion (SD) or median with range were determined. To detect significant differences in non-
related samples, the non-parametric Mann-Whitney-U-test was used. For related samples, the 
paired t-test was used. The differences were considered significant when the significance level 
(p-value) was smaller than 0.05 (* = p < 0.05; ** = p < 0.01; *** = p < 0.001).  
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3 RESULTS 
3.1 Pathogenesis study - portal of viral entry (I) 
3.1.1 Detection of calpox virus in organs 
The aim was to determine the portal of viral entry by sacrificing infected animals in the pre-
symptomatic phase at defined time points, i.e. 3, 5, 7, 10 and 12 days following inoculation. 
Therefore, a broad panel of different organs was analysed for the presence of calpox virus. 
The organs were analyzed for infectious calpox virus and calpox viral DNA.  
3.1.1.1  Replicating calpox virus and calpox DNA copies in different organs at dif-
ferent time points after infection 
Infectious virus was quantified in tissues by endpoint dilution assay and compared to qRT-
PCR results using the same tissue preparation (Figure 3-1 and 3-2). Data generated by the two 
different analyses were normalized to one gram tissue. As it was difficult to anticipate at 
which time point after viral inoculation first traces of virus were detectable by the different 
virological techniques, first of all animals being inoculated for five days with the low viral 
dose were sacrificed. Actually, low levels of viral DNA (7x104-4.7x106 copies/gram tissue) 
were found in two of the three animals in very few organs close to or representing the inocu-
lation site, i.e. in one animal in the tonsil and in the other one in nasal mucosa and subman-
dibular lymph node (Figure 3-1A), but no infectious virus was isolated from any of the tissues 
analysed. Next, animals inoculated with the same dose were euthanized at day 7, 10 and 12. 
In the day-7-animals the data indicated a systemic spread of the virus. When merging the 
findings of all three animals of this group, all organs tested positive for viral DNA and from 
half of them infectious virus was detected. Notably, highest viral loads were observed in one 
animal in the nasal mucosa (animal 14483: 2.2x1011 DNA copies and 2.3x108 TCID50). Viral 
loads were considerably lower in the other organs ranging from approximately 105-109 DNA 
copy numbers and 102-4x107 TCID50 (Figure 3-1B). At day 10, viral loads obviously had not 
increased compared to those observed in the animals sacrificed three days earlier. On this day 
of necropsy, however, infectious virus was more readily detectable in around 50% of the tis-
sues. Levels of infectivity were either similar to viral DNA copies (animal 15149, nasal mu-
cosa) or between one and five orders of magnitude lower than the copy numbers (Figure 3-
1C). Altogether, highest viral levels were observed in the animals sacrificed at day 12 reach-
ing up to 1016 copy numbers (animal 14702, nasal mucosa, bone marrow and adrenal gland) 
and up to 109 infectious units (animal 14702, bone marrow). Remarkably, from each organ of 
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mostly all three animals infectious virus was recovered at this late time point (Figure 3-1D). 
Taken into account the very low viral loads detected at day five following calpox infection 
thus rendering it unlikely to find any virus at an earlier time point, the viral dose was in-
creased 40-fold to study infection events on day 3.  In two of the three animals sacrificed at 
that day, viral DNA and infectious virus was found, one further animal remained negative for 
any viral parameter in any organ. Those two animals exhibited 6x108-5x109 viral DNA copy 
numbers as well as considerable levels of infectious virus (105 TCID50) in the nasal mucosa. 
Moreover, in one of the two, tonsil, tongue lung, and eyes tested positive for calpox DNA, but 
copy numbers were by three or more orders of magnitude lower compared to the nasal muco-
sa (≤106 copy numbers). Two thousandfold lower numbers of infectious virus (~ 50 TCID50) 
were recovered from tongue and esophagus when compared to the nasal mucosa. All the other 
organs remained negative for the two viral parameters (Figure 3-2). 
Figure 3-1. Calpox virus DNA copy numbers and TCID50 of infectious calpox virus in different tissues at different 
time points after i.n. infection. (A-D) Comparison of calpox DNA copy numbers per g tissue (red) and infectious calpox 
virus titre (black) at different time points after infection. Tissues are indicated at the x-axes. Calculation of the DNA copy 
numbers for calpox virus is based on the mean value of duplicate measurements and a plasmid standard for the real-time PCR 
assay. The detection limit is 50,000 calpox DNA copy numbers/g tissue. All day-5 animals were negative for infectious virus; 
BM, buccal mucosa; CNS, central nervous system; dpi, days post infection; gl, gland; ing, inguinal; int, intestine; LN, 
lymph node; mes, mesenteric; NM, nasal mucosa; sub, submandibular; TCID50, 50 % tissue culture infective dose.  
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Figure 3-2. Calpox virus DNA copy numbers and TCID50 of infectious calpox virus in different tissues three days after 
i.n. infection. Comparison of calpox DNA copy numbers per g tissue (red) and infectious calpox virus titre (black) at 3 dpi. 
Tissues are indicated at the x-axes. Calculation of the copy numbers for calpox virus is based on the mean value of duplicate 
measurements and a plasmid standard for the real-time PCR assay. The detection limit is 50,000 calpox DNA copy num-
bers/g tissue. One animal (#14991) was negative in real-time PCR and plaque assay; BM, buccal mucosa; CNS, central nerv-
ous system; dpi, days post infection; gl, gland; ing, inguinal; int, intestine; LN, lymph node; mes, mesenteric; NM, nasal 
mucosa; sub, submandibular; TCID50, 50 % tissue culture infective dose.  
3.2 Pathogenesis study - early dissemination and pathological sequelae of infec-
tion (II) 
In the pathogenesis study the analysis of the early dissemination and pathological sequelae of 
infection (II) was in focus. The detection of the start of viremia and calpox virus antigens in 
immune cells were aims of the study.  
3.2.1 Detection of calpox virus in blood 
The start of viremia as determined by real-time PCR is dose dependent 
Calpox viral DNA in blood was determined by real-time PCR at different time points after 
infection. Earliest calpox viral DNA in blood was detected in one of the two day-3 animals 
(#14484) (Figure 3-3) which also was positive for viral DNA and infectious virus in organs 
close to the virus application site. Following inoculation with the lower viral dose, calpox vi-
ral DNA became first detectable in two of three animals at 7 dpi (#14966 and #14483) while 
all day-5 animals did not exhibit viremia. Unexpectedly, one of the day-10 animals remained 
calpox viral DNA negative in blood, although virus could be isolated from a number of or-
gans. By contrast, all day-12 animals were viral DNA positive in blood exhibiting the highest 
copy numbers. The start of viremia is dose dependent since viremia was detected at 3 dpi with 
the high dose (3.5 x 105 pfu calpox virus) and at 7 dpi with the low dose (8.3 x 103 pfu calpox 
virus).  
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Figure 3-3. Calpox virus DNA in blood was determined by real-time PCR at the indicated time points after infection. 
d, day; The detection limit was 10 calpox DNA copy numbers/ µl blood. 
 
First replicating virus was detected by cocultivation of buffy coat in one animal of the 
low-dose group at 7 days post infection (dpi)  
To get an estimate on how calpox DNA copy numbers in blood translated into infectious vi-
rus, the calpox virus titre was determined by cocultivating leucocytes from buffy coat with 
Vero E6 cells. For this analysis, material was only available from the groups sacrificed on day 
3 and day 12 after infection. In addition to the day of necropsy, blood from the day-12 group 
was also tested at days 3, 7, and 10. In contrast to the results from tissues, in the day-3 group 
no replicating virus was isolated from blood (Figure 3-4). First replicating virus was found in 
buffy coat of one animal (#15095) from the day-12 group at 7 dpi. Infectious virus particles 
[pfu/µl] were detected in all tested animals at 10 dpi and at the last available time point at 12 
dpi. The highest number of 3808.51 pfu/µl was reached in animal 15095 at 12 dpi. 
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Figure 3-4. Replicating calpox virus in blood at different time points after infection by cocultivation of buffy coat with 
Vero E6 cells. First replicating virus (1/3) was detected in the low-dose group at 7 dpi. d, day; pfu, plaque forming units. 
3.2.2 Detection of calpox virus antigen in various immune cells by flow cytometry 
Although viremia was detectable either by PCR or limiting dilution assay, the infected cell 
type within the leucocytes could not be identified by these two techniques. To analyze which 
immune cells were infected, multicolour flowcytometry was used to differentiate between 
neutrophils, monocytes, T and B cells and NK cells. For this type of analysis again only blood 
from the groups sacrificed on day 3 and 12 after infection was available. The gating strategy 
is shown in the Materials and Method section (Figure 2-4).  
Calpox virus antigen positive (calpox+) cells were already detected in the day 3 group 
infected with the high calpox dose 
Flowcytometric analyses revealed that calpox antigen was detected in the CD3+CD20+ lym-
phocyte subset in two out the three monkeys, in the classical monocytes (CD14+CD16-) and in 
the intermediate monocytes (CD14+CD16+) of one of the day-3 animals (Figure 3-5, Figure 3-
6).  
In day-12 animals calpox antigen became readily detectable in all investigated immune cells 
at varying levels except for the neutrophils, which remained almost entirely negative for cal-
pox virus antigen. Strikingly, all different immune cells of animal 15095 were positive for 
calpox protein. The animal 15095 was euthanized at the planned 12 dpi and also for ethical 
reasons because of its moribund endpoint. In this animal the highest percentage of infected 
cells was observed in the CD3+CD20+ cell population (almost 100 %), followed by around 75 
to 90 % infection of B cells and the different monocyte subtypes. CD3+ T cells were infected 
by 40 % and NK cells by 55 %. The other two animals presented with a varying pattern of 
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infection in the different cell types. However, calpox virus antigen was preferentially ob-
served in the CD3+CD20+ subset and the monocytes.  
The results regarding the detection of calpox+ cells in PBMCs were similar to the results of 
buffy coat. The courses were identical to the results in buffy coat, but the values in the con-
troles were notably higher. Thus, only data from buffy coat staining are shown. 
In summary, calpox virus infected in the initial phase preferentially CD3+CD20+ and CD14+ 
cells, and in the later phase also NK cells and B cells. 
 
Figure 3-5. Calpox virus antigen was detected in immune cells of buffy coat by flow cytometry. The day-3 animals re-
ceived a higher dose (3.5 x 105 pfu calpox virus) than the animals euthanized on day 12 (8.3 x 103 pfu calpox virus). Medians 
with the range of percent calpox antigen positive (calpox+) stained cells are shown. Calpox+ stained cells of the control ani-
mals were used to determine the baseline level. Calpox+ cells of the day-3 animals were close to the calpox+ cells of naïve 
baselines, except for calpox+ cells of CD3+CD20+ cells and CD14+CD16+ monocytes. Levels of calpox+ cells in the day-12 
animals were all higher than the calpox+ cells of baselines except for the neutrophils. Calpox+ cells of CD3+ cells and calpox+ 
cells of CD14+CD16- cells were low at 12 dpi. The cut off was defined as the highest control value of each of the respective 
cells. dpi, days post infection; Calpox+, calpox virus antigen positive. 
 
Figure 3-6. Exemplary dot plot showing calpox antigen positive (calpox+) immune cell populations in buffy coat. Rep-
resentive dot plot of different calpox+ cells are depicted. Example of VACV antigen stimulated (1:100) cells of buffy coat 
(#15095) at 12 dpi. Pink lines, one gate; pink number, events within a gate given as percentages of the previous population; 
SSC-A, side scatter pulse area. 
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3.3 Vaccination studies – identification of immune correlates (II) 
3.3.1 Immunization with MVTT showed highest vaccine efficacy  
The efficacy of two different live-attenuated VACV vaccines was compared after different 
waiting periods following immunization and by varying the vaccination route for one vaccine. 
One read-out for comparing vaccine efficacy was to determine the survival time of the differ-
ent vaccinees after challenge with calpox virus (Figure 3-7). All mock immunized control an-
imals died between 12 and 16 days post challenge confirming the high lethality of calpox vi-
rus in CM. By contrast, among the tested live-attenuated VACV vaccines immunization with 
MVTT protected more animals (67 %) than MVA (13 %), independent of the vaccination 
route and waiting period.  
In study I that included a 4-week waiting period, 75 % animals of the animals vaccinated i.n. 
with MVTT survived whereas all animals immunized i.m. with MVA died within 24 dpi. 
In vaccination study II the waiting period was extended to 10 weeks after immunization. After 
this longer waiting period one MVA-vaccinated animal survived challenge virus exposure.  
Independently of the route of vaccination, MVTT conferred protection between 50 and 75 %, 
which is in line with the efficacy level of MVTT following challenge after the shorter waiting 
period. Notably, vaccine failures survived considerably longer than the untreated control ani-
mals. The time period until the animals died (days post challenge) differed significantly be-
tween the vaccine failures and the mock immunized group (***; p = 0.0002). 
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Figure 3-7. Kaplan-Meier plot on survival of vaccinated and unvaccinated CM after a lethal challenge with calpox 
virus. Comparing the survival of the different vaccinees shows that MVTT protected more individuals (67 %) than MVA (13 
%), independently of the vaccination route. When different vaccination strategies are compared vacciniation with MVTT p.o. 
protected more animals than MVTT i.n. in vaccination study II (10-weeks waiting period). All mock immunized control ani-
mals died between 12 and 16 dpc. dpc, days post challenge; i.m., intramuscular immunization; i.n., intranasal immunization; 
MVA, modified vaccinia virus Ankara; MVTT, modified vaccinia virus Tiantan; PBS, Phosphate-buffered saline; p.o., pero-
ral Immunization. 
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3.3.2 Post-challenge viral load confirms survival rates 
3.3.2.1  Detection of calpox DNA copies in blood 
Vaccination study I 
As a further read-out of the vaccination studies viral loads in blood were investigated. The 
second parameter besides survival to assess protection included measurement of calpox viral 
DNA copy number in and reisolation of infectious calpox virus from blood (see 3.3.2.2 Infec-
tious virus detected by viral plaque assay). Calpox viral DNA was detected in blood by RT-
PCR in all control animals and vaccine failures. Surprisingly, all three protected vaccinees 
from the MVTT group exhibited transient low-level calpox DNA blips (1.9 x 102 DNA copy 
numbers/µl blood) which appeared between days 14 and 21 and lasted in one animal until day 
42 after challenge (Figure 3-8). In all infected animals viral DNA copy numbers continuously 
increased reaching in the controls 105-107 copies/µl blood shortly before or at death. In vac-
cine breakthroughs mean peak loads at death were significant lower (p=0.0159) compared to 
the controls and ranged between 7.5x103- 1.9x105 copies.  
 
Figure 3-8. Calpox viral DNA in blood of vaccinees of study I by qRT-PCR longitudinally post challenge. Viral DNA 
was quantified by qRT-PCR and expressed as calpox DNA copy numbers per µl blood. The detection limit was 10 calpox 
DNA copies/µl blood. DL, detection limit; i.m., intramuscular immunization; i.n., intranasal immunization; MVA, modified 
vaccinia virus Ankara; MVTT, modified vaccinia virus Tiantan; P, passage; †, unprotected animals.  
 
Vaccination study II 
Calpox viral DNA loads in the second study confirmed peak levels and kinetics in control an-
imals and unprotected vaccinees similar to what was observed in vaccination study I (Figure 
3-9). While one control animal did not exceed peak viral loads above 105copies/µl blood, in 
the other one more than 1010 copies were measured. Again, mean peak DNA viral loads in the 
vaccine failures were lower (but not significantly) compared to the controls (3.7x103 - 1.9x105 
copy numbers). Also, in two of the protected vaccines (both from either of the MVTT groups) 
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transient blips of viral DNA appeared by day 14 after challenge, but dropped below the detec-
tion limit by day 21 and 29.  
 
Figure 3-9. Calpox viral DNA in blood of vaccinees of study II by qRT-PCR longitudinally post challenge. Viral DNA 
levels were determined by qRT-PCR and are expressed as calpox DNA copy numbers per µl blood. The detection limit was 
10 calpox DNA copies/ µl blood. DL, detection limit; i.m., intramuscular immunization; i.n., intranasal immunization; 
MVA, modified vaccinia virus Ankara; MVTT, modified vaccinia virus Tiantan; P; passage; †, unprotected animals.  
3.3.2.2  Infectious virus detected by viral plaque assay 
To find out whether the transient low-level DNA viral blips in blood of protected MVTT vac-
cinees form study I were also mirrored by the presence of replicating calpox virus, an end-
point dilution assay was set up to isolate and quantify infectious calpox virus.  
Replicating calpox virus increased strongest in all animals of the mock group (Figure 3-10). 
The highest value of 4.94x102 pfu/μl blood was measured in animal #14365 at the time of 
death. MVA immunized vaccine failures presented with viral titres between 2 pfu/µl and 
2.7x102 pfu/μl calpox virus at the time of death. In contrast, the two MVTT immunized vac-
cine failures had lower viral titres between 0.05 pfu/µl and 0.17 pfu/μl at the final stage.  
No infectious virus could be isolated from any of the protected animals. 
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Figure 3-10. Replicating calpox virus in blood of animals from vaccine study II. Virus was isolated by cocultivation of 
buffy coat with Vero E6 cells. i.n., intranasal; MVA, modified vaccinia virus Ankara; MVTT, modified vaccinia virus 
Tiantan; p.o., per oral; †, unprotected animals.  
3.3.3  Humoral responses following immunization 
3.3.3.1  No significant influence of binding serum Abs against whole virus parti-
cles on protection 
To identify possible immune correlates between humoral immune responses and vaccine effi-
cacy, at first binding antibodies against particles of VACV LE and calpox were analyzed by 
ELISA. In general, in both vaccine studies serum antibody levels against VACV LE (Figure 
3-11A; Figure 3-12A) were higher than against calpox virus (Figure 3-11B; Figure 3-12B) at 
the time of challenge.  
At challenge in vaccine study I, MVA vaccinees had considerably higher antibody levels 
against the VACV antigen (Figure 3-13A), while against calpox virus antigen responses were 
mixed and varied within the two vaccine groups (Figure 3-13B).  
Significant differences in binding antibodies against VACV between vaccination groups 
(MVTT, i.n. and MVA, i.m.) (p= 0.0286) were detected for vaccination study I at day of chal-
lenge (Figure 3-14). In vaccination study II involving the 10-week waiting period, antibody 
levels in the MVTT vaccinees against VACV antigen were similar to or even higher than 
those in the MVA vaccinated animals, but in each group high variation was observed. Also, 
the different vaccination routes chosen for MVTT had no influence on immunogenicity, as 
overall levels in the MVTT vaccinees were similar. 
Overall, at challenge the binding antibody level against VACV in MVA, i.m. vaccinees was 
higher than in the MVTT, i.n. group in study I. No other association between binding anti-
body levels, neither against VACV nor calpox antigen, and protection were noticed in any of 
the vaccinees.  
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Two weeks after challenge in all animals from vaccination study I immunized with MVA, 
antibody levels against both OPXV antigens markedly increased suggesting an anamnestic 
response (Figure 3-11). The same was true for three of the four animals vaccinated with 
MVTT. Interestingly, this rise was not only observed in the one vaccine failure, but also in 
two vaccinees which according to the criteria survival and viral load were considered to be 
protected. The majority of animals from vaccination study II independant of being protected 
or not protectd also developed anamnestic antibody responses against both viral antigens ex-
cept for two protected animals, i.e. one MVA vaccinee (# 14309) and one MVTT vaccinee 
(#14334) (Figure 3-12).    
                   
Figure 3-11. Levels of vaccine-induced binding antibodies were not associated with protection in vaccination study I. 
Binding antibodies against (A) VACV LE and (B) calpox virus were determined by ELISA in plasma from the day of chal-
lenge and after challenge. The cut-off  (0.21 and 0.23) was double the value of the highest OD of each of the negative con-
trols. Plasma samples were were diluted 1:200 in blocking buffer and 100 µl/well was used in double detection.  i.m., intra-
muscular Immunization; i.n., intranasal Immunization; MVA, modified vaccinia virus Ankara; MVTT, modified vaccinia 
virus Tiantan; p.o., peroral immunization; P, passage. 
 
All mock immunized control animals remained antibody negative.  
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Figure 3-12. Levels of vaccine-induced binding antibodies were not associated with protection in vaccination study II. 
Binding antibodies against (A) VACV LE and (B) calpox virus were quantified by ELISA. The cut-off value (0.21 and 0.23) 
was the double amount of the highest OD value of each of the negative controls. Plasma samples were diluted 1:200 in block-
ing buffer and 100 µl/well was used in dublicate. i.m., intramuscular immunization; i.n., intranasal immunization; MVA, 
modified vaccinia virus Ankara; MVTT, modified vaccinia virus Tiantan; p.o., peroral immunization; P, passage.  
 
 
     
Figure 3-13. Results for vaccination study I and II revealed no differences in binding antibodies between vaccination 
groups by ELISA at day of challenge. Binding antibodies against (A) VACV LE and (B) calpox virus were determined by 
ELISA. No significant differences were detected when vaccination groups in study I and II were compared together. Howev-
er, significant differences in binding antibodies against VACV between groups (MVTT, i.n. and MVA, i.m.) (p= 0.0286) 
were detected for vaccination study I at day of challenge (see Figure 3-14). Mean  SD of all animals per group are shown. 
i.m., intramuscular immunization; i.n., intranasal immunization; MVA, modified vaccinia virus Ankara; MVTT, modified 
vaccinia virus Tiantan; p.o., peroral immunization; P, passage. 
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Figure 3-14. Results for vaccination study I revealed significant differences in binding antibodies determined by ELI-
SA between vaccination groups at challenge. Coating with 5 µg/ml VACV. Mean  SD of all animals per group is shown. 
The mean value of the MVA immunized group was significantly higher than that of the MVTT immunized group at chal-
lenge. The cut-off value (0.21 and 0.23) was the double amount of the highest OD value of each of the negative controls. i.m., 
intramuscular immunization; i.n., intranasal immunization; MVA, modified vaccinia virus Ankara; MVTT, modified vaccin-
ia virus Tiantan; P, passage; p, significance level. 
 
The antibody levels against calpox virus of all protected animals were higher than those of the 
unprotected animals of vaccination study I and II (Figure 3-15A). However, differences did 
not reach significance.  
 
Figure 3-15. ELISA antibodies against viral particles of calpox virus at the day of challenge virus exposure. Medians of 
all protected animals against unprotected animals of vaccination study I (A) and vaccination study II (B) are shown. Statistics 
revealed no significance. 
3.3.3.2  Successful validation of the poxvirus peptide microarray chip 
MAbs against already known epitope regions were used to validate the poxvirus peptide mi-
croarray chip. All regions of the epitopes were mapped identically to the known epitope re-
gions by peptide microarrays (data not shown).  
3.3.3.3  High resolution mapping of antibody linear targets revealed unique 
epitopes in protected CM 
ELISA test applying whole viral particles cannot discriminate between the quality of antibody 
responses in protected and unprotected CM. Therefore, an OPXV-specific high-resolution 
peptide microarray assay was employed to map antibodies against calpox virus linear 
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epitopes, which can be correlated with protection from infection. Plasma samples from con-
trol animals as well as all vaccinees before and after challenge were screened with peptide 
microarray chips. In vaccinees before challenge, no reaction with unique epitopes can be cor-
related to protection (see Appendix: Table A.3-3 - A.3-14). Surprisingly, four epitopes from 
three of the six investigated proteins were exclusively observed in plasma collected post chal-
lenge from protected animals (Table 3-1).  
Table 3-1: List of detected epitopes in protected animals after challenge.  
Epitope  
no. 
Study Vaccine Protein Animal  
ID 
Spot 
no. 
Sequence 
1 
2 
3 
 
4 
 
5 
I 
I 
II 
 
II 
 
II 
MVTT, i.n. 
MVTT, i.n. 
MVTT, i.n. 
MVTT, p.o. 
MVTT, i.n. 
MVTT, p.o. 
MVTT, i.n. 
MVTT, p.o. 
L1 
A33 
L1 
 
A33 
 
B5 
14327 
14414 
14469 
15098 
14469 
15098 
14469 
15098 
245 
337-338 
240 
240 
370-371 
370-371 
452-455 
452-455 
28-ASAQTKCDIEIGNFY-421 
64-SANEAAITDAAVAVA-811 
79-LTPEQKAYVPAMFTA-931 
 
163-TSDYQDSDVSQEVRKYFC-1801 
 
235-PICVRTNEEFDPVDDGPDDETDLS-2582 
ID, identification; i.n., intranasal Immunization; MVTT, modified vaccinia virus Tiantan; no., number; p.o., peroral Immun-
ization; Study, Vaccination study. 
1
The epitopes 1-4 were only detected after challenge.  
2Epitope 5 was already detected at 2 weeks post second immunization. 
 
In study II the total number of epitopes (12 epitopes) identifies during immunization was 
higher than in study I (4 epitopes) (Table 3-2). 
Table 3-2: List of all mapped epitopes induced by vaccination.  
Study Epitope  
no.  
Vaccine Protein Animal  
ID 
Spot 
no. 
Sequence 
I 
 
 
 
 
 
 
 
 
 
 
1 
2 
 
3 
4 
 
 
 
 
 
 
MVA, i.m. 
MVTT, i.n. 
MVTT, i.n. 
MVTT, i.n. 
MVA, i.m. 
MVA, i.m. 
MVA, i.m. 
MVA, i.m. 
MVTT, i.n. 
MVTT, i.n. 
MVTT, i.n. 
B5 
D8 
D8 
B5 
B5 
B5 
B5 
B5 
B5 
B5 
B5 
14482 
14414 
14327 
14327 
14144 
14403 
14482 
14707 
14414 
14575 
15007 
458 
97 
97 
381-383 
398-400 
398-400 
398-400 
398-400 
398-400 
398-400 
398-400 
253-DETDLSKLSKDVVQY-267  
190-NIHSDQLSKFRTLLS-204 
190-NIHSDQLSKFRTLLS-204 
22-TVPTMNNAKLTSTETSFNDKQ-42 
73-KKMCTVSDYISELYNKPLYEV-93 
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73-KKMCTVSDYISELYNKPLYEV-93 
II 
 
 
 
1 
2 
3 
4 
 
5 
MVA, i.m. 
MVA, i.m. 
MVTT, p.o. 
MVA, i.m. 
MVTT, p.o. 
MVTT, p.o. 
A27 
A27 
D8 
D8 
D8 
D8 
14309 
14233 
15098 
14233 
15098 
15098 
3 
12 
34 
47 
47 
79-80 
7-PGDDDLAIPATEFFS-21 
34-AIVKADEDDNEETLK-48 
1-MPQQLSPINIETKKA-15 
40-GKLVRINFKGGYISG-54 
40-GKLVRINFKGGYISG-54 
136-NQLDSIRSANTSAPFDSV-153 
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6 
7 
8 
 
 
9 
10 
 
11 
 
 
 
 
 
12 
MVA, i.m. 
MVA, i.m. 
MVTT, i.n. 
MVTT, i.n. 
MVTT, p.o. 
MVTT, p.o. 
MVTT, i.n. 
MVTT, p.o. 
MVA, i.m. 
MVA, i.m. 
MVA, i.m. 
MVTT, i.n. 
MVTT, p.o. 
MVTT, p.o. 
MVA, i.m. 
MVA, i.m. 
MVA, i.m. 
MVA, i.m. 
MVTT, i.n. 
MVTT, i.n. 
MVTT, p.o. 
MVTT, p.o. 
MVTT, p.o. 
D8 
D8 
A33 
A33 
A33 
A33 
B5 
B5 
B5 
B5 
B5 
B5 
B5 
B5 
B5 
B5 
B5 
B5 
B5 
B5 
B5 
B5 
B5 
14233 
14372 
14469 
14409 
15098 
15098 
14469 
15098 
14309 
14248 
14372 
14603 
14334 
15100 
14233 
14309 
14248 
14372 
14469 
14603 
15098 
14334 
15100 
81 
102-103 
317-319 
317-319 
317-319 
370 
454-455 
452-455 
457-478 
457-478 
457-478 
457-478 
457-478 
457-478 
398-400 
398-400 
398-400 
398-400 
399-400 
398-400 
398-400 
399-400 
398-400 
142-RSANTSAPFDSVFYL-156 
205-SSNHDGKPHYITENYRNP-222 
4-PENDEEQTSVFSATVYGDKIQ-24 
4-PENDEEQTSVFSATVYGDKIQ-24 
4-PENDEEQTSVFSATVYGDKIQ-24 
163-TSDYQDSDVSQEVRK-177 
244-FDPVDDGPDDETDLSKLS-261 
235-PICVRTNEEFDPVDDGPDDETDLS-258 
250-GPDDETDLSKLSKDVVQY-267 
250-GPDDETDLSKLSKDVVQY-267 
250-GPDDETDLSKLSKDVVQY-267 
250-GPDDETDLSKLSKDVVQY-267 
250-GPDDETDLSKLSKDVVQY-267 
250-GPDDETDLSKLSKDVVQY-267 
73-KKMCTVSDYISELYNKPLYEV-93 
73-KKMCTVSDYISELYNKPLYEV-93 
73-KKMCTVSDYISELYNKPLYEV-93 
73-KKMCTVSDYISELYNKPLYEV-93 
73-KKMCTVSDYISELYNKPLYEV-93 
73-KKMCTVSDYISELYNKPLYEV-93 
73-KKMCTVSDYISELYNKPLYEV-93 
73-KKMCTVSDYISELYNKPLYEV-93 
73-KKMCTVSDYISELYNKPLYEV-93 
ID, identification; i.m., intramuscular immunization; i.n., intranasal immunization; MVA, modified vaccinia virus Ankara; 
MVTT, modified vaccinia virus Tiantan; no., number; p.o., peroral immunization; Study, vaccination study. 
3.3.3.4  Neutralizing antibodies did not correlate with protection 
Neutralizing antibodies against VACV LE and calpox virus were determined by a plaque re-
duction neutralization test (PRNT) in plasma collected at day of challenge (Figure 3-16).  In 
vaccination study I the titres against VACV LE varied between 1:20 and 1:320 in all immun-
ized animals. No differences between the two vaccine groups were evident. When samples 
were tested against calpox virus the titres varied between 1:10 and 1:80 in all immunized an-
imals indicating lower neutralizing capacity against the challenge virus compared to VACV. 
Two of the vaccinees (one protected MVTT immunized animal, #14414, and one unprotected 
MVA immunized animal, #14403) were tested negative for neutralizing antibodies against 
calpox virus. Neutralizing titres were not associated with protection. Being in line with this, 
neutralizing antibodies were also detected in animals that died, e.g. #15007. 
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Figure 3-16. Neutralizing antibodies against VACV LE and calpox virus in animals of vaccination study I at time of 
challenge. Values are shown as mean of duplicate testing. Plasma from control animals was always negative. i.m., intramus-
cular immunization; i.n., intranasal immunization; MVA, modified vaccinia virus Ankara; MVTT, modified vaccinia virus 
Tiantan; nt, neutralizing antibody titre as determined by PRNT; P, passage.  
The mean values against calpox virus were lower than against VACV LE (Figure 3-17). No 
significant difference between the mean values of the titres between the groups was detected. 
 
Figure 3-17. Titres of neutralizing antibodies per vaccination group in vaccination study I. Plasma samples were exam-
ined pre-immunization and at the day of challengefor the presence of VACV LE and calpox virus neutralizing antibodies by a 
plaque reduction test. The vaccine groups did not differ significantly from each other. Controls were alsways negative. Mean 
with SD is shown. i.m., intramuscular immunization; i.n., intranasal immunization; MVA, modified vaccinia virus Ankara; 
MVTT, modified vaccinia virus Tiantan; nt, neutralizing antibody titre as determined by PRNT; P, passage. 
In vaccinees from vaccination study II neutralizing antibody titres against VACV LE were 
lower compared to vaccination study I ranging between 1:10 and 1:80 (Figure 3-18). The neu-
tralizing activity against calpox virus was in the same range (Figure 3-19B). Notably, the 
mean neutralizing titre against VACV in the group vaccinated perorally with MVTT was sig-
nificantly higher compared to the MVA vaccinated animals (Figure 3-19, p = 0.0487). 
In summary, there were no significant differences between neutralizing titres in protected and 
unprotected animals in study II. 
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Figure 3-18. Neutralizing antibodiy titres in animals of vaccination study II. Plasma samples were examined at the day 
of challenge for the presence of VACV LE and calpox virus neutralizing antibodies by a plaque reduction test. The vaccine 
groups did not differ significantly from each other. Controls were always negative. i.m., intramuscular immunization; i.n., 
intranasal immunization; MVA, modified vaccinia virus Ankara; MVTT, modified vaccinia virus Tiantan; nt, neutralizing 
antibody titre as determined by PRNT; p.o., peroral immunization; P, passage 
M V T T  i.n . M V T T  p .o . M V A  P 5 6 8  i.m . M V T T  i.n . M V T T  p .o . M V A  P 5 6 8  i.m .
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Figure 3-19. Mean  SD of the detected titres of neutralizing antibodies per vaccination group for vaccination study 
II. Plasma samples collected at the day of challenge were examined for the presence neutralizing antibodies against VACV 
LE and calpox virus. The titres against VACV LE of the MVTT p.o. immunized group were significantly higher (p = 0.0487) 
than those of the MVA i.m. immunized group titre .m., intramuscular immunization; i.n., intranasal immunization; MVA, 
modified vaccinia virus Ankara; MVTT, modified vaccinia virus Tiantan; nt, neutralizing antibody titre as determined by 
PRNT; P, passage; *, p < 0.05. 
The analyses showed that the levels of neutralizing antibodies were higher after the 4-week 
waiting period, but there was no significant difference notable (i). 
Compared to the neutralizing antibody titres after the 4-week waiting period, the titres were 
lower after the 10-week waiting period (ii). 
No association was detectable between the development of levels of neutralizing antibodies 
and protection (iii). Animals mit moderate neutralizing antibody titres were not protected and 
animals without were protected as well. 
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3.3.4  Phenotyping of immune cells and cellular immune response 
3.3.4.1 Longitudinal phenotyping of innate and adaptive immune cells in whole 
blood 
The phenotyping of different immune cells was done to assess the influence of VACV im-
munization and of calpox virus infection on a variety of cell subsets of the innate and adaptive 
immune response. A particular focus was laid on monocytes/macrophages because this subset 
is discussed to be responsible for spreading the virus (Davies and Parekh, 2017). Moreover, 
the proliferative cellular response against VACV was investigated and related to challenge 
outcome. For these kind of analyses only material from vaccination study II was available. 
Longitudinal phenotyping of innate immune cells 
In CD14+ cells (monocytes) (Figure 3-20) and myeloid dendritic cells (mDCs) (Figure 3-21) 
was a cell drop detected after immunization. The cell numbers increased at 21 dpc. Cell num-
bers increased in moribund animals (#14248 and #14372).  
In pDCs (Figure 3-22), NK cells (Figure 3-23) and γδ T cells (Figure 3-24) no differences 
were observed in absolute cell numbers during the analyzed time.  
Longitudinal analysis of CD14+ cells (monocytes) and myeloid dendritic cells (mDCs) 
Absolute numbers of CD14+ monocytes (Figure 3-20) and myeloid dendritic cells (mDCs) 
(Figure 3-21) dropped after immunization and increased after challenge at day 21. Notably, 
cell numbers increased further in two moribund animals that were vaccinated with MVA 
(#14248 and #14372).  
No significant differences were detected in absolute cell numbers between vaccination groups 
at the day of challenge. There was also no significant difference between cell numbers of pro-
tected and unprotected animals at challenge.  
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Figure 3-20. Absolute cell numbers of CD14+ cells (monocytes) in vaccination study II are shown over time. Absolute 
cell numbers are given in percent baseline. abs, absolute cell numbers; dpc, days post challenge; i.n., intranasal; i.m., intra-
muscular; MVA, modified vaccinia virus Ankara; MVTT, modified vaccinia virus Tiantan; p.o., per oral; P, passage, w, 
weeks. 
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Figure 3-21. Absolute cell numbers of myeloid dendritic cells (mDCs) in vaccination study II are shown over time. 
Absolute cell numbers are given in percent baseline. abs, absolute cell numbers; dpc, days post challenge; i.n., intranasal; 
i.m., intramuscular; MVA, modified vaccinia virus Ankara; MVTT, modified vaccinia virus Tiantan; p.o., per oral; P, pas-
sage, w, weeks. 
 
Longitudinal analysis of pDCs, NK cell and γδ T cell numbers 
In the majority of animals, no significant changes in the absolute cell numbers of pDCs (Fig-
ure 3-22), NK cells (Figure 3-23), and γδ T cells (Figure 3-24) were observed. Notably, cell 
numbers increased in two moribund animals that were vaccinated with MVA (#14248 and 
#14372). Furthermore, one protected MVTT p.o. animal (#14334) had higher absolute γδ T 
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cell numbers compared to the other animals. They increased 900-fold at 8-weeks post second 
immunization, decreased 600-fold at challenge, but remained higher after challenge. 
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Figure 3-22. Absolute cell numbers of plasmacytoid dendritic cells (pDCs) in vaccination study II are shown over 
time. Absolute cell numbers are given in percent baseline. abs, absolute cell numbers; dpc, days post challenge; i.n., intrana-
sal; i.m., intramuscular; MVA, modified vaccinia virus Ankara; MVTT, modified vaccinia virus Tiantan; p.o., per oral; P, 
passage, w, weeks. 
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Figure 3-23. Absolute cell numbers of NK cells in vaccination study II are shown over time. Absolute cell numbers are 
given in percent baseline. abs, absolute cell numbers; dpc, days post challenge; i.n., intranasal; i.m., intramuscular; MVA, 
modified vaccinia virus Ankara; MVTT, modified vaccinia virus Tiantan; p.o., per oral; P, passage, w, weeks. 
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Figure 3-24. Absolute γδ T cells in vaccination study II are shown over time. Absolute cell numbers are given in percent 
baseline. abs, absolute cell numbers; dpc, days post challenge; i.n., intranasal; i.m., intramuscular; MVA, modified vaccinia 
virus Ankara; MVTT, modified vaccinia virus Tiantan; p.o., per oral; P, passage, w, weeks. 
 
Longitudinal phenotyping of adaptive immune cells 
Longitudinal analysis of CD3+, CD4+ and CD8+ T cell numbers  
In absolute CD3+, (Figure 3-25), CD4+ (Figure 3-26), CD8+ (Figure 3-27) and CD4+CD8+ 
(Figure 3-28) T cell numbers were no differences observed during immunization. The pox-
virus infection did also not have a strong effect cell numbers or frequencies (data not shown) 
of CD3+, CD4+, CD8+ and CD4+CD8+ T cells.  
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Figure 3-25. Absolute cell numbers of CD3+ T cells in vaccination study II are shown over time. Absolute cell numbers 
are given in percent baseline. abs, absolute cell numbers; dpc, days post challenge; i.n., intranasal; i.m., intramuscular; 
MVA, modified vaccinia virus Ankara; MVTT, modified vaccinia virus Tiantan; p.o., per oral; P, passage, w, weeks. 
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Figure 3-26. Absolute cell numbers of CD4+ T cells in vaccination study II are shown over time. Absolute cell numbers 
are given in percent baseline. abs, absolute cell numbers; dpc, days post challenge; i.n., intranasal; i.m., intramuscular; 
MVA, modified vaccinia virus Ankara; MVTT, modified vaccinia virus Tiantan; p.o., per oral; P, passage, w, weeks. 
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Figure 3-27. Absolute cell numbers of CD8+ T cells in vaccination study II are shown over time. Absolute cell numbers 
are given in percent baseline. abs, absolute cell numbers; dpc, days post challenge; i.n., intranasal; i.m., intramuscular; 
MVA, modified vaccinia virus Ankara; MVTT, modified vaccinia virus Tiantan; p.o., per oral; P, passage, w, weeks. 
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Figure 3-28. Absolute cell numbers of CD4+CD8+ cells in vaccination study II are shown over time. Absolute cell num-
bers are given in percent baseline. abs, absolute cell numbers; dpc, days post challenge; i.n., intranasal; i.m., intramuscular; 
MVA, modified vaccinia virus Ankara; MVTT, modified vaccinia virus Tiantan; p.o., per oral; P, passage, w, weeks. 
Longitudinal analysis of CD20+ B cells cell numbers  
Absolute CD20+ B cell numbers remained below or at baseline during the observation period 
in the majority of the animals (Figure 3-29). Only, in two MVA i.m. immunized animals 
(#14248 and #14372) the cell numbers of CD20+ B cells increased shortly before animals be-
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came moribund. Between groups there were no significant differences detected at the day of 
challenge.  
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Figure 3-29. Absolute cell numbers of CD20+ B cells in vaccination study II are shown over time. Absolute cell numbers 
are given in percent baseline. abs, absolute cell numbers; dpc, days post challenge; i.n., intranasal; i.m., intramuscular; 
MVA, modified vaccinia virus Ankara; MVTT, modified vaccinia virus Tiantan; p.o., per oral; P, passage, w, weeks 
 
Longitudinal analysis of the expression of activation marker CD86+ on CD14++, CD14+ 
CD16+ and CD16+ cells  
Expression of CD86+ was assessed on CD14++ (Figure 3-30), CD14+ CD16+ (Figure 3-31) and 
CD16+ cells (Figure 3-32). The frequencies of the activated cells dropped after immunization 
but increased strikingly after challenge at day 21. Thereafter the percentages decreased again 
and stayed below the baseline. Between groups there were no significant differences detected 
at the day of challenge.  
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Figure 3-30. Percentages of CD86+ cells of CD14++ cells in vaccination study II are shown over time. Percentages of cell 
numbers are given in percent baseline. dpc, days post challenge; i.n., intranasal; i.m., intramuscular; MVA, modified vaccin-
ia virus Ankara; MVTT, modified vaccinia virus Tiantan; p.o., per oral; P, passage, w, weeks. 
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Figure 3-31. Percentages of CD86+ cells of CD14+ CD16+ cells in vaccination study II are shown over time. Percentages 
of cell numbers are given in percent baseline. dpc, days post challenge; i.n., intranasal; i.m., intramuscular; MVA, modified 
vaccinia virus Ankara; MVTT, modified vaccinia virus Tiantan; p.o., per oral; P, passage, w, weeks. 
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Figure 3-32. Percentages of CD86+ cells of CD16+ cells in vaccination study II are shown over time. Percentages of cell 
numbers are given in percent baseline. dpc, days post challenge; i.n., intranasal; i.m., intramuscular; MVA, modified vaccin-
ia virus Ankara; MVTT, modified vaccinia virus Tiantan; p.o., per oral; P, passage, w, weeks. 
 
No significant differences in T and B cell numbers and their expression of certain activa-
tion markers  
No significant difference between vaccination groups in activation markers (e.g. CD69, HLA-
DR and CD80) expressed on T and B cells were detected at the day of challenge. The course 
of the cell frequencies was thus similar to the parental T and B cell numbers (data not shown). 
3.3.4.2  T cell proliferation assay 
Proliferating T cells over time 
CD3+ T cells as well as their subpopulations CD4+, CD4+CD8+ and CD8+ T cells were ana-
lyzed for their proliferating capacity after stimulation with orthopoxvirus antigen by evalua-
tion of percentages of CFSE- cells. Before immunization hardly any proliferating cells were 
detected. No significant differences between the vaccination groups were observed during the 
observation period (no data shown).  
Frequencies of CD3+CFSE-, CD3+CD8+, CD3+CD4+, and CD3+CD4+CD8+ cells (Figure 3-
33A, 33B, 34A and 34B) were increased at 4-weeks post first immunization in protected and 
unprotected animals, whereas the frequencies of CD3+CFSE- cells in mock immunized ani-
mals were also increased at that time point (Figure 3-33A). CD3+CD8+CFSE- cell frequencies 
(Figure 3-33B) increased at 8-weeks post second immunization. In the two protected animals 
#14478 and #14334 of the MVTT p.o. immunized group those frequencies slightly increased 
longitudinally even after challenge.  
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Figure 3-33. Proliferating CD3+ and CD3+CD8+ cells (CFSE-) frequencies were measured and increased at one time 
point (4-weeks post first immunization). PBMCs were labeled with the fluorescent dye CFSE to analyze T cell prolifera-
tion. PBMCs were stimulated with MVA for 6 days. Subsequently PBMCs were stained for flow cytometric analyses. Results 
of the MVA-stimulated samples are given as %CFSE- cells of A) CD3+ or B) CD3+ CD8+ cells. death, animals were not 
protected and died after calpox virus challenge; imm, immunization; i.m., intramuscular; i.n., intranasal; MVA, modified 
vaccinia virus Ankara; MVTT, modified vaccinia virus Tiantan; P, passage; p.o., per oral; protected, animals were protect-
ed, w, weeks. 
 
CD3+CD4+CD8+CFSE- cells slightly increased longitudinally in MVTT vaccination groups in 
protected as well as cells of the unprotected animals (Figure 3-34B), while these cells in the 
mock immunized animals did not proliferate. Eight weeks post second immunization (2 week 
before challenge) the MVTT vaccinees had higher CD3+CD4+CD8+CFSE- cell frequencies 
than MVA vaccinees and mock immunized animals. Highest cell frequencies were detected in 
one protected MVTT vaccinee (#15098) 4-weeks post challenge. The proliferative activity 
was not associated with the protection of the animals from the calpox virus challenge. After 
challenge, CD3+CD4+CD8+CFSE- cells did not proliferate in one protected animal (#14309) 
and in some unprotected animals an increase of cell frequencies was measured (#14248, 
#14603 and #15100). 
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Figure 3-34. Frequencies of CD3+CD4+CFSE- and CD3+CD4+CD8+CFSE- cells over time. T cells of the control group 
(mock immunized animals) did not proliferate. A) CD3+CD4+CFSE- cells. B) CD3+CD4+CD8+CFSE- cell frequencies. T cell 
proliferation in blood was analyzed at different time points by labeling PBMCs with CFSE. PBMCs were labeled with the 
fluorescent dye CFSE to analyze T cell proliferation. PBMCs were stimulated with MVA. Subsequently PBMCs were stained 
for flow cytometric analyses. Results of the MVA-stimulated samples are given as % of CFSE- of CD3+CD4+ or CD4+CD8+ 
cells. death, animals were not protected and died after calpox virus challenge; imm, immunization; i.m., intramuscular; i.n., 
intranasal; MVA, modified vaccinia virus Ankara; MVTT, modified vaccinia virus Tiantan; P, passage; p.o., per oral; pro-
tected, animals were protected, w, weeks. 
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4 DISCUSSION 
4.1 Pathogenesis study 
4.1.1 Following intranasal application calpox virus enters through the nasal epithe-
lium 
In 2010 the calpox virus marmoset model was first described offering a new non-human pri-
mate model to study OPXV pathogenesis, therapy and prophylaxis (Kramski et al., 2010). 
However, there have only been reports about the severe pathological alterations in the late 
stage of the disease caused by that orthopoxvirus (Kramski et al., 2010; Mätz-Rensing et al., 
2012). Therefore, a study was designed in which serial necropsies were carried out during the 
asymptomatic phase of calpox virus infection in CMs. At each defined time point, a broad 
spectrum of organs was collected. In parallel to the virological analyses, organs were analyzed 
histologically for the occurrence of alterations by the Pathology Unit of the DPZ. One aim (I) 
was to determine primary target cells and organs of infection as well as to determine the portal 
of viral entry. (II) Another aim was to shed light on the early viral dissemination and the 
pathological sequelae of infection by detection of replicating calpox virus and calpox viral 
DNA in different organs and blood. In addition, cells that replicate the virus should be identi-
fied by flow cytometry.  
Previous studies have shown that very low doses of calpox virus applied intranasally were 
sufficient for the infection of CM when compared to doses used in common OPXV models 
(Kramski et al., 2010). Since infection of the upper respiratory tract closely resembles the 
natural infection route of smallpox via aerosols, all animals were inoculated intranasally. Vi-
rus containg aerosols are inhaled, thereby passing the nasal, oral, and, pharyngeal mucosae or, 
if inhaled deeper reaching the lung and causing disease at this location (Barnewall et al., 
2012; Fenner et al., 1988b). Therefore, these tissues could be targets of initial replication. 
It is known that the initial site of the OPXV infection is the skin, a mucosal surface or the res-
piratory tract (Munoz, 2014a). For the calpox/marmoset model it was assumed that the nasal 
epithelium and the nasal-associated lymphoid tissue (NALT) represent the principal target for 
primary infection (Mätz-Rensing et al., 2012).  
To increase the likelihood for the detection of even minute quantities of virus at the earliest 
time point of euthanasia, i.e. day 3, approximately 3.5x105 PFU were administered. By qRT-
PCR and endpoint dilution assay, virus was detected in nasal mucosa and tongue at this early 
time point. Highest viral loads were found in nasal mucosa (epithelial layer of the mucous 
membranes) in the nose by both assays. Animals sacrificed at later time points after viral in-
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oculation received a 42-fold lower dose which had reliably infected 16 animals from unrelated 
studies (Kramski et al., 2010). Under these conditions in animals sacrificed at 5 dpi, only low-
level calpox viral DNA was detectable in the nasal mucosa (1/3 CM) and two adjacent organs, 
but no infectious virus was recovered. This also indicated viral replication at the site of inocu-
lation and was corroborated by high viral levels in the nasal mucosa of one out of three ani-
mals euthanized at 7 dpi. All these findings underline that nasal epithelial cells are the princi-
ple target cells for calpox virus. The results of the immunohistochemical analyses conducted 
by scientists of the DPZ Pathology unit demonstrated that the nasal epithelial cells serve as 
the portal of viral entry. Viral antigen was detected within inclusion bodies in this location at 
3 dpi (Schmitt et al., 2017). Additionally, first alterations in the nasal ciliated epithelium were 
visible as well as immunohistochemical reactivity in respiratory epithelium at this early time 
point (Schmitt et al., 2017).  
The nasal-associated lymphoid tissue (NALT) as well as the nasal epithelium have been as-
sumed to serve as the principal target for primary infection in this model (Mätz-Rensing et al., 
2012). The NALT is functionally active against infectious agents such as airborne transmitted 
viruses (e.g. VARV) or other pathogens and contains many immunocompetent cells like B 
cells, dendritic cells, macrophages and T cells (Bienenstock and McDermott, 2005). Further-
more, the NALT is rich in microfold cells. M cells take up viral antigen and transport them to 
the immune cells. Dendritic cells with captured antigen will then migrate to the draining 
lymph node and present the antigen to T cells (Xu et al., 2014).  
4.1.2. Identification of calpox virus replicating immune cells 
To identify cell subsets in blood harbouring calpox virus a flowcytometric assay was adapted 
for the analysis of purified PBMCs and buffy coat. An anti-VACV hyperimmune serum 
cross-reacting with calpox was used for viral detection. As no autologous preinfection values 
were available positivity was assessed by simultaneously analyzing blood from uninfected 
CM. Calpox virus antigen was observed in CD3+CD20+ cells in two of three animals and in 
intermediate CD14+CD16+ monocytes in one of three animals by day 3 post infection (high 
dose-infected animals). For cynomolgus macaques infected intravenously with the cowpox 
virus, it is known that especially monocytes and granulocytes became infected (Song et al., 
2013b), and to a lesser extent, B cells, NK cells and T cells. In this study, calpox virus antigen 
was mainly present in CD20+ B cells and CD3+CD20+ cells. Only a small proportion of neu-
trophils stained positive for calpox antigen in one animal of the day-12 group (Figure 3-5) 
while this subset was negative in all the other animals tested. By contrast, in monocytes 
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(CD14+CD16-, CD14+CD16+ and CD14+CD16-) calpox virus antigen was readily detected at 
12 dpi. Levels of infected CD3+ T cells and NK cells were lower compared to those of mono-
cytes and CD20+ B cells. With respect to infected immune cells in blood, CD3+CD20+ cells 
and monocytes appeared to be the preferred subset of calpox virus replication early in infec-
tion whereas the spectrum of infected cell types broadened in the late preclinical stage. 
These findings are in agreement with a study of VACV WR infection of human PBMCs 
(Sanchez-Puig et al., 2004). When macrophages become infected, their ability to act as acces-
sory cells to activate T-cells or natural killer (NK) cells and secrete cytokines is blocked 
which is of advantage for the virus (Smith and Kotwal, 2002). Perhaps the virus infects the 
immune cells that play an important role in host defense like NK cells in early (first three 
days) host immune response after poxvirus infection. The latter implies that a T cell response 
seems to play a more important role in early rather than the late phase of primary, acute infec-
tions (Gordon et al., 2011; Xu et al., 2004a).  
A novel finding was the detection of calpox virus antigen in CD3+CD20+ cells. To my 
knowledge, nothing is known about CD3+CD20+ cells in CM so far and further research is 
needed to clarify their function. The existence of CD3+CD20+ cells have been controversely 
discussed and were thought to be an artifact of flow cytometry (Henry et al., 2010). They 
were also described as a storage-dependent phenomenon (Nagel et al., 2014). By contrast, 
according to more recent studies (Neumann et al., 2015; Schuh et al., 2016) CD3+CD20+ T 
cells seem to represent a true population, pervading lymphatic organs and the cerebrospinal 
fluid. Functional properties of human CD3+CD20+ T cells comprise the production of differ-
ent cytokines (IL-4, IL-17, IFN-γ, TFN-γ). They also respond to multiple sclerosis disease 
modifying drugs (Schuh et al., 2016). 
4.1.3. Comparison of methods for the detection of calpox virus in blood samples 
Calpox virus levels were determined in blood by different methods, i.e. detection of the cal-
pox virus antigen by flow cytometry, by real-time PCR and by plaque assay. qRT-PCR and 
calpox virus antigen staining by flow cytometry were more sensitive than virus isolation. 
When samples from the day-3 animals were analyzed by the same techniques in parallel, cal-
pox virus DNA was detected in only one of three animals by real-time PCR, in two of three 
animals the fraction of CD3+CD20+ cells was positive for calpox virus antigen by flow cy-
tometry, but no virus could be isolated from buffy coat. In animals exhibiting highest percent-
ages of calpox virus positive cells as determined by flow cytometry, also highest levels of 
calpox DNA copy numbers were observed.  
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Real-time PCR and poxvirus antigen staining by flow cytometry were the most time-efficient 
methods. Moreover, staining for calpox virus antigen by flow cytometry has the advantage 
that antigen expression in different immune cells can be tested in one approach. Because of a 
lower background staining (baseline) in samples from the controls animals, the calpox virus 
antigen staining by flow cytometry with cells from buffy coat is preferred to PBMCs.  
4.1.4. (II)  The early dissemination and pathological sequelae of infection 
The pathogenesis study provides evidence that early dissemination starts in the nasal mucosa.  
Calpox viral DNA and replicating calpox virus were already detectable in the nasal mucosa of 
two animals of the high-dose group sacrificed at 3 dpi. Also, few organs adjacent to the inocu-
lation site were either positive for viral DNA or infectious virus. Presence of virus in tonsil, 
tongue, esophagus and lung most likely resulted from passing or swallowing of virus-
containing droplets and in the case of lung from deep inhalation.  The presence of viral DNA 
in the eye was unexpected, but might be explained by smear infection. In the animals infected 
with the lower calpox virus dose and sacrificed at day 5, low levels of viral DNA were detect-
ed in the nasal mucosa, tonsil and submandibular lymph node. Parallel analyses of the organs 
by immunohistochemistry for the detection of calpox virus antigen (Schmitt et al., 2017) sug-
gested that trafficking of infected macrophages presumably led to a secondary replication in 
the submandibular lymph nodes (Schmitt et al., 2017). Nasal mucosa was also positive for 
virus at day 7 in one animal (#14483) which exhibited high viral loads in that organ. Those 
were a couple of magnitudes higher compared to viral loads in the other organs of this animal 
or the loads in the other two animals of that group being either positive for viral DNA and/or 
infectious virus. Overall, in the day-7 animals only mild histological lesions were observed 
(Schmitt et al., 2017). 
In addition to the analyses of viral loads in a multitude of organs, also blood was investigated 
to define at which point in time viremia occurred. One animal of the day-3 high dose group 
presented with low level viremia based on viral DNA copy numbers (100 copies per µl). This 
animal was one of the two animals, which had comparable high levels of viral DNA and in-
fectious virus in the nasal mucosa. Thus, considerable viral replication at the portal of viral 
entry did not automatically resulted in viremia. Rather, early systemic viral spread might have 
been contained in the organ-positive, but blood-negative animal by short-lived innate immune 
responses. In the animals infected with the low calpox virus dose, viremia was only observed 
in two of three animals sacrificed at day 7. It can therefore be assumed that the onset of vire-
mia is dose dependent since it started later in low-dose infected animals. Most of the animals 
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became viremic at 10 and 12 dpi. The results of the endpoint dilution assay were in line with 
the results of the real-time PCR.  
Not surprisingly, the highest calpox DNA copy numbers in blood were detected in all animals 
euthanized at the latest predefined time point (12 dpi). The immune system probably collapses 
around that day followed by death within a few days. Discrepancies between pathological and 
molecular biological findings (e.g. trachea was negative for all 12 dpi animals in immuno-
histochemistry and no histological lesions were found (Schmitt et al., 2017), but had detecta-
ble calpox virus DNA and particles, (see Figure 3-1D)) can be explained by the different loca-
tions of primary material/tissue of an organ analyzed by the different techniques. This sug-
gests that even in the late preclinical stage of infection viral replication is still focal within an 
organ. 
The preferred organs of calpox replication before appearance of clinical signs appear to be 
nasal mucosa, bone marrow, liver and generally the lymphoid tissues, as indicated by high 
viral loads, i.e. 109-1017 calpox DNA copy number/g tissue and 107-109 TCID50/g tissue. 
Lower levels of calpox virus were observed in the central nervous system (CNS), parotid 
gland, small intestine and stomach. These findings are consistent with other studies (Tucker, 
2011). Overall, calpox virus replicated in a broad panel of organs tested, albeit to a different 
extent. 
My own data suggests that the calpox virus initially replicated in the upper respiratory tract, 
i.e. the nasal mucosa. From there the virus probably reaches via lymphatics the adjacent lym-
phatic tissue (submandibular LN and tonsil) in which secondary replication takes place. Next, 
the virus is transported through the blood stream all over the body (day 7). Lower viral loads 
(by real-time PCR and plaque assay) were found in the central nervous system (CNS), parotid 
gland, small intestine, stomach, esophagus, parotid gland and vagina/testicle indicating that 
the calpox virus replicated less inefficiently in these organs. These findings are consistent 
with other studies (Tucker, 2011).  
The viral dissemination/pathogenesis in the calpox virus/marmoset model is comparable to 
that of human smallpox infection (Fenner et al., 1988b), because it also starts in the respirato-
ry mucosa, spreads then to the draining lymph nodes and finally disseminates via blood to 
other organs. The same way of distribution was observed in a study in which cynomolgus ma-
caques were infected with aerosolized MPXV by using a head-only exposure chamber with a 
collision nebulizer (Zaucha et al., 2001). As in my study, the virus was detected in various 
organs in lethal MPXV infection. Moreover, Kramski and colleagues described the involve-
ment of organs of the digestive tract in the calpox virus/marmoset model as opposed to human 
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VARV infections (Fenner et al., 1988b; Kramski et al., 2010), which was also confirmed by 
this study. Following high-dose viral exposure, a monocytic cell-associated viremia was ob-
served in one animal at 3 dpi. By day 7, virus was detectable in a broad spectrum of organs. 
Mainly epithelial cells and macrophages, but also endothelial cells were infected (Schmitt et 
al., 2017). 
Because the last time point for predefined euthanasia (day 12) was very close to the time span 
of infection-related death, viral loads were highest compared to the earlier time point of nec-
ropsy. On that day, multiple immune cell subsets were also positive for calpox virus antigen. 
The broad cell tropism of the calpox virus is demonstrated in a study by Kramski and col-
leagues (Kramski et al., 2010). It has been shown that independent of the infection route and 
inoculated viral dose, high copy numbers of genomic viral DNA and virus-specific mRNA 
indicating active replication were found in a broad spectrum of organs and tissues (Kramski et 
al., 2010). Since VACV WR and MVA as well as the calpox virus seem to have also prefer-
ences for certain cell populations (Sanchez-Puig et al., 2004), this may indicate that factors 
other than host range genes like the accessibility and the amount of receptors, ability to inter-
nalize the virus and the metabolic state of the cell might influence the infection rate of 
PBMCs and immune cells. 
In lethal human monkeypox virus (MPXV) and variola virus (VARV) infection virus was also 
found in various organs (Fenner et al., 1988c). It has been shown for VARV infections in 
cynomolgus macaques that viral replication was probably associated with organ dysfunction 
and multisystem failure of all the organs (Jahrling et al., 2004), which assumably was also the 
case in this study. In the calpox virus/marmoset model, all animals that developed clinical 
signs died which is in contrast to natural human VARV and MPXV infections, where only 
part of the diseased patients became moribund. Seroconversion was not observed in animals 
that died within 12 days (Kramski et al., 2010) and was not analyzed in this pathogenesis 
study. Obviously, when the survival time is too short, virus-specific IgM antibodies are not 
mounted until the time point of death.  
In the calpox virus/marmoset model a clearly shorter time was reported between the first ap-
pearance of clinical signs until death, i.e. one or two days (Kramski et al., 2010), compared to 
human smallpox or MPXV infection. There, a period of two to five days was reported during 
which fever, malaise, prostration, headache and backache occurred that was followed by the 
development of a maculopapular rash. Animals of this study that were euthanized or died un-
expectedly between 12 or 16 dpi, showed varying clinical signs (Schmitt et al., 2017). Two 
animals from the group for which euthanasia was predetermined at 12 dpi had only very few 
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typical pox lesions on the skin, at mucocutaneous junctions and mild nasal discharge. The an-
imals with clinical signs showed fatigue, anorexia, moderate to severe seromucous nasal dis-
charge, and multiple pox lesions on skin and mucocutaneous junctions one to two days prior 
to death. Also, MPXV and VARV patients develop a more or less confluent rash (Fenner et 
al., 1988a; Fenner et al., 1988b; Fenner et al., 1988c; Jezek et al., 1987; Parker et al., 2007) 
which is lacking in the calpox virus infected monkeys (Kramski 2010). Only small, however 
multiple skin lesions distributed on the face, abdomen and thighs after i.n. infection with cal-
pox virus occurred in CM (Kramski et al., 2010). Studies have already shown that even a high 
calpox viral dose did not lead to confluent skin lesions, which are characteristic for and previ-
ously demonstrated in macaques infected with MPXV and VARV (Hooper et al., 2004; 
Jahrling et al., 2004; Paluku and Szczeniowski, 1988; Stittelaar et al., 2005).  
The morphology of the skin lesions induced by calpox virus differs from VARV or MPXV 
lesions. While in calpox infection skin lesions were flat and small in size (2-5 mm in diame-
ter), VARV- or MPXV-associated lesions reach a diameter of up to 10 mm. However, the size 
of the animal may also be related to the size of the skin lesions. A severe lymphadenopathy 
was found in calpox virus infection and represent a classic alteration in many OPXV infec-
tions. The lymphadenopathy is comparable to the clinical picture of cowpox virus (CPXV) 
and MPXV infections in humans and also in NHP, but is not observed in human smallpox 
(Fenner et al., 1988a; Heraud et al., 2006; Hooper et al., 2004; Sale et al., 2006). 
4.1.5. Virus titration and viral DNA quantification of organ homogenates 
The infectious virus titre of a tissue is known to be lower than the titre of the viral load since 
real-time PCR not only measures the replicating virus (like TCID50/g tissue) but also other 
viral particles. Results of endpoint dilution assay and real-time PCR mostly matched with the 
pathological finding e.g. nasal mucosa was negative for all 7 dpi animals, except in one ani-
mal (#14483) with the highest viral load and replicating viral titre at 7 dpi. In a parallel pro-
cessed dissertation (Schmitt, 2015), mild histological lesions were detected in this animal. 
Discrepancies between pathological and molecularbiological findings (e.g. trachea was nega-
tive for all 12 dpi animals in immunohistochemistry and no histological lesions were found, 
but had detectable viral load and was also positive in endpoint dilution assay, see Figure 3-
1D) can be caused by using different primary material/tissue of an organ.  
Expectedly, the highest TCID50/g tissue and calpox DNA copy number/g tissue were meas-
ured in 12 dpi animals, because of the close time to the expected moribund endpoint at 12 dpi. 
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Since the comparison of the two assays (real-time PCR and endpoint dilution assay) shows 
that the bone marrow, nasal mucosa and submand. LN were strongly positive organs in both 
tests, the calpox virus consequently replicated efficiently in these organs. Low viral levels in 
both assays were determined in the central nervous system (CNS), parotid gland, small intes-
tine and stomach, which indicate that the calpox virus replicated less efficiently in these or-
gans. These findings are consistent with other studies (Tucker, 2011).  
Both assays were positive at 3 dpi for nasal mucosa and tongue, the highest values however, 
were measured in nasal mucosa (epithelial layer of the mucous membranes in the nose) in 
both assays. The highest viral load in 5 dpi animals (with the low inoculation dose) was also 
detected in the nasal mucosa in one of three animals, which indicates earliest replication of 
the virus in the nose for both inoculation doses. There is no evidence for a viremia at 5 dpi, 
because no infectious virus was detected and only few tissues were positive in of two of three 
animals. Calpox DNA copy numbers and infectious virus titres were found in a broad spec-
trum of organs from 7 dpi to 12 dpi. In conclusion the viremia then starts between 5 and 7 dpi 
after a local virus replication at the viral application site. 
To sum up the results of the endpoint dilution assay and real-time PCR, the data provide evi-
dence that the calpox virus first replicates where the virus is applied (in the nose) and evi-
dence for viremia starting between 5 and 7 dpi is shown. 
4.1.6  (I) Portal of viral entry 
One of the aims was to determine the portal of viral entry. Only very mild histological altera-
tions were detected at day 5, 7 and 10 as described in a dissertation conducted in parallel 
(Schmitt, 2015). Also, in almost all day-5 animals, no calpox virus DNA and no infectious 
calpox virus was detected. Therefore, a second study was performed where 3 more animals 
were infected with an approximately 42-fold higher dose in order to increase sensitivity of the 
analyses.  
There have only been reports about the severe pathological alterations of the late stage of the 
disease caused by calpox virus. Therefore, a study where serial necropsies were carried out 
during the asymptomatic phase of calpox virus infection in common CM (CM) was designed. 
At each defined time point, a broad spectrum of organs was collected and analyzed for the 
occurrence of alterations (see dissertation by Schmitt, 2015). The aim was to determine pri-
mary target cells and organs of infection as well as to determine the portal of viral entry (I). 
Another aim was to investigate the early dissemination and the pathological sequelae of infec-
tion (II) by detection of replicating calpox virus and calpox viral DNA in different organs 
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(present study). In addition, the detection of replicating calpox virus and calpox virus DNA in 
blood was in focus. The aims of the study were to detect the start of viremia and to analyze by 
flow cytometry which are the preferred immune cell subsets for calpox infection. Studies have 
shown that in the calpox model when employing intranasal virus inoculation very low infec-
tious doses are sufficient to establish infection compared to common OPXV models (Kramski 
et al., 2010). Therefore, in this study, animals were inoculated via the intranasal (i.n.) route. 
Also, the infection of the upper respiratory tract closely resembles the natural infection route 
of smallpox, which occurs via aerosols. Aerosols with an infectious virus are inhaled, exposed 
to the oral, nasal, pharyngeal mucosae or if inhaled deeper to the lung, could lead to disease in 
the lower respiratory tract (Barnewall et al., 2012; Fenner et al., 1988b). 
It is known that the initial site of the orthopoxvirus (OPXV) infection is the skin, a mucosal 
surface or the respiratory tract (Munoz, 2014b). For the calpox/marmoset model it was as-
sumed that the nasal epithelium and the nasal-associated lymphoid tissue (NALT) represent 
the principal target for primary infection when the virus is administered intranasally (Mätz-
Rensing et al., 2012). To understand the pathogenesis of the calpox virus infection in CM the 
pathogenesis study was conducted to analyze the early replication site. The detection of repli-
cating calpox virus and viral DNA in the nasal mucosa three days after inoculation leads to 
the conclusion that calpox virus first multiplies at the inoculation site, the nasal mucosa. The 
portal of viral entry and the location of primary replication is thus the nasal mucosa (nose) 
when the virus is inoculated intranasally. Different findings underline the observation that na-
sal epithel cells are the principle target cells. First, viral DNA was also almost exclusively de-
tectable in the nasal mucosa at 5 dpi when the low infectious dose was given. In addition, the 
results of the immunohistochemical analyzes presented in a dissertation conducted in parallel, 
show that the nasal epithelial cells serve as the principal target cells for primary replication 
since viral antigen within inclusion bodies was detected in that study at 3 dpi (Schmitt, 2015). 
Additionally, first alterations in the nasal ciliated epithelium were visible as well as immuno-
histochemical reactivity in respiratory epithelium at 3 dpi.  
The nasal mucosa is the location of viral entry. The nasal mucosa´s immune system is the na-
sal-associated lymphoid tissue (NALT) that has been assumed to be the principal target for 
primary infection in this model (Mätz-Rensing et al., 2012). The NALT can protect against 
infectious agents such as airborne transmitted viruses (e.g. VARV) or other pathogens and 
contains many immunocompetent cells (e.g. B cells, dendritic cells, macrophages, T cells) 
(Bienenstock and McDermott, 2005). Furthermore, NALT consists of follicle-associated epi-
thelium, the overlying epithelium with microfold M cells. M cells take up viral antigen and 
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transport them to the immune cells. Dendritic cells with antigen will then migrate to the drain-
ing lymph node and present the antigen to T cells (Xu et al., 2014). 
Consistently, the first targets for naturally acquired smallpox infection are the cells of the mu-
cous membranes of the mouth, the nasal cavity, the oropharynx and the alveoli of the lungs. 
The findings in this study seem reasonable, because in other CPXV and ECTV species the 
replication site is the infected epithelia (Patel et al., 1986).   
4.1.7 Calpox virus detected in blood 
Infectious virus in buffy coat and viral DNA quantification from whole blood 
Earliest calpox viral DNA in blood was detected in two of three animals at 7 dpi (#14966 and 
#14483). Therefore, supposably viremia starts between 5 dpi (when no viral DNA was detect-
ed) and 7 dpi following inoculation with the lower viral dose (8.3 x 103 pfu). It is assumed 
that the dose was too low to cause viremia at 5 dpi animals, since all three animals at 5 dpi 
were negative in blood for viral DNA. Most of the animals became viremic after calpox infec-
tion at the following time points. 
To increase the probability to track down the virus, the day-3 animals received an approxi-
mately 42-fold higher dose (3.5 x 105 pfu) and one of three animals at 3 dpi became viremic. 
Earliest viral DNA in blood was found in one animal at 3 dpi (#14484) (3.2.1.2 Viral DNA 
quantification from whole blood), however, this did not coincide with detection of replicating 
virus in buffy coat. This can be explained by the fact that the infectious virus titre in buffy 
coat is known to be lower than the titre of viral load since real-time PCR method is more sen-
sitive. The real-time PCR measures the replicating virus as well as non-replicating viral parti-
cles.  
The results of the plaque assay using buffy coat for cocultivation with sensitive indicator cells 
appeared to be valid when compared to the results of the real-time PCR at 7 dpi. Day -5, -7 
and -10 group animals were not tested for replicating calpox virus in blood because the meth-
od was not established at that time point. Instead, the day-12 group was tested at 7, 10 and 12 
dpi. The first replicating virus was detected in one of three animals (#15095) of the day-12 
group (animals were infected with 8.3 x 103 pfu calpox virus) at 7 dpi, but analysis for viral 
DNA was not done. However, calpox viral DNA was detected in two of three animals 
(#14966 and #14483) from the day-7 group. 
Most of the animals became viremic at 10 and 12 dpi and at 10 dpi the replicating virus and 
calpox viral DNA increased because the end of the incubation period is at approximately 11 
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days post infection. As expected, the highest calpox DNA copy numbers in blood were de-
tected in all animals euthanized at the latest time point (12 dpi).  
To sum up the results of testing blood for infectious virus as analyzed by plaque assay with 
buffy coat and for viral DNA by real-time PCR with whole blood, it can be postulated that a 
start of viremia (DNA copies in blood) is dose dependent. In this model viremia starts at 3 dpi 
(with the high inoculation dose) or between 5 and 7 dpi (with the low inoculation dose). 
4.1.8 Detection of calpox virus infection with anti-vaccinia virus (VACV) serum  
The viremia starts at day 3 with the high dose (3.5 x 105 pfu calpox virus) 
Calpox virus antigen positive (calpox+) cells were detected in cells from buffy coat and 
PBMCs. The detection of calpox+ cells of CD3+CD20+ cells in two of three animals and the 
detection of calpox+ cells of intermediate CD14+CD16+ monocytes in one of three animals of 
the 3-day group indicates the start of viremia at day 3. These results are in line with other 
findings. Therein, the calpox virus was detected in the blood of one of three animals at that 
time point by real-time PCR (4.1.7 Calpox virus detected in blood).  
Early reports have indicated that VACV causes a cytopathic effect in human leukocytes and 
an infection of leukocytes has also been reported in monkeys. For cynomolgus macaques in-
fected intravenously with cowpox virus, it is known that especially monocytes and granulo-
cytes were positive for the virus (Song et al., 2013b). Monocytes and granulo-
cytes/neutrophils were also the major populations that were stained positive for pox antigen, 
whilst frequencies of B cells, NK cells and T cells were low in cynomolgus macaques. How-
ever, in the pathogenesis study presented herein neutrophils were tested negative in day-3 and 
only a very small proportion of neutrophils appeared to be positive in one day-12 animal. 
Monocytes (CD14+CD16-, CD14+CD16+ and CD14+CD16-) were tested calpoxvirus antigen 
positive at 12 dpi. But their proportion was not as high as that of CD20+ B cells and of 
CD3+CD20+ cells. To my knowledge, nothing is known about CD3+CD20+ cells in CM so far 
and further research is needed to clarify their function in common CM (CM). Double positive 
CD3+CD20+ cells are usually only detected in e.g. lymph nodes of rhesus macaques (Macaca 
mulatta), but not in blood. Schuh and colleagues reported that 3-5 % of the T cells in human 
blood express CD20 and that the CD3+CD20+ T cells produce different cytokines, pervade 
lymphatic organs and the cerebrospinal fluid. (Schuh et al., 2016). They also respond to MS 
disease modifying drugs. The existence of CD3+CD20+ cells have been controverely dis-
cussed and were thought to be an artifact of flow cytometry in the past (Henry et al., 2010). 
  108 
They also have been described as a storage-dependent phenomenon (Nagel et al., 2014). Fol-
lowing recent studies (Neumann et al., 2015; Schuh et al., 2016) CD3+CD20+ T cells do exist. 
The function of human CD3+CD20+ T cells is the production of different cytokines (IL-4, IL-
17, IFN-γ and TFN-γ), pervading lymphatic organs and the cerebrospinal fluid. They also re-
spond to MS disease modifying drugs.  
This study clearly demonstrated the presence of the calpox virus antigen in different immune 
cells (neutrophils, monocytes, T and B cells and NK cells) by flow cytometry. In marmostes 
infected for 12 days, multiple immune cell subsets were positive for calpox virus antigen. Fur-
thermore, the results of this study point to a preference of calpox virus infecting certain cell 
types. Infection was detected in all tested immune cells (monocytes, T and B cells and NK 
cells) except for the neutrophils. Followed by CD20+ B cells and NK cells CD3+CD20+ cells, 
the monocytes were most susceptible. CD3+ T cells were infected at very low frequencies. 
These findings are conform with the results of VACV WR infection of human PBMCs by 
Sanchez-Puig and colleagues (Sanchez-Puig et al., 2004). When macrophages get infected, 
their normal ability to act as accessory cells to activate T-cells or natural killer (NK) cells and 
secrete cytokines is blocked which is of advantage for virus infection (Smith and Kotwal, 
2002). Perhaps the virus infects the immune cells that play an important role in host defense 
as e.g. NK cells play an important role in early (first three days) host immune response after 
poxvirus infection. The latter implies that T cell responses seems to play a more important 
role in the early rather than the late phase of primary, acute infections (Gordon et al., 2011; 
Xu et al., 2004b).  
Not only did Sanchez-Puig and colleagues find that VACV WR and MVA showed a prefer-
ence for certain cell populations (Sanchez-Puig et al., 2004), but this study also showed that 
the calpox virus seems to have preferences for certain cell populations. This may indicate that 
factors other than host range genes like the accessibility and the amount of receptors, ability 
to internalize the virus and the metabolic state of the cell might influence the infection rate of 
PBMCs and immune cells in the buffy coat. 
4.1.9 Detection method for calpox virus 
The calpox virus was detected in blood by using different methods. The first method was the 
detection of the calpox virus antigen in buffy coat and PBMCs by flow cytometry, secondly 
viral DNA was quantified by real-time PCR and the third method was the virus isolation from 
buffy coat by plaque assay. Comparison of the different calpox virus detection methods re-
vealed that real-time PCR and calpox virus antigen staining by flow cytometry are very sensi-
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tive methods and more sensitive than virus isolation. When the same animals were first tested, 
calpox virus DNA was detected in only one of three animals at 3 dpi by real-time PCR. Cal-
pox viral antigen was detectable in immune cells of at least two day-3 animals in CD3+CD20+ 
cells by flow cytometry. In animals that had the highest percentages of calpox+ cells by flow 
cytometry, the highest viral loads were also detected by real-time PCR. Aside from real-time 
PCR, calpox virus antigen detection in buffy coat and PBMCs by flow cytometry was the 
most sensitive method used here. 
The real-time PCR and poxvirus antigen staining by flow cytometry methods are also the 
fastest methods. Since replicating calpox virus detection by plaque assay was first observed at 
7 dpi in one of three animals, this seems to be the least sensitive of the tested methods. 
Calpox virus antigen staining by flow cytometry has its advantages. It is possible to test dif-
ferent immune cells in one approach and detect the infection of animals supplementing real-
time PCR and plaque assay. Because a lower background staining (baseline) was detected in 
cells from buffy coat of the controls animals compared to purified PBMCs, the calpox virus 
antigen staining by flow cytometry with cells from buffy coat is prefered.  
4.1.10 Onset of viremia is dose dependent as determined by real-time PCR, plaque 
assay and calpox viral antigen staining 
Viremia starts at 3 dpi in cases with high dose infection (3.5 x105 pfu calpox virus) as calpox 
virus antigen positive (calpox+) cells in buffy coat and PBMCs were detected at this time 
point (#14484 and #14991) and calpox virus DNA in blood was detected by real-time PCR at 
3 dpi (#14484). Replicating virus was not detected at 3 dpi.  
However, based on the results of calpox DNA copy numbers in different organs from 7 to 12 
dpi, it can be concluded that after a local virus replication at the viral application site the vi-
remia starts between 6 and 7 dpi (with the low inoculation dose). In the low-dose group (8.3 x 
103 pfu calpox virus) earliest calpox viral DNA in blood was detected in two of three animals 
at 7 dpi (#14966 and #14483) but not at 5 dpi. At 7 dpi the first replicating virus was also de-
tected in one of three animals (#15095). Evidence of a viremia that starts between 6 and 7 dpi 
with the low dose (8.3 x103 pfu calpox virus), exists and it can therefore be assumed that the 
onset of viremia is dose dependent.   
4.1.11 (II) Early dissemination and pathological sequelae of infection 
It has been reported that once cells became pox-antigen positive and remained positive, the 
non-human primates (NHPs) developed more severe symptoms and reached moribund end-
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points (Song et al., 2013a). Unfortunately, this was not analyzed here because animals were 
euthanized at defined time points even though in this study the CD3+CD20+ subset and inter-
mediate CD14+CD16+ monocytes were positive for calpox antigen as determined by flow cy-
tometry at 3 dpi. Future studies with the testing for poxvirus antigen positive cells in this 
model might give insights of a correlation between early positive poxvirus antigen staining, 
disease progression and lethality since early positive pox staining is also a strong predictor for 
lethality in the studies of Song and colleagues.  
Little was known about the early phase of the calpox virus pathogenesis. To understand the 
early dissemination and pathological sequelae of calpox virus infection in CM the pathogene-
sis study was conducted. The pathogenesis study provides evidence that after intranasal cal-
pox virus application the nose represents the portal of viral entry in the calpox/maroset model 
and therefore early dissemination starts in the nasal mucosa.  
Earliest and highest detection of calpox virus DNA and replicating calpox virus was in the 
nasal mucosa at 3 dpi (with the high inoculation dose). The earliest and highest detection of 
the calpox virus DNA was also detected in the nasal mucosa at 5 dpi (with the low inoculation 
dose). Therefore, this location is the portal of viral entry. Other organs (eyes, esophagus, lung, 
tongue and tonsil) were positive for calpox viral DNA and/or replicating calpox virus at 3 dpi 
and for calpox DNA copy numbers at 5 dpi (with the low dose) (nasal mucosa, submandibu-
lary LN and tonsil). When analyzing the early dissemination, viremia starts at 3 dpi (with the 
high inoculation dose) in the calpox/marmoset model after i.n. inoculation. The results out-
lined in a dissertation conducted in parallel show that the trafficking of infected macrophages 
presumably lead to a secondary replication in the submandibulary LN and the spleen 
(Schmitt, 2015).  
Virus replicated efficiently in the bone marrow, nasal mucosa and submandibulary LN. Two 
assays (real-time PCR and endpoint dilution assay) were compared and the organs contained 
high viral levels as manifested in both tests (between 1012 and 1017 calpox DNA copy num-
ber/g tissue and between 108 and 109 TCID50/g tissue). This also indicates a progressive in-
fection. In comparison to the intravenous (i.v.) inoculation route decribed by Kramski and 
colleagues, the highest viral loads were measured in skin, spleen, lung, lymph node, tonsils 
and trachea and indicate lower viral loads when compared to the results of this study (between 
107 and 108 calpox virus genome equivalents (GE)) (Kramski et al., 2010).  
The data suggests that the calpox virus initially replicated in the upper respiratory tract fol-
lowed by the systemic spread. Calpox virus probably disseminated through the blood stream 
(viremia; see 4.1.6). Onset of viremia is dose dependent as determined by real-time PCR, 
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plaque assay and VACV antigen staining. It is probable that the calpox virus first replicated in 
the nasal mucosa and then spread from the nasal mucosa to the surrounding lymphatic tissue 
(submandibulary LN and tonsil) where it leads to secondary replication. The virus probably 
spreads from there to other organs of the respiratory tract and other surrounding tissues (eyes, 
esophagus, lung and tongue) by viremia followed by diffuse dissemination in other organs. 
Low level infection as indicated by the results from both assays (real-time PCR and endpoint 
dilution assay) were determined in the central nervous system (CNS), parotid gland, small 
intestine, stomach, esophagus, parotid gland and vagina/testicle suggesting that the calpox 
virus replicated less efficiently in these organs. These findings are consistent with other stud-
ies (Tucker, 2011).  
The pathogenesis in this model is comparable to that of smallpox infection, because it also 
starts in the respiratory mucosa, spreads to the lymph nodes and is followed by viremia. The 
same process was observed in a study where cynomolgus macaques were infected with aero-
solized MPXV by using a head-only exposure chamber with a collision nebulizer (Zaucha et 
al., 2001). 
As in this study, the virus was detected in various organs in lethal human MPXV and VARV 
infections. Kramski and colleagues described the involvement of organs of the digestive tract 
in the calpox virus/marmoset model opposed to human VARV infections (Fenner et al., 
1988c), which was verified in this study. A monocytic cell associated viremia starts at 7 dpi 
and causes systemic dissemination of the virus. The virus is detectable in a broad spectrum of 
organs, mainly in epithelial cells and macrophages, but also in endothelial cells. The viremia 
proceeds in viral replication and typical calpox lesions in lung, liver, lymphatics, adrenal 
gland, mucocutaneous junctions, and skin as described in a parallel dissertation (Schmitt, 
2015). 
Because 12 dpi is already close to the moribund endpoint, the highest TCID50/g tissue and 
calpox DNA copy number/g tissue were measured in 12 dpi animals. In late state infection 
(12 dpi), multiple immune cell subsets were also positive for calpox virus antigen. The wide 
cell tropism of the calpox virus is demonstrated in a study of Kramski and colleagues. It has 
been shown that independent of the infection route and inoculated viral dose, high copy num-
bers of virus genomic DNA and virus-specific mRNA indicating active replication were 
found in a broad spectrum of organs and tissues (Kramski et al., 2010). In lethal human mon-
keypox virus (MPXV) and variola virus (VARV) infections, multiple organs are also general-
ly involved and the virus was also found in various organs (Fenner et al., 1988b). It has been 
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described that a systemic macrophage response is required to contain a peripheral poxvirus 
infection (Davies and Parekh, 2017). 
It has already been shown for VARV infections in cynomolgus macaques that the virus repli-
cation was probably associated with organ dysfunction and multisystem failure of all the or-
gans (Jahrling et al., 2004), which assumably was also the case in this study. In the calpox 
virus/marmoset model, all animals that developed clinical symptoms died. In natural VARV 
and MPXV infections, only part of the diseased patients had a lethal outcome. Seroconversion 
was not observed in animals that died within 12 days and was not analyzed in the pathogene-
sis study. Obviously, the survival time of the CM after infection is too short to detect titres of 
virus-specific IgM antibodies at the time point of death. It has also been reported that intrana-
sal infection of the calpox virus probably resulted in an overwhelming infection and death 
occurred before the humoral immune system could respond by developing IgG and neutraliz-
ing antibodies (Kramski et al., 2010). 
In the calpox virus/marmoset model, most of the clinical signs resemble those commonly 
found in smallpox. In this model, however a drastically shorter time was reported between the 
first appearance of clinical signs only one or two days before death (Kramski et al., 2010; 
Schmitt, 2015). In human smallpox and MPXV infection a longer period of two to five days 
were reported where fever, malaise, prostration, headache and backache occurred which were 
followed by the development of a maculopapular rash. The first symptoms rapidly developed 
into more severe clinical findings in the upper respiratory tract and the lymphatic system as 
well as hemorrhagic edema. As reported in a dissertation conducted in parallel (Schmitt, 
2015), animals that were euthanized or died unexpectedly between 12 or 16 dpi, showed vary-
ing symptoms. Two animals from the group that was euthanized at 12 dpi had only a very few 
typical pox lesions on the skin, mucocutaneous junctions and mild nasal discharge. The ani-
mals with symptoms showed signs of fatigue, anorexia, moderate to severe seromucous nasal 
discharge and multiple pox lesions on skin and mucocutaneous junctions one to two days pri-
or to death. Another difference to MPXV and VARV patients is that those present with a 
more or less confluent rash (Fenner et al., 1988a; Fenner et al., 1988c; Jezek et al., 1987; 
Parker et al., 2007). Only sporadic and small skin lesions distributed on the face, abdomen, 
and thighs after i.n. infection with calpox virus occurred in CM (Kramski et al., 2010). Stud-
ies have already shown that even with a high calpox virus dose it was impossible to induce an 
infection that led to skin lesions that were distributed confluently on the body of CM that is 
characteristic and previously demonstrated in macaques infected with MPXV and VARV 
(Hooper et al., 2004; Jahrling et al., 2004; Jezek et al., 1988; Stittelaar et al., 2005).  
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The morphology of the skin lesions differs between calpox virus and VARV or MPXV le-
sions. The calpox virus induced skin lesions were flat and small in size (2-5 mm in diameter) 
whereas the lesions induced by VARV or MPXV, reach a diameter of up to 10 mm, but the 
size of the animal might also play a role (Kramski et al., 2010). The severe lymphadenopathy 
was found in calpox virus infection and occurs as a classic alteration in many OPXV infec-
tions. The lymphadenopathy is comparable to the clinical picture of the cowpox virus (CPXV) 
and MPXV infections in humans and also NHP models but not in human smallpox (Fenner et 
al., 1988a; Heraud et al., 2006; Hooper et al., 2004; Kramski et al., 2010; Sale et al., 2006). 
4.2 Vaccination studies  
4.2.1 Vaccine efficacy 
In addition to efficacy testing of next-generation vaccines against orthopoxviruses in mouse 
models, further proof has to be provided by using suitable large animal models. In this respect 
animal models with an immune system very similar to the human one are preferable. This is 
the reason why non-human primates were chosen as large animals for such studies. To this 
end, efficacy of candidate vaccines has been investigated in macaques which were challenged 
with MXPV or VARV. However, mostly monkeys were exposed to high viral doses by the 
intravenous route, thus not representing the natural transmission route of the two human-
virulent viruses. Since in the calpox virus/marmoset model very low viral doses administered 
intranasally are sufficient for infection and rapidly lead to death of all animals, this model can 
provide meaningful efficacy data through a natural transmission setting in a short period of 
time. The primary read-outs for protection are viral loads and survival.  
Earlier studies in the calpox virus/marmoset model have shown that after a waiting period of 
ten weeks between single vaccination with vaccinia virus Lister Elstree (VACV LE) intra-
dermally (i.d.) and intranasal calpox challenge all vaccinees were protected. When vaccinees 
were already challenged four weeks after VACV LE was given, only one of four was protect-
ed (Kramski, 2009). The conventional VACV vaccine against smallpox is known to be asso-
ciated with considerable side effects, particularly in older or immunocompromised vaccinees 
(Mota et al., 2011). Thus, in this study the differently attenuated, safer VACV vaccines 
MVTT and MVA were evaluated in CM for their efficacy against intransal low-dose calpox 
virus exposure after a 4- (study I) or 10-week waiting period (study II) between last immun-
ization and viral challenge. To compensate for their reduced replication capacity compared to 
replication-competent VACV LE, both vaccines were given twice four weeks apart as was 
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reported for MVA before (Stittelaar et al., 2005). Because MVTT was highly immunogenic in 
mice after noninvasive mucosal administration, either through the intransal (Yu et al. 2009) or 
peroral route (Huang et al. 2009), the same routes were chosen for immunization of CM with 
MVTT. As numbers of monkeys were limited not allowing to test both mucosal routes com-
bined with the different waiting periods, relying on efficacy data in the mouse model (Yu et 
al., 2010) in vaccine study I only the efficacy of intranasal MVTT applicaton was investigat-
ed. By contrast, intranasal and peroral immunizations were compared side by side, when a 
longer waiting period (10 weeks) should allow for prolonged maturation of vaccine-induced 
immune responses and thus for better protective effects.  
When the time period until the animals died (days post challenge) is compared between the 
vaccine failures and the mock immunized control animals a significant difference was de-
tetcted (***; p = 0.0002). Therefore, a vaccination effect is present in the vaccine failures, but 
this effect can not be explained by the data raised in this thesis.  
Overall, independently of the waiting period immunization with MVTT protected 67 % of the 
animals whereas immunization with MVA was only protective in 13 % of the test animals.  
While MVA was not protective when last immunization and challenge were spaced four week 
apart, intranasal immunization with MVTT protected three out of four monkeys after this 
waiting period, thereby confirming MVTT efficacy findings in the mouse model (Yu et al., 
2010). The longer waiting period seemed to slightly improve protection in the MVA immun-
ized group as indicated by survival of one of four vaccinees, whereas in animals immunized 
with MVTT i.n. no increased protection rate was observed. Similar protective rates were ob-
served after peroral MVTT immunization. Thus, MVTT immunization by the two different 
mucosal routes seemed to provide similar protection levels, which however did not reach 
those achieved by the fully replication-competent VACV LE. The high efficacy of VACV LE 
still represents the gold standard for a prophylaxis against orthopoxviruses. This high level of 
protection could not be achieved by the more attenuated VACV vaccines, but considering the 
potential side effects of the conventional smallpox vaccine, MVTT seems to be a safe and 
well-tolerated smallpox vaccine candidate for humans. Compared to MVTT, MVA-mediated 
protection was poor in the calpox virus/marmoset model. This might be attributable to the 
stringency of the calpox virus challenge. If calpox virus replicates to a certain threshold, the 
virus is always lethal for CM. This is in contrast to the MPXV/macaque model in which dose-
dependent stages of infection occur. In that model MVA mediated protection from disease, 
but not from infection (Earl et al., 2004; Stittelaar et al., 2005). Because of the reduced repli-
cation competencies of MVA and MVTT (MVA < MVTT) in contrast to the fully replication 
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competent VACV LE development of protective immune responses through these vaccines 
may require even a longer period of time as compared to VACV LE. Still, MVTT- or MVA 
induced immune reactions may never be sufficient for complete protection in the calpox vi-
rus/marmoset model. Interestingly, and controversial to the own calpox challenge data, al-
ready four days after a single MVA immunization macaques were protected from pathogenic 
sequelae of a MPXV challenge, most likely due to rapidly developing antibody and CD8+ T 
cell responses (Earl et al., 2008).  
Kinetics of calpox viral DNA load in blood from all vaccine failures were comparable to 
those observed in mock immunized animals. Moreover, in study II the data on replicating vi-
rus confirmed those on viral DNA.  
In three protected MVTT-vaccinees of study I very low levels of calpox virus DNA were 
transiently observed starting on day 14 or 21. Whether this also translated into infectious vi-
rus, could not be assessed. In study II two protected vaccinees exhibited those viral blips as 
well, but remained negative for infectious virus. Thus, albeit calpox virus probably replicated 
in some protected animals, the immune responses were obviously able to control viral dissem-
ination and to finally eliminate the virus. Therefore, these animals were protected against cal-
pox virus-induced clinical manifestations and overall are regarded as protected. Vaccinees 
were considered being protected according to the criteria survival and viral load. 
Low-level viral DNA blips in blood of protected vaccinees were detected. It seems as when 
the calpox DNA copy numbers increase upon a certain threshold (between 103 and 104) ani-
mals die from disease. 
4.2.2 The role of the humoral immune response in the calpox virus/marmoset model 
In this study the role of humoral serum responses was analyzed by the analysis of binding an-
tibodies by enzyme-linked immunosorbent assay (ELISA), mapping antibodies against linear 
B cell epitopes and the investigation of neutralizing antibody titres. In non-human primates as 
well as mouse models, no protection was observed before antibodies were developed (within 
a period of seven to ten days after vaccination) (Staib et al., 2006; Stittelaar et al., 2006).  
In this system it was not possible to test the role of the complement due to the limited availa-
bility of plasma. Plasma samples were only tested without heat inactivation because of the 
type of sample used here.  
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Binding antibodies by enzyme-linked immunosorbent assay (ELISA) 
A correlation between the presence of serum antibodies and protection has been reported for 
human orthopoxvirus (OPXV) infections (Downie and Mc, 1958; Mack et al., 1972; Sarkar et 
al., 1975). In the vaccination studies presented here the antibody responses determined in the 
day-of-challenge plasma were not associated with protection. 
The reasons for this are not clear, but should not be a matter of immune response maturation. 
In this respect it has been reported that in macaques MVA immunization led to a more rapid 
development of cellular and humoral immune responses compared to Dryvax immunization 
and was already 100 % protective against a lethal MPXV dose ten days after vaccination (Earl 
et al., 2008). Furthermore, those reactions were stable and very similar in the two vaccine 
groups four weeks after vaccination. Thus, such stability of immune responses is also to be 
expected in the marmorset vaccinees, and lack of an immune correlation cannot be explained 
by waning immunity. It should be noted that ELISA antibody levels against calpox virus (ex-
pressed as OD450 nm) were considerably lower than against VACV which might me attributa-
ble to lower affinity of antibodies towards calpox viral particles.   
Interestingly, independent of the vaccine variant and the immunization routes used an anan-
mnestic antibody response was not only noticed in all MVA and MVTT vaccine failures, but 
also in 75 % of the protected MVTT vaccinates. This indicates that low-level calpox virus 
replication must have occurred in those protected animals displaying the stark rise in antibody 
levels after challenge, presumably at the vaccination site, however, not leading to viremia. 
When considering all protected animals, two MVTT and one MVA vaccinate lacked this re-
sponse which suggests sterile immunity. 
Specificity of antibodies against B cell linear epitopes in relation to challenge outcome 
Since binding antibody levels against whole orthopoxvirus antigen did not discriminate be-
tween protected and unprotected vaccines, antibodies were analyzed at a high resolution level 
by means of peptide microarrays. This technique allows to measure antibodies against linear 
epitopes of an antigen, in this case against vaccinia virus proteins. For the generation of over-
lapping peptide libraries, the immunodominant VACV WR proteins A27, A33, B5, D8, H3, 
and L1 (Matho et al., 2012) were chosen. They represent surface proteins and are targets of 
neutralizing and protective antibodies (Moss 2011). 
The proteins A27, D8, H3 and L1 are involved in virus entry and/or fusion (Moss, 2011), 
whereas the proteins A33 and B5 play a role in virus spread (Moss, 2011). 
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A27 is an enveloped protein and is anchored to the viral membrane of the MV and one of the 
three glycosaminoglycan adhesion molecules. Linear epitopes in A27 have already been de-
scribed as targets of protective antibodies induced by vaccination against smallpox (Kaever et 
al., 2016).  
A33 (Roper et al., 1996) and B5 (Engelstad et al., 1992; Isaacs et al., 1992) are transmem-
brane proteins that are exposed on the outer surface of the enveloped virion (EV), but are not 
found on the intracellular mature virions (IMV) (Chan and Ward, 2010). These proteins were 
chosen, because deletion of their genes resulted in decreased virus spread (Moss, 2011). A33 
and B5 have also been shown to be targets of comet-reducing antibodies. A33 and B5 are EV 
membrane proteins and were protective in the intranasal VACV and ectromelia virus (ECTV) 
footpad infection mouse models (Fang and Sigal, 2006; Fogg et al., 2004; Galmiche et al., 
1999). 
D8 is another membrane protein, which was chosen because the mAb LA5 binds to the 
VACV envelope protein D8 and is able to neutralize VACV when complement is present 
(Matho et al., 2012). D8 binds to the chondroitin sulfate on the host cell surface, but not to 
heparan sulfate like proteins H3 and A27 (Matho et al., 2012). 
H3 is, like A27, involved in cell adhesion of the MV to glycosaminoglycan heparan sulfate of 
the host cell (Matho et al., 2012). 
L1 is a capsid protein of the MV, which is located on the mature virion (MV) and functions as 
an entry/fusion protein. L1 is likely associated with the neutralization of VACV (Kaever et 
al., 2016). Furthermore, antibodies against A33, B5 and L1 were able to protect mice against 
lethal challenge with VACV (Fogg et al., 2004). 
In this study, unique antibodies against linear B cell epitopes in proteins L1, A33, and B5 
were only identified in protected animals almost exclusively after (epitopes 1-4), but in one 
case also before challenge (epitope 5). The failure to detect a specific reaction pattern of anti-
bodies directed against distinct amino acid sequences might be explained by (i) low antibody 
levels which were not sufficient to result in a reaction in the peptide array. Another reason for 
not detecting antibodies against B cell epitopes that correlate with protection might be that (ii) 
the sequences of the printed VACV WR peptides are too divergent to those of the vaccines 
(MVA and MVTT) thereby missing antibody responses. Alternatively, (iii) at least antibodies 
against epitopes 1-4 developed de novo post challenge. The theory behind this is that other 
antibodies may play a role in the exposure of these four epitopes to the immune system upon 
binding to the challenge virus thereby unmasking usually unaccessible regions. This phenom-
enon was observed (a change in the 3D structure) in the presentation of an important neutral-
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izing epitope in the haemagglutinin of the influenza virus upon binding of antibody to differ-
ent regions (Leikina et al., 2002). Finally, another plausible argument for lack of antibodies 
against linear amino acid sequences could be that (iv) almost all generated antibodies were 
directed against conformational or discontinuous epitopes which prevents any detection in the 
peptide microarray.   
A further reason why protective antibodies might not have been screened by peptide microar-
ray at challenge could be that the proteins that were synthetized and printed on the peptide 
microarrays did not include the relevant sequence.  
Also of note is that after the longer waiting period between last immunization and challenge 
in study II, the total number of identified epitopes (n=12) was higher than in study I (n=4) 
suggesting maturation of the humoral response over time.  
Despite the uniqueness of the development of antibodies against some epitopes after chal-
lenge (Table 3-3), because of the timing those responses could not have contributed to protec-
tion from the calpox challenge.  
Detection of neutralizing antibody titres 
Neutralizing antibodies play an important role in the protection against poxviruses (Gilchuk et 
al., 2016b; Moss, 2011). Since the level of neutralizing activity in immune serum in thought 
to be the best laboratory predictor of protective immunity to OPXV infections in humans 
(Mack et al., 1972), I analyzed the neutralizing antibody titres in this study.  
Assumably, vaccination with MVTT p.o. induced more neutralization than MVA i.m. Levels 
of binding antibodies and neutralizing antibody titres were lower against the calpox virus than 
the immunogen VACV LE.  
In vaccination study II the mean value of the MVTT p.o. immunized group titres was higher 
than MVTT i.n. followed by MVA i.m. immunized group titres when the serum samples were 
tested against VACV LE and calpox virus. One can assume that MVTT p.o. induced more 
neutralizing antibodies than MVTT i.n. and MVA i.m. 
There were no neutralizing antibody titres detected in some animals that were protected, e.g. 
#14414. Previous studies have shown that immunological protection can also be provided by 
preventing the release of virions rather than by neutralization (Vanderplasschen and Smith, 
1997) of the EEV particles. In that case antibodies against EEV particles can cause the aggre-
gation of EEV particles on the cell surface (Ichihashi, 1996).  
To sum up, there was no correlation between protected and unprotected animals in the devel-
opment of neutralizing antibodies as well as the other tests like B cell epitope fine mapping by 
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peptide microarray and ELISA when analyzing the humoral response at challenge. When ana-
lyzing the humoral response, it can be assumed that MVTT p.o. induced more neutralizing 
antibodies than MVTT i.n. and MVA i.m.. In peptide microarray, antibodies against different 
epitope regions that are exclusive in protected animals were detected at different time points 
after challenge (Table 3-1). There was no correlation between the level of binding antibody 
responses in protected and unprotected animals detected (ELISA).  
4.2.3 The role of the cellular immune response in the calpox virus/marmoset model 
Polychromatic flow cytometric staining of differently fluorescently marked cells in 
whole blood  
Significant differences in T and B cell numbers, their expression of activation markers CD69 
as well as HLA-DR and CD80, were neither observed between the different vaccine groups 
nor between protected and unprotected animals on the day of the challenge. This suggests that 
the different vaccination strategies did not affect innate and adaptive immune cell numbers. 
There was also no correlation between cell numbers of protected and unprotected animals at 
challenge (data not shown). Furthermore, the kinetics of the tested cell subset frequencies 
(e.g. T and B cell frequencies) were similar and no differences between vaccination groups 
were detected. Although cell numbers did not change and frequencies were similar as well, it 
is possible that differences in the vaccine-induced secretion of cytokines occur that might play 
an important role in the protection of CM in the calpox virus/marmoset model. To my 
knowledge, there are no reports on phenotyping of immune cells after poxvirus infection for 
CM. Mucker and colleagues (Mucker et al., 2015) infected CM with MPXV, but no pheno-
typing of immune cells was done after the infection. Song and colleagues found that a mon-
keypox virus (MPXV) infection of rhesus macaques led to expanded frequencies and absolute 
numbers of NK cells in blood (Song et al., 2013b). In the calpox virus/marmoset model, this 
effect was not detected by flow cytometric staining. Unfortunately, earlier studies in the cal-
pox virus/marmoset model with VACV LE BN vaccination did not include analyses of the 
vaccine induced cellular response.  
In the vaccination studies, cell numbers of CD20+ B cells, CD3+, CD4+ and CD8+ T cells, 
CD4+CD8+ T cells, CD14+ cells (monocytes), NK cells, mDCs, pDCs, CD16+CD86+cells, 
CD14++CD86+cells increased shortly before the animals became moribund. Also, increases in 
the expression of the activation marker CD86 in CD14+CD16+ cells were observed. This 
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strong increase of the absolute cell numbers shortly before death may be due to a possible cy-
tokine storm for which, however, no evidence exists. 
 
Proliferation of CD3+, CD3+CD8+ and CD3+CD4+ T cells 
Proliferation of  CD3+, CD3+CD8+ and CD3+CD4+ T cells upon stimulation with VACV (here 
MVA) was analyzed and at no measured time point were significant differences between the 
vaccination groups detected. Therefore, the different vaccines did not differ in their 
proliferating activities of T cells. 
Moise and colleagues evaluated a T cell epitope vaccine based on vaccinia/variola sequences 
and induced protective immunity against VACV infection in mice by T cell responses alone 
and without the necessity of  B cell priming (Moise et al., 2011). In contrast, the proliferative 
activity of CD3+CD4+CD8+ cells was present even though animals died (e.g. #15100). The 
proliferative activity was not associated with the protection of the animals from the calpox 
virus challenge. It needs to be clarified what exact role the T cell proliferation plays in 
protection.  
4.3  (III) Identification of immune correlates  
Little is known about the immune response in CM after a poxvirus infection (Kramski et al., 
2010).  Data from two vaccination studies were merged to identify any immune correlates of 
protection. So far, it is still unclear why the vaccine failures died. These animals all developed 
high viral load viremia and in case where analysis was possible, also moderate to high titres 
of infectious virus in whole blood when compared to unvaccinated control animals. Lower 
levels of infectious virus shortly before or at death were observed in MVTT vaccine failures 
independent of the vaccination route when compared to those not protected by MVA immun-
ization.  
This suggests that calpox virus replication was slightly reduced in MVTT vaccine break-
throughs which, however, did not prevent the animals from becoming moribund. A correla-
tion between the presence of serum antibodies and protection from death has already been 
reported for human orthopoxvirus (OPXV) infections (Downie and Mc, 1958; Mack et al., 
1972; Sarkar et al., 1975). There is, however, no relation between the levels of ELISA anti-
body responses and protection. If neutralizing antibodies (nAbs) are present, protection does 
not depend on a high level of antibody response in ELISA because animals were protected 
also with a low titre (e.g. #14478) and vice versa (e.g. #14603). No association was observed 
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between the breadth of high resolution antibody responses as determined by peptide microar-
ray and protection. Nevertheless, neutralizing antibodies seem to play an important role since 
B cell epitope fine mapping by peptide microarray revealed antibodies against epitope regions 
that are exclusicely present in protected animals at different time points post challenge. Neu-
tralizing antibodies were determined, because it has been reported that those play an im-
portant role in the protection against poxviruses (Edghill-Smith et al., 2005). Data from this 
study suggest that MVTT was a better inducer for neutralizing antibodies than MVA. Poorer 
induction of neutralizing antibodies through MVA compared to Dryvax immunization has 
also been reported for macaques (Earl 2008). Also, there was no correlation between titres of 
neutralizing antibodies determined in plasma from the day of challenge and protection. In-
deed, the MVTT vaccine failures developed moderate neutralizing antibody titres (e.g. 
#14169) suggesting that the presence of these functional antibodies did not influence the dis-
ease course. The phentopyping of immune cells was analyzed, but since no significant differ-
ences between groups were detected in the analyzed T- and B cells and activation markers at 
the day of challenge, the different vaccination strategies did not have an effect on the different 
cell numbers at challenge. The T cell proliferation assay also revealed no significant differ-
ences between the vaccine groups at the time points analysed. The proliferative activity was 
also not associated with the protection of the animals from calpox virus challenge.  
It is tempting to speculate that death of calpox-infected animals resulted from a collapse of 
the immune system and organ dysfunction. With the findings of a dissertation conducted in 
parallel (Schmitt, 2015), it seems to be reasonable that the deaths are related to multi-organ 
system failure, immune system compromise and resulting opportunistic bacterial infections 
with sepsis. Another explanation for the death of common CM (CM) might be a cytokine 
storm, since in human hemorrhagic smallpox the cause of death was often suggested as toxe-
mia or a cytokine storm (Councilman et al., 1904; Fenner et al., 1988b; Jahrling et al., 2004; 
Johnson et al., 2011; Martin, 2002; Ricketts, 1908). A cytokine storm is also assumed to play 
an important role in a MPXV model in cynomolgus macaques (Macaca fascicularis). Strong-
ly elevated levels of certain cytokines (CCL2, IL-6, IL-8, IFN-γ) were detected in cynomol-
gus macaques following intravenous infection with VARV and cowpox virus (Jahrling et al., 
2004; Johnson et al., 2011). The cytokines that seem to play an important role in poxvirus 
immune response were not analyzed here. Due to the limited availability of reagents for CM, 
details of the immunology of calpox virus pathogenesis have not been studied and are difficult 
to elucidate.  
In the studies of Zielinski and colleagues, cynomologous macaques were immunized with the 
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cell culture grown ACAM 2000 vaccine (Wyeth strain) Wyeth-IL15, the genome of Wyeth 
strain of VACV with the integrated human cytokine IL15, a cytokine with pleiotropic immune 
modulatory activities (Zielinski et al., 2010). Three years after immunization with that vac-
cine animals were challenged with a lethal dose of MPXV. Following challenge most vac-
cinates presented with milder clinical manifestations and complete recovery. This study 
showed that the immunization with Wyeth-IL15 confered long term protection. IL-15 is es-
sential in the functioning and differentiation of NK cells. Because of the positive effect of 
vaccination with Wyeth-IL15 as well as the clearance of VACV it contributes to the control 
(Hugin et al., 1993). Other cytokines (e.g. IL-18) were also detected in cowpox viruses 
(Smith et al., 2000) as well as cytopkine receptor homologs (e.g. vTNFR, vIFNγR, vIL-1R) 
(Alcami and Smith, 1992; Loparev et al., 1998; Smith and McFadden, 2002). 
In this study, no distinct immune correlates were identified. Poxviruses are able to defend 
themselves through encoded proteins that are involved in immune evasion and immune modu-
lation (Smith and Kotwal, 2002). Such proteins are able to block several strategies of the host 
defense, e.g. blocking the activity of many chemokines, cytokines, serine proteases and even 
complement.  
4.3.1 Advantages and disadvantages of the calpox virus/marmoset model  
When selecting an animal model for viral pathogenesis or prophylactic studies, different as-
pects (e.g. applicability, costs, ethics) must be considered. The advantages and disadvantages 
of different OPXV NHP models have been discussed in Schmitt and colleagues (Schmitt et 
al., 2014).  
One disadvantage of the calpox virus/marmoset model is the relatively high maintenance 
costs compared to rodents or other non-rodent species (Jagessar et al., 2013). For ethical rea-
sons, using this model has the disadvantage that the common marmoset (CM) is closer related 
to humans than rodents. The small size of the CM also plays a role: animal experimentation 
and sampling is more difficult to perform in small animals and also the blood volume which 
can be collected is limited. Another disadvantage of this model is the absence of disease stag-
es as observed for smallpox in humans and MPXV infection of macaques (Schmitt et al., 
2014). Although calpox virus belongs to the specific of cowpox viruses and therefore is po-
tentially infectious for humans, epidemiological investigations demonstrated no evidence of 
transmission to man because persons being in close contact to calpox virus infected and dis-
eased CM were all seronegative for OPXV antibodies (Mätz-Rensing et al., 2012). Still, in-
fectivity in general cannot be excluded (Dr. Stahl-Hennig, personal communication) (Schmitt 
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et al., 2014). Furthermore, in non-human primate models there are less animals available than 
in smaller animal models (Schmitt, 2015). Also, the availability of some critical immunologi-
cal tools is still very limited for CM.  
In general, non-human primates including cynomolgus macaques, rhesus macaques, African 
green monkeys and CM are the gold-standard for pathogenesis studies and the evaluation of 
new medical countermeasures, because they fulfill the criteria of the FDA Animal Rule for 
the highly pathogenic viruses (Safronetz et al., 2013). Advantages of the CM compared to 
other NHPs are that they are not endangered, are inexpensive to keep and easy to handle 
(Kramski et al., 2010). Their reproductive rate in captivity is high and they are also available 
at a reasonable price. CPXV was reported as suitable to study human smallpox, because it 
shares 19 immunomodulatory genes with VARV, the smallpox agent (Johnson et al., 2011; 
Seet et al., 2003). Furthermore, the disease in the calpox virus/marmoset model is comparable 
to human smallpox. The incubation period is similar to that of human smallpox. Another ad-
vantage of the calpox virus/marmoset model is that infected animals can be kept at biosafety 
level (BSL) -2 whereas MPXV must be handeled at BSL-3, and VARV even at BSL-4. Ex-
periments with this virus can therefore be conducted by a larger number of laboratories 
(Mätz-Rensing et al., 2012). Also, the CMs develop a reproducible lethal, systemic disease 
with cutaneous pox lesions and die upon low-dose intranasal inoculation within 12-16 dpi 
(Kramski et al., 2010). Also, a very low infectious viral dose is sufficient to establish infec-
tion. The i.n. calpox virus application was established in CM because VARV infection in hu-
mans normally occurs via airborne transmission. By infecting the upper respiratory tract, the 
major natural route of the human VARV infection is mimicked. This inoculation route has 
been described as advantage to the non-physiological i.v. route because that one “bypasses the 
mucosa and circumvents a primary replication of the virus in regional lymph nodes and the 
successive systemic spread via the lymphatic system, altogether representing the first vire-
mia” (Kramski et al., 2010).  
This is why the calpox virus/marmoset model is a suitable animal model for the validation of 
vaccines and antiviral drugs, but also for studying OPXV pathogenesis.  
4.3.2 Relevance of modified vaccinia virus Ankara (MVA) and modified vaccinia 
virus Tiantan (MVTT) in developing a safer, but efficacious smallpox vac-
cine 
The studies of Chen and colleagues suggest that MVTT is a safe and noninvasive smallpox 
vaccine candidate which induces neutralizing antibodies upon i.n. immunization (Yu et al., 
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2010). MVTT replicates in many mammalian cell lines, but replication in the brain of mice is 
lacking underlining the safety of this vaccine (Yu et al., 2010). Mucosal immunization with 
MVTT protected mice from VACV Western Reserve (WR) challenge. Accordingsly, MVTT 
is not only a potentially safe and noninvasive smallpox vaccine, but also effective. The effica-
cy in CM remained to be tested in these studies. MVTT protected 67 % of the animals whilst 
MVA protected only 13 % of the vaccinees independently of the waiting period. Thus, MVTT 
seems to provide better protection, but because of small animal numbers per group careful 
interpretation is required. When comparing all MVTT-induced immune responses with those 
mounted after MVA, MVTT appeared to be more immunogenic than the highly attenuated 
MVA and thus looks like a promising new smallpox vaccine candidate. Yet, it is unclear why 
lethal vaccine breakthroughs occurred in some MVTT vaccinated animals. One explanation 
was previously given (Schmitt, 2015). The interaction of intranasally applied MVTT with the 
NALT could stimulate a local respiratory mucosal immunity (Xu et al., 2014). Cytotoxic T-
lymphocytes that recognize the intranasally calpox virus challenge could have evoked exces-
sive immune responses that resulted in severe pneumonia (Schmitt, 2015). This could have 
held true for MVTT vaccine failure. As MVA breakthroughs shared the same pathological 
alterations, local expansion of challenge virus at the portal of entry might have attracted sys-
temic virus-specific CTLs leading to a similar burst of immune reaction.  
This study could not clarify whether the mucosal application of MVTT led to a cytotoxic T 
cell response. Besides the fact that the virus-specific proliferative activity of the 
CD3+CD4+CD8+ subset was slightly higher in MVTT vaccines compared to that of MVA 
ones, there were no hints of a cytotoxic T cell response that may be the cause for the severe 
pulmonary lesions as described in a parallel dissertation (Schmitt et al., 2017). Another ex-
planation for the pulmonary changes might be a cytokine storm, which can occur inde-
pendently of the vaccination route. When a pathogen enters a susceptible host, the immune 
sytem fights against it, different cytokines signal the immune cells (e.g. T cells, macrophages) 
and then they migrate to the infection site.  
4.3.3 The role of the different vaccination routes 
Mucosal vaccination with VTT in mice (i.n. or oral) induced higher sustained levels of neu-
tralizing antibodies (nAbs) than i.m. and subcutaneous vaccination (Lu et al., 2011). There-
fore, the intranasal and peroral routes were tested here. MVTT was developed from the Asian 
Tiantan strain by removing the hemagglutinin gene and its mucosal application protected 
mice against the VACV Western Reserve (WR) strain (Yu et al., 2010). Mucosal immuniza-
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tion seems to be a successful application route using this vaccine. In comparison to systemic 
vaccine application, the mucosal application has the advantage that it triggers local (in the 
NALT) as well as systemic humoral and cellular immune responses (Holmgren and 
Czerkinsky, 2005). In addition, a better compliance with this noninvasive vaccination is ex-
pected. Technically, the application is easy and can be done by untrained personnel. The mu-
cosal application is also of advantage, because no injection needles are required thus prevent-
ing the risk of iatronic transmission of blood-borne infections (Lycke, 2012). A disadvantage 
is that the mucosally applied vaccine might be swallowed or eliminated through sneezing. 
Therefore, it would not be clear as to how much of the applied dose remains in the organism 
and whether there is enough time for antigen adsorption before mucociliary clearance 
(Velasquez et al., 2011). Therefore, in a future approach systemic vaccination of CM with 
MVTT should be analyzed. It would be interesting to know if the same dose given intranasal-
ly confers a higher level of protection. Huang and colleagues showed in a mouse model that 
mucosal application of MVTT led to higher levels of nAbs than an intramuscular injection 
(Huang et al., 2009), but the results in a monkey model might be different. 
Nevertheless, distinguishing between different mucosal application routes (i.n. or p.o.) in 
MVTT immunized animals in this study does not seem to be of importance when considering 
the humoral responses. Neutralising antoibody titres did not vary significantly between the 
MVTT p.o. group and the MVTT i.n. group. These data are in accordance with findings by 
Huang and colleagues in mice (Huang et al., 2009). MVA was chosen because of its high at-
tenuation resulting in lack of replication in most mammalian cell lines. Thus, it was important 
that all MVA particles were contained in the body through injection. 
The mucosal vaccination route does not seem to have an influence on the ELISA antibody 
titres because no significant difference in titres between the vaccine groups was observed. B 
cell epitope fine mapping resulted in the detection of antibodies against different epitope re-
gions that were exclusively found in protected animals with no notable difference in MVTT 
i.n. and MVTT p.o. immunized animals. Antibodies against epitope 2 were only discovered in 
one MVTT p.o. animal, but antibodies against the other epitopes appeared in both MVTT 
immunized groups. Therefore, mucosal immunization with MVTT is advantageous for many 
reasons, but the route seems to be less relevant.  
4.4 Conclusion and outlook 
From the findings of this thesis it can be concluded that the first replication of the calpox vi-
rus is located at the inoculation site, i.e. the nasal mucosa. It can be postulated that the onset 
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of dissemination of the virus via blood (viremia) (DNA copies in blood) is dose dependent 
and starts already at 3 dpi when a high inoculation dose is used and between 6 and 7 dpi when 
a low inoculation dose is administered. The data suggests that the calpox virus initially repli-
cated in the upper respiratory tract, most likely in the nasal mucosa, next in the surrounding 
lymphatic tissue (submandibular LN and tonsil) and finally spread systemically through vire-
mia. When a high dose of calpox virus is applied intranasally, a not quantifiable proportion of 
virus is probably swallowed, thereby leading to infection of tissues located more distant from 
the viral entry (tongue and esophagus). In the prefinal phase, all organs became infected. 
MVA did not provide solid protection to CM in this model. In this approach, the overall high-
est protection was mediated by MVTT independent of the vaccination route and waiting peri-
od. When comparing the serological findings in MVTT and MVA vaccinees, MVTT seemed 
to be more immunogenetic in this model. Accordingly, the mucosal needle-free application of 
MVTT appears to be a promising smallpox vaccine candidate. Little is known about the im-
mune response in CM after a poxvirus infection and unfortunately, no obvious immune corre-
lates of protection were found in this study.  
Details of the immunology of calpox virus pathogenesis (e.g. the role of cytokines in the cal-
pox virus/marmoset model) have not been studied so far, and due to the limited availability of 
reagents for common CM (CM), they are difficult to elucidate. This remains to be studied in 
the future.  
According to Zielinski and colleagues (Zielinski et al., 2010) studies with human cytokines 
integrated into VACV genome represent an interesting approach which is worthwhile to be 
investigated in the calpox virus/marmoset model. 
In further studies, recombinant proteins that are known to be determinants for the induction of 
protective and neutralizing antibody could be used for seroanalysis in order to ultimately dis-
cover immune correlates that could help to inform smallpox vaccine development. New stud-
ies could also show if efficacy of MVTT immunization is increased through systemic vac-
cination. Moreover, it would be interesting to test the efficacy of a further third generation 
live-attenuated smallpox vaccine (e.g. the Japanese strain LC16m8) and how it compares to 
MVTT and MVA in the calpox virus/marmoset model.  
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5 SUMMARY 
Li Lin Gan (2017) 
Smallpox was successfully eradicated in 1980 and mass vaccination stopped between 1976 
and 1984 in Europe. Herd immunity has been waning since then and left the population un-
protected against orthopoxvirus (OPXV) infections. In the light of bioterrorism and emerging 
zoonotic diseases an increasing interest in the development of antiviral drugs and safer vac-
cines against OPXVs arises. A non-human primate model was established in cooperation with 
the Robert Koch Institute (RKI). Common CM (CM, Callithrix jacchus) were intranasally 
infected with a cowpox virus that is lethal for this non-human primate species and designated 
calpox virus. The calpox virus/marmoset model was established to study pathogenesis and to 
evaluate new vaccines and therapeutics.  
The aim of this doctoral thesis is to contribute to the understanding of the pathogenesis of the 
calpox virus infection in CM and other OPXV infections in humans. The calpox vi-
rus/marmoset model was used to (i) determine the portal of viral entry, (ii) analyze the early 
dissemination as well as the pathological sequelae of infection in a time-course pathogenesis 
study. The purpose of this research is also to (iii) analyze the immune response of the differ-
ent vaccines and vaccination routes and to identify immune correlates of protection in two 
vaccination studies. The calpox virus/marmoset model, a hypothesized model for smallpox or 
other OPXV infections in humans was used to evaluate the protective effect of different at-
tenuated vaccines.  
For the pathogenesis study two groups of three animals each were formed. First group was 
infected with a 3.5x105 pfu calpox virus (low dose group) and euthanized on day 3 post in-
oculation. Second group was challenged with 8.3x103 pfu calpox virus (high dose group) and 
euthanized on days 5, 7, 10 or 12 post infection. Blood and various organs were collected 
from the animals and analyzed for infectious virus using a plaque assay, endpoint dilution as-
say and for viral DNA using real-time PCR. PBMCs and buffy coat were analyzed for the 
calpox virus antigen in immune cells by flow cytometry.  
The earliest replicating virus was detectable at the inoculation site, the nasal mucosa and at a 
much lower levels in the esophagus and tongue at 3 dpi after the high dose challenge. After 
the low dose challenge, earliest viral DNA was detected in the nasal mucosa, submandibular 
lymph nodes and tonsils at 5 dpi and in blood and several organs at 7, 10 and 12 dpi. In ani-
mals received high dose infection, double positive CD3+CD20+ cells and intermediate 
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CD14+CD16+ monocytes were already VACV antigen positive (calpox+). In late state of in-
fection (12 dpi) multiple immune cell subsets were tested positive for vaccinia virus antigen. 
In the performed vaccination studies, two attenuated smallpox vaccines, i.e. modified vaccinia 
virus (VV) Tian Tan (MVTT) and modified VV Ankara (MVA) were tested for their efficacy 
after a 4- and a 10-week waiting period. Binding antibodies were quantified with enzyme-
linked immunosorbent assay (ELISA). For the analysis of neutralizing antibodies (nAb´s) was 
B cell epitope fine mapping performed with peptide microarray as well as plaque reduction 
neutralization test (PRNT). The cellular immune response was analyzed by flow cytometric 
analysis of innate and adaptive immune cells in blood as well as T cell proliferation assay.  
When testing the different smallpox vaccines an overall protection of 67 % was observed fol-
lowing immunization with MVTT and 13 % after MVA vaccination, independently of the 
vaccination route and waiting period. All vaccine failures became virus positive by real-time 
PCR. MVTT-immunized vaccine failures had lower viral titres in blood than MVA immun-
ized vaccine failures at the final stage. Binding antibodies against viral particles measured by 
ELISA were not associated with the protection of the CM from the calpox virus challenge. In 
both vaccination studies binding antibodies did not significantly differ between the vaccine 
groups at day of challenge. Peptide microarrays revealed antibodies against linear B cell 
epitope regions in different proteins (A33, B5 and L1) that were exclusively found in protect-
ed animals post challenge. Neutralizing antibodies were detected in both vaccination studies 
at day of challenge by PRNT but no correlation of measured titres between protected and un-
protected animals was detected. When serum samples were tested against VACV Lister El-
stree (LE), the titres of the MVTT per oral (p.o.) immunized group were significantly higher 
(p = 0.0487) than the titres of the MVA intramuscularly (i.m.) immunized group at challenge. 
The cellular response was analyzed by flow cytometric staining. T and B cell numbers did not 
differ significantly between vaccination groups. The expression of activation markers (e.g. 
NK cells, γδ T cells, CD3+ cells, CD69, HLA-DR and CD80) were detected at the day of 
challenge. Virus-specific T-cell proliferation was observed in some animals vaccinated with 
MVTT, but the proliferative activity was not associated with the protection of the CM from 
the calpox virus challenge.  
In conclusion, the data suggests that the calpox virus initially replicated in the upper respirato-
ry tract followed by systemic spread. The calpox virus probably first replicated in the nasal 
mucosa and spread from the nasal mucosa to the surrounding lymphatic tissue (submandibular 
lymph node and tonsil), where secondary replication occured. Subsequently, the virus proba-
bly spreads to other organs of the respiratory tract and then to surrounding organs (eyes, 
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esophagus, lung and tongue). In the prefinal phase, all organs became infected. Furthermore, 
the onset of viremia (DNA copies in blood), is probably dose dependent and starts at 3 dpi 
(with the high inoculation dose) and at 7 dpi (with the low inoculation dose) in this model. 
The overall highest protection mediated by live-attenuated VV was observed with MVTT in-
dependently of the vaccination route and waiting period. Little is known about the immune 
response in CM after poxvirus infection and unfortunately, no obvious immune correlates of 
protection were found in this study. 
Since peptide microarrays revealed antibodies against linear B cell epitope regions in different 
proteins that were present exclusively in protected animals post challenge, neutralizing anti-
bodies seem to play an important role in poxvirus protection. Details of the immunology of 
calpox virus pathogenesis (e.g. the role of cytokines in the calpox virus/marmoset model) 
have not been studied so far and due to the limited availability of reagents for CM, their elu-
cidation is difficult and remains a future object for investigation. This study suggests, that re-
combinant proteins known as protective and neutralizing antibody-inducing determinants 
against linear epitopes should be analyzed. Further studies could also verify if the efficacy of 
MVTT immunization can be increased through systemic vaccination. Another third-
generation vaccine (e.g. the Japanese strain LC16m8) may represent another option to test for 
the efficacy in the calpox virus/marmoset model.  
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6 ZUSAMMENFASSUNG 
Li Lin Gan (2017) 
Die Pocken wurden 1980 erfolgreich ausgerottet und Massenimpfungen wurden in Europa 
zwischen 1976 und 1984 eingestellt. Seitdem nahm die Herdenimmunität gegen Orthopo-
ckenviren (OPV) ab und hinterlässt die Population gegen Infektionen des Orthopockenvirus 
ungeschützt. In Anbetracht des Bioterrorismus und neu entstehender zoonotischen Erkran-
kungen entsteht ein wachsendes Interesse an der Entwicklung von antiviralen Medikamenten 
und sichereren Impfstoffen gegen Orthopockenviren. In Zusammenarbeit mit dem Robert 
Koch Institut (RKI) wurde ein nicht-menschliches Primatenmodell etabliert. Die Weißbü-
schelaffen (WA, Callithrix jacchus) wurden intranasal mit einem Kuhpockenvirus infiziert, 
welches für diese nicht-humane Primatenart tödlich ist und Calpox Virus genannt wurde. Das 
Calpox Virus/Marmosetten Modell wurde etabliert um die Pathogenese und die Evaluierung 
von neuen Impfstoffen und Therapeutika zu studieren.  
Das Ziel dieser Doktorarbeit ist, zu dem Verständnis der Pathogenese der Calpox Virus Infek-
tion in WA und anderen OPV-Infektionen in Menschen beizutragen. Das Calpox Vi-
rus/Marmosetten Modell wird benutzt um (i) die virale Eintrittspforte zu ermitteln, (ii) die 
frühe Verbreitung sowie die pathologischen Folgen der Infektion in einem Zeitverlauf einer 
Pathogenesestudie zu analysieren. Auch die (iii) Analyse der Immunantwort der verschiede-
nen Impfstoffe und Impfrouten sowie die Identifizierung von schützenden Immunkorrelaten 
in zwei Impfstudien ist der Zweck dieser Forschung. Das Calpox Virus/Marmosetten Modell, 
ein hypothetisches Modell für Pocken oder andere OPV-Infektionen beim Menschen, wurde 
verwendet um die schützende Wirkung von unterschiedlich abgeschwächten Impfstoffen zu 
bewerten.  
Für die Pathogenesestudie wurden zwei Gruppen mit jeweils drei Tieren gebildet. Die erste 
Gruppe wurde mit 3,5x105 pfu des Calpox Virus infiziert (niedrige Dosis) und am Tag 3 nach 
der Infektion euthanasiert. Die zweite Gruppe wurde mit 8,3x103 pfu des Calpox Virus infi-
ziert (hohe Dosis) und an den Tagen 5, 7, 10 und 12 nach der Infektion euthanasiert. Von den 
Tieren wurden Blut und verschiedene Organe asserviert und mit dem Plaque-Assay, der End-
punkt-Verdünnungsanalyse, auf infektiöses Virus und mit Real-Time PCR auf virale DNA 
untersucht. PBMCs und Buffy Coat wurden mit der Durchflusszytometrie auf Calpox Virus 
Antigen in Immunzellen analysiert.  
Mit der niedrigen Infektionsdosis wurde am Tag 5 nach der Infektion die früheste virale DNA 
in der Nasenschleimhaut, submandibulären Lymphknoten und Tonsille nachweisbar und in 
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Blut und vielen Organen an den Tagen 7, 10 und 12 nach der Infektion. Die höchsten viralen 
DNA-Kopien wurden in Tieren nachgewiesen, die am Tag 12 nach der Infektion euthanasiert 
wurden. 
In Tieren, die mit der hohen Inkeftionsdosis behandelt wurden, waren die doppelten positiven 
CD3+CD20+-Zellen und intermediären-CD14+CD16+-Monozyten an Tag 3 nach der Infektion 
bereits Calpox Virus-Antigen-positiv gefärbt. Im späten Zustand der Infektion (12 Tage nach 
Infektion) waren mehrere Unterguppen der Immunzellen Calpox Virus-Antigen-positiv.  
In den durchgeführten Impfstudien wurden zwei attenuierte Pockenimpfstoffe, d. h. modifi-
ziertes Vaccinia-Virus (VV) Tian Tan (MVTT) und modifiziertes VV Ankara (MVA) nach 
einer 4- und 10-wöchigen Wartezeit auf ihre Wirksamkeit getestet. Bindende Antikörper wur-
den durch den enzyme-linked immunosorbent assay (ELISA) quantifiziert. Für die Untersu-
chung von neutralisierenden Antikörpern (nAb´s) wurde die B-Zell-Epitop-Feinkartierung mit 
dem Peptide-Mikroarray durchgeführt sowie der Plaque-Reduktions-Neutralisationstest 
(PRNT). Die zelluläre Antwort der angeborenen und adaptiven Immunantwort im Blut wurde 
mit der Durchflusszytometrieanalyse und dem T-Zell-Proliferationstest analysiert.  
Beim Testen der verschiedenen Pockenimpfstoffe wurde, unabhängig von der Impfroute und 
der Wartezeit, nach der Immunisierung mit MVTT 67 %-iger Schutz und 13 %-iger Schutz 
nach der MVA-Impfung beobachtet. Alle Impfdurchbrüche wurden in der Real-Time PCR 
Virus positive. Infektiöses Virus wurde im Blut nachgewiesen und in der Endphase erreichten 
MVTT-immunisierte Impfdurchbrüche im Blut niedrigere Virus-Titre durch den Plaque-
Assay als MVA-immunisierte Impfdurchbrüche. Bindende Antikörper gegen virale Partikel, 
die durch ELISA gemessen wurden, waren nicht mit dem Schutz des WA gegen den Calpox 
Virus Challenge assoziiert. In beiden Impfstudien waren die bindenden Antikörper zwischen 
den Impfgruppen zum Zeitpunkt des Challenge nicht signifikant unterschiedlich. Peptid-
Mikroarrays zeigten Antikörper gegen lineare B-Zell-Epitop-Regionen in verschiedenen Pro-
teinen (A33, B5 und L1), die ausschließlich bei geschützten Tieren nach dem Challenge vor-
handen waren. Neutralisierende Antikörper wurden an dem Tag des Challenge in beiden 
Impfstudien mit dem PRNT nachgewiesen, jedoch wurde keine Korrelation der gemessenen 
Titre zwischen geschützten und ungeschützten Tieren nachgewiesen. Zum Zeitpunkt des 
Challenge war der MVTT per oral (p.o.) immunisierte Gruppen Titre signifikant höher (p = 
0,0487) als der MVA intramuskulär (i.m.) immunisierte Gruppen Titre, als die Serumproben 
gegen VACV Lister Elstree (LE) getestet wurden.  
Die zelluläre Antwort wurde mit der durchflusszytometrischen Färbung untersucht. T und B 
Zellzahlen zeigten keine signifikanten Unterschiede zwischen den Impfgruppen. Am Tag des 
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Challenge wurde die Expression der getesteten Aktivierungsmarker (z. B. NK-Zellen, γδ-T-
Zellen, CD3+-Zellen, CD69, HLA-DR und CD80) nachgewiesen. Virusspezifische T-Zell-
Proliferation wurde bei einigen Tieren beobachtet, die mit MVTT geimpft wurden, aber die 
proliferative Aktivität war nicht mit dem Schutz des WA vor dem Calpox Virus Challenge 
assoziiert.  
Folglich deuten die Daten darauf hin, dass das Calpox Virus zunächst in den oberen Atemwe-
gen repliziert, gefolgt von systemischer Ausbreitung. Calpox Virus repliziert vermutlich zu-
erst in der Nasenschleimhaut und breitet sich von der Nasenschleimhaut zum umgebenden 
lymphatischen Gewebe (submandibuläre Lymphknoten und Tonsille) aus, wo es zur sekundä-
ren Replikation führt. Das Virus verbreitet sich wahrscheinlich durch eine Viremie von dort 
zu anderen Organen der Atemwege und anderen umgebenden Organen (Augen, Speiseröhre, 
Lunge und Zunge). In der präfinalen Phase wurden alle Organe infiziert. Außerdem ist der 
Beginn der Virämie (DNA Kopien im Blut) wahrscheinlich dosisabhängig und startet 3 Tage 
nach der Infektion (mit der hohen Dosis) und 7 Tage nach der Infektion (mit der niedrigen 
Dosis). Insgesamt wurde durch lebendiges abgeschwächtes VV der höchste Schutz durch 
MVTT beobachtet, unabhängig von der Impfroute und Wartezeit. In Weißbüschelaffen ist 
über die Immunantwort nach der Pockenvirus-Infektion wenig bekannt und leider wurden in 
dieser Studie keine offensichtlich schützenden Immunkorrelate gefunden.  
Neutralisierende Antikörper scheinen mit dem Schutz gegen Pockenviren eine wichtige Rolle 
zu spielen, da der Peptid-Mikroarray Antikörper gegen lineare B-Zell-Epitop-Regionen in 
verschiedenen Proteinen zeigte, die ausschließlich in geschützten Tieren nach dem Challenge 
vorhanden waren. Einzelheiten der Immunologie der Calpox Virus-Pathogenese (z. B. die 
Rolle von Cytokinen im Calpox Virus/Marmosetten Modell) wurden bisher auch noch nicht 
untersucht und sind aufgrund der begrenzten Verfügbarkeit von Reagenzien für WA schwer 
zu ermitteln und bleiben deswegen Gegenstand künftiger Untersuchungen. Weitere Studien 
könnten auch zeigen, ob die Wirksamkeit der MVTT-Immunisierung durch eine systemische 
Impfung erhöht werden kann. Ein Impfstoff der dritten Generation (z. B. der japanische 
Stamm LC16m8) könnte eine weitere zu testende Möglichkeit repräsentieren, der auch auf die 
Wirksamkeit im Calpox Virus/Marmosetten Modell analysiert werden könnte.  
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A Appendix 
A.1 Abbreviations 
A  area 
aa  amino acid 
AEC   3-Amino-9-EthylCarbazole 
APCs  antigen-presenting cells 
BC  before Christ 
BN  Bavarian Nordic  
bp  base pairs  
BSL  Biosafety level 
b.w.  body weight 
calpox+  calpox virus antigen positive  
ConA   Concanavalin A 
CO2  Carbon dioxide 
CFSE  Carboxyfluorescein succinimidyl ester 
cm  centimetres 
CM  common CM 
CMLV Camelpox virus  
CNS  central nervous system 
CPXV  cowpox virus 
°C  degree celsius 
ddH2O  double-distilled water 
DMEM Dulbecco’s modified Eagle’s medium 
DMF  Dimethylformamide 
dpc days post challenge 
dpi  days post infection 
DPZ  German Primate Centre (Deutsches Primatenzentrum GmbH) 
ECTV ectromelia virus 
EDTA Ethylenediaminetetraacetic acid 
EEV   extracellular enveloped virus 
e.g.  exempli gratia 
ELISA  Enzym-linked Immunosorbent Assay  
et al.  et alli 
EV   enveloped virion 
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FA  formaldehyde 
FAM  6-FAM (6-Carboxyfluorescein) 
FCS  fetal calf serum 
fmol  femtomole 
h  hour 
HLA-DR  human leukocyte antigen - antigen D related 
H2O2   Hydrogen peroxide 
i.d.  intradermally 
i.e.  id est 
IEV  intracellular enveloped virus 
i.m.  intramuscularly 
IMV  intracellular mature virus 
i.n.  intranasally 
i.p.  intraperitoneal 
i.v.  intravenous 
kb  kilobase 
KCl  potassium chloride 
kDa  kilodalton 
kg  kilograms 
LE  Lister Elstree  
LN   lymph node 
mM  Millimol 
M  molar mass 
mAbs  monoclonal antibodies 
min  minutes 
MOI   Multiplicity of infection 
MV   mature virion  
MVA  Modified vaccinia virus Ankara 
MVTT  Modified vaccinia virus Tiantan 
mDCs   myeloid dendritic cells  
mg  milligrams 
MID50  median monkey infectious doses  
ml  millilitres 
MPXV monkeypox virus 
MQs   macrophages 
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nAb  neutralizing antibody 
NaCl  sodium chloride 
NALT  nasal-associated lymphoid tissue 
NaOAc  sodium acetate 
nm  nanometers 
NHP  non-human primate  
OD  optical density 
OPXV  orthopoxvirus 
pfu  plaque forming units 
pi  post infection 
p.o.  per oral 
P  passage 
PBMCs Peripheral blood mononuclear cells  
PBS  Phosphate-buffered saline 
pDCs  plasmacytoid dendritic cells  
PCR  Polymerase Chain Reaction  
pfu  plaque forming units 
P/S  Penicillin-Streptomycin 
rcf  relative centrifugal force 
RKI   Robert Koch Institute 
SD  standard deviation 
sec  seconds 
SSC   side scatter  
submand.  submandibular  
TBS   Tris-buffered saline  
™  Trademark 
TMB  3,3’,5,5’-Tetramethylbenzidine 
TMR  5-TAMRA (5-Carboxytetramethylrhodamine) 
T-TBS  Tween TBS  
VACV  vaccinia virus  
VARV  variola virus 
vIFNγR viral interferon gamma receptor 
vIL-1R viral interleukin 1 receptor 
vTNFR viral tumor necrosis factor receptor 
WR  Western Reserve 
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wt   wild type 
xg  times gravity 
%  percent  
µg  micrograms 
µl  microlitres 
A.2 Tables and Protocols  
Table A.2-1: Göttinger Mixture II (GMII). 
Ketamine (100 mg/kg) 
Xylazine (10 %) 
Atropine (1 %) 
Aqua ad injectionem 
5 ml 
1 ml 
0.1 ml 
3.9 ml 
 
Table A.3-1: Detected replicating calpox virus in Callithrix jacchus individuals´ blood for the pathogenesis study by viral 
plaque assay. Infectious calpox virus was isolation from buffy coat. Plaque assay was processed at 3, 7, 10 and 12 dpi. From 
day-3-group (animals got the high dose of 3.5 x 105 pfu calpox virus) no replicating virus was detected. First replicating virus 
(1/3) was detected in the low-dose group at 7 days post infection (dpi) (animals were infected 8.3 x 103 pfu calpox virus). Infec-
tious virus particles [pfu/µl] were detected in all tested animals at 10 dpi and at the last available time point at 12 dpi.  
days post infec-
tion (dpi) 
Study Identification (Group)   
 
3 
7 
10 
12 
14325 (I) 
0 
n.d. 
n.d. 
n.d. 
14484 (I) 
0 
n.d. 
n.d. 
n.d. 
14991 (I) 
0 
n.d. 
n.d. 
n.d. 
14702 (V)   
n.d. 
0 
0.20 
1595.74 
15122 (V) 
n.d. 
0 
0.06 
446.81  
15095 (V) 
n.d. 
0.01 
0.16 
3808.51 
dpi, days post infection; Infectious virus particles [pfu/µl], final amount of infectious virus particles [pfu/µl]; n.d., not detected; 
pfu, plaque forming units. 
 
 
Table A.3-2: Virus isolation of infectious calpox virus from buffy coat.  
Study  Vac-
cination  
group 
Vaccine Study  
Identifica-
tion 
Plaque assay processed at different 
days post infection (dpi) 
Infectious virus particles  
[pfu/µl] 
Vac-
cination 
study II 
III 
 
 
 
MVA 
i.m. 
 
 
14233 
 
 
 
10 
12 
14 
17 
0 
0.067 
0.173 
3.95 
  14309 
 
 
 
 
 
 
 
10 
12 
14 
17 
21 
24 
29 
35 
0 
0 
0 
0 
0 
0 
0 
0 
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  14248 
 
 
 
 
10 
12 
14 
17 
21 
0 
0 
0 
0.1 
1.993 
  14372 10 
12 
14 
17 
21 
0 
0,001 
0 
0,166 
270.667 
IV 
 
 
 
MVTT 
i.n. 
 
 
14169 
 
 
 
10 
12 
14 
17 
0 
0.013 
0.013 
0.053 
  14603 
 
 
 
10 
12 
14 
16 
0 
0.033 
0.083 
0.2 
  14409 
 
 
 
 
 
 
 
10 
12 
14 
17 
21 
24 
29 
35 
0 
0 
0 
0 
0 
0 
0 
0 
  14469 10 
12 
14 
17 
21 
24 
29 
35 
0 
0 
0 
0 
0 
0 
0 
0 
control PBS i.n. 14365 10 
12 
1 
494 
V MVTT 
p.o. 
15098 
 
10 
12 
14 
17 
21 
24 
29 
35 
0 
0 
0 
0 
0 
0 
0 
0 
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14478 
 
10 
12 
14 
17 
21 
24 
29 
35 
0 
0 
0 
0 
0 
0 
0 
0 
  14334 
 
10 
12 
14 
17 
21 
24 
29 
35 
0 
0 
0 
0 
0 
0 
0 
0 
  15100 10 
12 
14 
17 
0 
0 
0.007 
0.173 
Vac-
cination 
study II 
control PBS 
p.o. 
14974 10 
12 
14 
0 
0.587 
1.66 
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Table A.3-3: Overview of the detected antibodies in A27 in vaccination study I. The samples of the animals were tested at 
different time points. When antibodies bound to a sequence of the A27 protein, the respective B cell epitope regions were 
marked red.   
 
Bold numbers, protected animals; i.m., intramuscular Immunization; i.n., intranasal Immunization; MVA, modified vaccinia 
virus Ankara; MVTT, modified vaccinia virus Tiantan. 
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Table A.3-4: Overview of the detected antibodies in D8 in vaccination study I. The samples of the animals were tested at 
different time points. When antibodies bound to a sequence of the D8 protein, the respective B cell epitope regions were marked 
red.  
 
Bold numbers, protected animals; i.m., intramuscular Immunization; i.n., intranasal Immunization; MVA, modified vaccinia 
virus Ankara; MVTT, modified vaccinia virus Tiantan. 
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Table A.3-5: Overview of the detected antibodies in H3 and L1 in vaccination study I. The samples of the animals were 
tested at different time points. When antibodies bound to a sequence of the H3 and L1 protein, the respective B cell epitope re-
gions were marked red.  
 
Bold numbers, protected animals; i.m., intramuscular Immunization; i.n., intranasal Immunization; MVA, modified vaccinia 
virus Ankara; MVTT, modified vaccinia virus Tiantan. 
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Table A.3-6: Overview of the detected antibodies in A33 in vaccination study I. The samples of the animals were tested at 
different time points. When antibodies bound to a sequence of the A33 protein, the respective B cell epitope regions were 
marked red. 
  
Bold numbers, protected animals; i.m., intramuscular Immunization; i.n., intranasal Immunization; MVA, modified vaccinia 
virus Ankara; MVTT, modified vaccinia virus Tiantan. 
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Table A.3-7: Overview of the detected antibodies in B5 in vaccination study I. The samples of the animals were tested at 
different time points. When antibodies bound to a sequence of the B5 protein, the respective B cell epitope regions were marked 
red.  
 
Bold numbers, protected animals; i.m., intramuscular Immunization; i.n., intranasal Immunization; MVA, modified vaccinia 
virus Ankara; MVTT, modified vaccinia virus Tiantan. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  163 
Table A.3-8: Overview of the detected antibodies in B5 in vaccination study I. The samples of the animals were tested at 
different time points. When antibodies bound to a sequence of the B5 protein, the respective B cell epitope regions were marked 
red.  
 
Bold numbers, protected animals; i.m., intramuscular Immunization; i.n., intranasal Immunization; MVA, modified vaccinia 
virus Ankara; MVTT, modified vaccinia virus Tiantan. 
 
 
 
 
 
 
 
protein:
spot #: 473
NHP I.D. #: time point:
14406
14646
14415
15006
14406
14646
14415
15006
14144
14403
14482
14707
14414
14327
14575
15007
14144
14403
14482
14707
14414
14327
14575
15007
14144
14403
14482
14707
14414
14327
14575
15007
14144
14403
14482
14707
14414
14327
14575
15007
14144
14403
14482
14707
14414 10 weeks post challenge
14327 6 weeks post challenge
14575 8 weeks post challenge
15007 10 weeks post challenge
Vaccine group 
I (MVA i.m.)
10 weeks post challenge
Vaccine group 
II (MVTT i.n.)
Vaccine group 
I (MVA i.m.)
2 weeks post 2nd 
immunization
Vaccine group 
II (MVTT i.n.)
Vaccine group 
I (MVA i.m.)
challenge
Vaccine group 
II (MVTT i.n.)
Vaccine group 
I (MVA i.m.)
2 weeks post challenge
Vaccine group 
II (MVTT i.n.)
Vaccine group 
I (MVA i.m.)
pre-immunization
Vaccine group 
II (MVTT i.n.)
420-422 452-455 457-458
B5
control PBS 
i.m.
pre-immunization
control PBS 
i.n.
control PBS 
i.m.
2 weeks post challenge
control PBS 
i.n.
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Table A.3-9: Overview of the detected antibodies in A27 in vaccination study II. The samples of the animals were tested 
at different time points. When antibodies bound to a sequence of the A27 protein, the respective B cell epitope regions were 
marked red.  
 
Bold numbers, protected animals; i.m., intramuscular Immunization; i.n., intranasal Immunization; MVA, modified vaccinia 
virus Ankara; MVTT, modified vaccinia virus Tiantan; p.o., per oral. 
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Table A.3-10: Overview of the detected antibodies in D8 in vaccination study II. The samples of the animals were tested at 
different time points. When antibodies bound to a sequence of the D8 protein, the respective B cell epitope regions were marked 
red.  
 
Bold numbers, protected animals; i.m., intramuscular Immunization; i.n., intranasal Immunization; MVA, modified vaccinia 
virus Ankara; MVTT, modified vaccinia virus Tiantan; p.o., per oral. 
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Table A.3-11: Overview of the detected antibodies in H3 and L1 in vaccination study II. The samples of the animals were 
tested at different time points. When antibodies bound to a sequence of the H3 and L1 protein, the respective B cell epitope re-
gions were marked red.  
 
 
Bold numbers, protected animals; i.m., intramuscular Immunization; i.n., intranasal Immunization; MVA, modified vaccinia 
virus Ankara; MVTT, modified vaccinia virus Tiantan; p.o., per oral. 
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Table A.3-12: Overview of the detected antibodies in A33 in vaccination study II. The samples of the animals were tested at 
different time points. When antibodies bound to a sequence of the A33 protein, the respective B cell epitope regions were 
marked red.  
 
Bold numbers, protected animals; i.m., intramuscular Immunization; i.n., intranasal Immunization; MVA, modified vaccinia 
virus Ankara; MVTT, modified vaccinia virus Tiantan; p.o., per oral. 
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Table A.3-13: Overview of the detected antibodies in B5 in vaccination study II. The samples of the animals were tested at 
different time points. When antibodies bound to a sequence of the B5 protein, the respective B cell epitope regions were marked 
red.  
 
Bold numbers, protected animals; i.m., intramuscular Immunization; i.n., intranasal Immunization; MVA, modified vaccinia 
virus Ankara; MVTT, modified vaccinia virus Tiantan; p.o., per oral. 
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Table A.3-14: Overview of the detected antibodies in B5 in vaccination study II. The samples of the animals were tested at 
different time points. When antibodies bound to a sequence of the B5 protein, the respective B cell epitope regions were marked 
red.  
 
Bold numbers, protected animals; i.m., intramuscular Immunization; i.n., intranasal Immunization; MVA, modified vaccinia 
virus Ankara; MVTT, modified vaccinia virus Tiantan; p.o., per oral. 
 
 
 
protein:
spot #: 473
NHP I.D. #: time point:
control PBS i.n. 14365
control PBS p.o. 14974
control PBS i.n. 14365
control PBS p.o. 14974
14233
14309
14248
14372
14469
14169
14603
14409
15098
14478
14334
15100
14233
14309
14248
14372
14469
14169
14603
14409
15098
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14334
15100
14233
14309
14248
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14469
14169
14603
14409
15098
14478
14334
15100
14233
14309
14248
14372
14469
14169
14603
14409
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14334
15100
B5
420-422 452-455 457-458
pre-immunization
8 weeks post 2nd 
immunization
Vaccine group 
III MVA i.m.
pre-immunization
Vaccine group 
IV MVTT i.n.
Vaccine group V 
MVTT p.o.
Vaccine group 
III MVA i.m.
2 weeks post 2nd 
immunization
Vaccine group 
IV MVTT i.n.
Vaccine group V 
MVTT p.o.
Vaccine group 
III MVA i.m.
challenge
Vaccine group 
IV MVTT i.n.
Vaccine group V 
MVTT p.o.
Vaccine group 
III MVA i.m.
8 weeks post challenge
Vaccine group 
IV MVTT i.n.
Vaccine group V 
MVTT p.o.
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